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SUMMARY 
Despite surgical resection and the combination of ionizing radiation and chemotherapy 
with temozolomide (TMZ), a DNA methylating agent introduced in 2005, glioblastoma (GBM) 
remains a lethal disease associated with poor prognosis, treatment resistance and inevitable 
relapse. Resistance to chemoradiation is mediated in great part by complex and redundant DNA 
repair mechanisms.  
The main aim of this project was to propose novel molecular targets and strategies in 
the fight against GBM, based on the identification and characterization of the DNA repair 
machineries that i) are altered during glioblastomagenesis and ii) mediate chemoresistance and 
tumor relapse. To this end, we have embarked on the expression analysis of a selection of genes 
encompassing the major DNA repair pathways and cell cycle-related factors, in a clinically-
relevant cohort of paired primary and recurrent biopsies from GBM patients. 
 In the first part of this thesis, we report the generation and validation of a DNA repair 
and cell cycle gene signature that clustered GBM specimens in two major groups displaying an 
inverse expression profile of the signature and a third, less defined group. Specific analysis of 
the tumor pairs revealed that GBM recurrences frequently displayed a gene expression profile 
different from that of the matched primary biopsy, indicating that tumor progression is 
associated with significant deregulation of DNA repair and cell cycle pathways. Furthermore, 
the gene signature expression pattern observed at relapse was linked to progression-free 
survival. Finally, our signature exposed therapeutic group-specific vulnerabilities to inhibitors 
of the DNA damage response and/or genotoxicants, as well as specific alterations in key core 
GBM pathways. Thus, our gene signature bears clinical relevance, with the prospect of better 
patient stratification and personalized therapeutic strategies. 
 In the second part of this thesis, we have exploited our gene expression dataset to 
uncover DNA repair genes specifically deregulated in GBM. We report the upregulation of 
NEIL3 encoding a member of the NEIL DNA glycosylase family, and the downregulation of 
NEIL1 and NEIL2, the other members of this family. In view of the documented role of NEIL3 
in promoting repair of oxidative DNA damage at telomeres, we investigated the impact of 
depleting NEIL3 in GBM cell lines. We found that NEIL3 knockdown resulted in telomere 
shortening, downregulation of the shelterin factor TRF1 and deregulation of chromosome-
specific telomeric repeat-containing RNAs (TERRAs). In parallel, we observed an increase in 
telomere dysfunction-induced foci (TIFs) after NEIL3 loss, suggesting the activation of the 
DNA damage response at telomeres. Finally, NEIL3 depletion was associated with increased 
xx 
 
sensitivity to oxidative DNA damage as well as TMZ. Hence, we propose that NEIL3 could 
represent an attractive therapeutic target for improved treatment of GBM. 
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INTRODUCTION 
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 CHAPTER 1 
1. Glioblastoma  
1.1. Description and standard of care 
Glioblastoma (GBM) is a grade IV astrocytoma (World Health Organization, WHO) that 
accounts for about 15% of all primary brain tumors and 50% of all malignant central nervous 
system (CNS) tumors (Ostrom et al., 2014).  In adults, the yearly incidence of GBM is estimated 
at 3.2 per 100.000 persons with a median age at occurrence of 64 years (Ostrom et al., 2014). 
In contrast, pediatric GBM (highest incidence between ages 15-19) account for about 3-15% 
of primary CNS tumors (Das and Kumar 2017). GBMs are associated with very poor patient 
prognosis with reported median overall survival (OS) in adults of about 15 months (Stupp et 
al., 2005) and in pediatric cases ranging from 13 to 72 months (Song et al., 2010).   
GBMs arise from astrocytes, mainly as de novo primary tumors (about 95% of the cases) 
without any measurable malignant precursor. Additionally, lower-grade astrocytomas (WHO 
grade II or III) can develop to secondary GBMs (5% of patients). Diagnosis of CNS tumors was 
originally based solely on the neuropathological analysis of a patient biopsy. In recent years, 
the WHO classification has been revised to integrate genotypic and phenotypic parameters 
(Louis et al., 2016), leading to a more robust and improved diagnosis of brain cancers (Figure 
1). Moreover, DNA methylation profiling emerged as a promising and complementary tool for 
routine diagnosis and classification of CNS tumors in the clinic (Capper et al., 2018).  
The current standard management of GBM consists of maximal surgical resection, 
followed by radiotherapy (RT) with concomitant and adjuvant chemotherapy with the DNA 
alkylating agent temozolomide (TMZ). This standard of care was first introduced in 2005 
following the seminal study by Stupp et al. (2005) (Figure 2). Prior to this date, alkylating 
agents including TMZ were mainly used as rescue therapy in patients with recurrent tumors 
(Gallego 2015; Weller et al., 2013). TMZ is an oral methylating agent capable of crossing the 
blood brain barrier (Patel et al., 2003). The survival benefit achieved by the use of TMZ in 
combination with RT is very limited with a median overall survival increase of about 2.5 
months compared to RT alone (Stupp et al., 2005). In addition, as will be discussed later, the 
efficiency of TMZ is limited to a patient population distinguished by the epigenetic silencing 
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of the MGMT gene, coding for the enzyme catalyzing the removal of the most cytotoxic lesion 
induced by TMZ, O6-methylguanine (O6-meG).  
Thus, despite an aggressive treatment combination, the median survival in newly 
diagnosed patient does not exceed 15 months (Stupp et al., 2005) and the estimated 5-year 
survival rate is only about 5% (American Cancer Society 2017). Favorable prognostic factors 
include younger age at diagnosis, higher performance status (e.g. the commonly used 
Karnofsky performance status, (Lamborn et al., 2004)), tumor location and extent of tumor 
resection (Thakkar et al., 2014). Elderly patients (> 60 years old) are often excluded from 
multimodal therapies because of higher risk of treatment intolerance. Nevertheless, TMZ 
monotherapy or hypofractionated radiotherapy (i.e. large doses in several sessions) have 
been proposed as tolerable alternatives in older patients (Zarnett et al., 2015). Presently, as 
no gold standard treatment for recurrent GBM has been established, treatment strategies are 
frequently proposed in the context of a clinical trial using novel therapeutic drugs (Weller et 
al., 2013). For lack of better alternatives, and despite its inefficacy in treating patients with a 
Figure 1. Current updated algorithm for the classification of diffuse gliomas. The current diagnosis of central 
nervous system tumors is based on histological and genetic features. The flow of analysis to determine tumor type 
and grade is not always top-down, and molecular signatures can sometimes outweigh histological features in order 
to achieve an integrated diagnosis. *Characteristic not required for diagnosis; NOS, not otherwise specified (adapted 
from Louis et al., 2016). 
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tumor harbouring an unsilenced MGMT gene, TMZ-based chemotherapy is still presently used 
in the clinic for newly diagnosed patients. 
 
1.2. Key genetic drivers of glioblastomagenesis and patient stratification 
GBM tumors exhibit an important inter- and intratumor heterogeneity both at the cellular 
and molecular level which translates into the inability of basic histopathological features to 
clearly define patient outcome. Moreover, incomplete knowledge of driving alterations and 
suboptimal disease classification also hinder therapy development for GBM patients. In an 
effort to identify putative GBM tumor drivers, whole genome analyses conducted by the 
Cancer Genome Atlas (TCGA) research network have generated an extensive list of gene 
expression alterations (i.e., deregulated genes, CpG island methylation patterns) and genomic 
Figure 2. Glioblastoma standard-of-care treatment strategy and impact on patient prognosis. A. Treatment scheme 
adopted following the seminal study by Stupp et al in 2005: standard radiotherapy plus daily concomitant TMZ, 
followed by adjuvant chemotherapy. B. Overall survival of GBM patients treated with radiotherapy alone or in 
combination with TMZ demonstrating a significant survival benefit (Stupp et al., 2005). To note, the specific impact 
of MGMT methylation on TMZ treatment efficacy is illustrated later (Fig. 9). 
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 CHAPTER 1 
abnormalities (i.e., mutations, copy number alterations) associated with glioblastomagenesis 
(Brennan et al., 2013; Cancer Genome Atlas Research 2008; Noushmehr et al., 2010). These 
include alterations of the tyrosine kinase receptor (RTKs) signalling pathway (observed in 90% 
of GBMs) manifested by the deregulation of specific RTKs and downstream factors. In 
particular, the EGFR receptor is found amplified in about 50% of GBMs, generally leading to 
overexpression of the protein (Furnari et al., 2015). Moreover, 50% of EGFR amplified tumors 
overexpressed a truncated protein called EGFR variant III (EGFRvIII) which is constitutively 
active (Gan et al., 2013). Amplification of PDGFRA is also observed in 10% of GBM tumors and 
is associated to poor prognosis in recurring patients (Phillips et al., 2013). In addition, the 
genes encoding negative regulators of the RAS and AKT downstream signalling pathway, NF1 
and PTEN, are frequently inactivated or deleted in GBM (Brennan et al., 2013). Likewise, 
inhibition of the apoptotic pathway by inactivating TP53 mutations is detected in about 30% 
of primary GBMs. Deregulation of the retinoblastoma pathway (RB) with most commonly 
inactivation or deletion of the CDKN2A/B locus (80% of tumors) and amplification of CDK4 
and CDK6 (16% of tumors) are  also observed (Brennan et al., 2013) (Figure 3A). Lastly, a 
subset of tumors has been identified, that are characterized by a similar profile of gene 
promoter methylation (called the glioma-CpG island methylator phenotype (G-CIMP)) and are 
associated with somatic IDH1 mutations (Noushmehr et al., 2010). Although not frequently 
observed in primary GBM (<5% of patients), the mutation status of the isocitrate 
dehydrogenase genes IDH1/2 (hereby referred to as IDH)  is a critical factor in low-grade 
gliomas and secondary GBM (70-80% of cases) which has been included as the primary 
determinant of the novel WHO glioma classification (Louis et al., 2016). The IDH mutations 
occur early in gliomagenesis and confer neo-enzymatic activity. Specifically, mutant IDH 
catalyzes the production of the oncometabolite 2-hydroxyglutarate (2-HG) from α-
ketoglutarate (α-KG) (Cohen et al., 2013) (details in section 2.2). The presence of these 
alterations in GBM patients were found to be related with patient prognosis (Noushmehr et 
al., 2010; Ruano et al., 2009; Verhaak et al., 2010).  
Importantly, the integration of these key alterations into a multidimensional genomic data 
study led to a robust gene expression-based molecular classification of GBM (Verhaak et al., 
2010). Originally, the patterns of somatic mutations and DNA copy number alterations 
described above were considered to define 4 subgroups; namely the classical, mesenchymal, 
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proneural and neural GBM subtypes. Interestingly, such a classification led to the observation 
that the survival advantage of treated patients varied according to the subtype (Verhaak et 
al., 2010) with the best prognosis seen in the proneural type and a clear treatment effect 
observed in both classical and mesenchymal subtypes. Importantly, the neural subtype, 
whose expression pattern was closely related to normal brain, was rapidly disproved by the 
community as a result of glial cell contamination in the considered patient biopsies (Verhaak 
et al., 2010). Nevertheless, this first milestone study demonstrated the relevance of stratifying 
patients based on molecular profiles. 
A similar study in pediatric GBM uncovered somatic driver mutations in the replication-
independent histone variant H3.3 gene (H3F3A) as well as in the H3.3 histone chaperones 
ATRX and DAXX (Schwartzentruber et al., 2012).  As a result, a novel classification was 
proposed that stratified GBMs across the entire age spectrum (adult and pediatric) into 6 
biologically-relevant subgroups based on DNA methylation clusters and carried clinical 
implications, with mutated H3F3A at position K27 associated to worst survival (Sturm et al., 
2012) (Figure 3B). 
Figure 3. Defining gene expression and molecular alterations in GBM. A. Overall alteration rates in the canonical 
PI3K/MAPK (upper panel), p53 signaling (bottom left panel) and Rb (bottom right panel) regulatory pathways. The 
color scale indicates the frequency and the type of genetic alteration, with activating mutation/amplification and 
inactivating mutation/deletion indicated in red and blue, respectively (adapted from Brennan et al., 2013) B. 
Heatmap of the updated Verhaak GBM classifiers obtained in an integrative multiomics approach in order to filter 
out the non-tumor gene signature. This approach resulted in the removal of the neural subtype which was thought 
to mostly consist of glial cells. Representative genes of the signature are shown for each subtype. Mesenchymal-
type GBMs are shown in green, proneural in purple and classical in light blue. Expression intensity is represented as 
a green (low expressed) to red (high expressed) color scale (adapted from Wang et al., 2017). 
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In the recent years, the constant optimization of multi-omics analysis and the rise of single 
cell transcriptomics have revolutionized the search for genetic biomarkers in cancer. In line 
with these advances, the GBM expression subgroups were further refined by eliminating the 
influence of the tumor-associated infiltrating cells on the gene signature, which further 
confirmed the exclusion of the neural subtype (Wang et al., 2017) (Figure 3C). Moreover, 
further characterization of the intra-tumoral heterogenenity using spatially distinct tumor 
fragments and single tumor cell transcriptomics revealed patterns of spatial and patient-
specific tumor evolution (Sottoriva et al., 2013) and dynamic transcriptional program 
transitions (Patel et al., 2014). In addition, a recent study describing the use of uncommon 
multifocal (several spatially distinct tumor entities in the same patient) GBMs in combination 
with a multi-omic approach, identified common genetic alterations in different tumor foci 
from the same patient. This observation suggests a monoclonal origin of multifocal GBMs, 
that in parallel gain distinct aberrations throughout their development, translating into a 
marked genetic heterogeneity in the patient’s tumor (Abou-El-Ardat et al., 2017). Finally, 
further developments illustrated by the multi-omics analysis of a comprehensive TCGA cohort 
containing adult gliomas of different grades (grade II, III and IV) have identified molecular 
correlations that provide insights into the progression from low- to high-grade disease, as well 
as 6 clinically relevant subsets based on the correlation of methylation and gene expression 
profiles (Ceccarelli et al., 2016).  
Despite these efforts, the mechanisms driving GBM development and response to 
treatment remain unclear and the implementation of successful GBM therapies still awaits 
efficient patient stratification and the identification of innovative subgroup-specific 
treatments. 
1.3. Treatment resistance and tumor relapse 
Several intrinsic or acquired mechanisms drive fast tumor repopulation/regrowth after 
resection and limit treatment efficacy, thus ultimately leading to tumor recurrence and 
patient death.  
The brain parenchyma is protected from the peripheral blood circulation by the blood–
brain barrier (BBB) (Chow and Gu 2015). Although the BBB offers protection against the 
toxicity of many xenobiotics and pathogens, it imposes a challenge on researchers and 
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clinicians who have to design/select drug compounds capable of penetrating into this 
shielded environment in order to reach the tumor. Additionally, the tumor microenvironment 
(TME) plays a crucial role in tumorigenesis, fostering tumor initiation, progression and 
invasion and also promoting resistance against cell death signals, the host immune response 
and therapeutics. The GBM TME is composed of highly proliferative cancer cells, resident or 
infiltrating immune cells, stromal and vascular endothelial cells. These different cell 
populations create distinct and heterogeneous niches within the tumor (Figure 4). 
Furthermore, GBMs show extensive neo-angiogenesis leading to vascular abnormalities due 
to elevated levels of vascular endothelial growth factor (VEGF) resulting in leaky blood vessels 
that fail to deliver constant oxygen delivery within the tumor (Wesseling et al., 1997). As a 
result, glioblastomas show extensive regions of hypoxia which translates in a decrease in 
oxygen molecules, thus limiting the potency of ionizing radiation (IR) to generate oxidative 
damage by producing reactive oxygen species and free radicals (Rockwell et al., 2009). These 
conditions also attract immune cells such as macrophages that display proangiogenic and 
immunosuppressive properties thus helping tumor expansion (Glass and Synowitz 2014). 
Additionally, GBM cells also have the propensity to invade the neighbouring normal brain 
tissue either as single cells or by taking advantage of adjacent blood vessels to reach normal 
brain parenchyma (Cuddapah et al., 2014). Thus, the infiltrative nature of GBM makes 
Figure 4. Representation of the different tumor microenvironment (TME) niches present in GBM. Glioblastoma 
cells are embedded in a heterogeneous TME which is not only composed of diverse stromal cells, including 
endothelial cells, the various infiltrating and resident immune cells, and other glial cell types, but also distinct regions 
whose anatomical and functional traits are partly driven by the GBM cells themselves. These niches actively regulate 
metabolic needs, immune surveillance, survival and invasion, and have also been proposed to play a crucial role in 
glioma stem cell maintenance. See text for details (De Vleeschouwer and Bergers, 2017). 
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complete tumor resection impossible as cells having escaped the tumor bulk to invade the 
brain parenchyma will not be removed. All these niches undergo dynamic spatio-temporal 
alterations during tumor growth creating protected tumor microenvironments that sustain 
the aggressive growth of GBM during progression as well as response to therapeutic agents 
(Hambardzumyan and Bergers 2015).  
Furthermore, a subpopulation of tumor propagating cells with stem-like cell properties, 
named glioma stem-like cells (GSCs), have been proposed to affect gliomagenesis, tumor 
recurrence and treatment resistance (Lathia et al., 2015). GSCs have been shown to promote 
the angiogenic tumor niche by expressing high levels of VEGF (Bao et al., 2006b) In addition, 
GSCs were also found to be enriched in perinecrotic tumor areas (near the hypoxic niche) 
(Seidel et al., 2010) where their stem cell properties are enhanced through upregulation of 
the hypoxia-induced factor HIF-1α (allowing survival in this more hostile environment) (Soeda 
et al., 2009). It has also been demonstrated that GSCs are inherently more resistant to 
chemoradiation (Bao et al., 2006a; Chen et al., 2012), in part because of their ability to find 
shelter in specific brain regions that have been reported to afford protection against DNA 
damage (Roos et al., 2017). Additionally, these cells have been proposed to initiate tumor cell 
repopulation after resection of the tumor mass (Singh et al., 2003). In this regard, a recent 
study has uncovered the presence of GBM-derived circulating tumor cells (CTCs) in a 
xenografted mouse model. These cells presented GSCs properties and were able to return to 
the brain where they induced tumor relapse (Liu et al., 2018). Finally, GSCs can be isolated 
from patient material and propagated as neurospheres (Azari et al., 2011) which possess the 
ability to recapitulate the phenotypes of the original tumor when xenotransplanted in mice 
(Galli et al., 2004) and thus represent an important tool for functional studies. 
2. DNA repair mechanisms and their role in GBM resistance 
The development of resistance to chemoradiation is promoted in great part by complex 
DNA repair machineries that remove DNA lesions. Here, following an introduction to the DNA 
damage response, we will briefly introduce the salient features of the major DNA repair 
pathways that affect the resistance of GBM cells to chemoradiation.  
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2.1. The DNA damage response and the DNA repair paradox 
Genomic DNA is constantly challenged with damages that arise from endogenous sources, 
for instance from normal cellular processes such as the misincorporation of bases by DNA 
polymerases during replication, oxidative DNA damage due to the generation of reactive 
oxygen species (ROS) by cellular metabolism and spontaneous hydrolysis of bases (Lindahl 
1993; Marnett and Plastaras 2001; Tubbs and Nussenzweig 2017). Moreover, DNA damage 
can result from exogenous insults like chemical mutagens, ionizing radiations (IR) and 
genotoxic compounds present naturally in the environment or administered, for instance as 
part of cancer therapy (Ciccia and Elledge 2010).  
In order to prevent the potentially lethal consequences of DNA damage, complex 
signalling and repair mechanisms have evolved to tackle the diverse threats to genome 
integrity. The major DNA repair pathways include direct repair (dedicated enzyme), base 
excision repair (BER), mismatch repair (MMR), nucleotide excision repair (NER), interstrand 
DNA cross-link (ICL) repair and finally, double-strand break (DSB) repair, itself consisting of 
two distinct major sub-pathways, namely homologous recombination (HR) and non-
homologous end-joining (NHEJ) (Figure 5).  
Specific checkpoint signalling pathways are activated upon genotoxic stress to block cell 
cycle progression and allow DNA repair to occur, or when DNA repair cannot be achieved, 
Figure 5. Schematic illustration of the types of DNA lesions incurred by DNA and the major DNA repair pathways 
that remove these lesions and maintain genomic stability. See text for details (adapted from Lord et al., 2012). A, 
adenine; G, guanine; CH3, methyl group. 
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trigger apoptosis (Haber 2015). The checkpoint signalling pathways are part of the DNA 
damage response (DDR) that orchestrates a sequence of events leading to the mobilization of 
the DNA repair machineries, access to the lesion site via remodelling of the local chromatin 
structure, DNA repair and restoration of an intact chromatin structure (Dabin et al., 2016; 
Soria et al., 2012). Central to the activation of the DDR are the ATM (Ataxia Telangiectasia 
mutated) and ATR (Ataxia Telangiectasia and Rad3-related) kinases which respond to 
different types of DNA lesions (Marechal and Zou 2013). Specifically, ATM is recruited to DSB 
sites through the MRN complex (MRE11-RAD50-NBS1) while ATR activation is promoted by 
recognition of ssDNA present at replication fork collapse by the 9-1-1 sensor (RAD9-RAD1-
HUS1) (Awasthi et al., 2015). Downstream effectors will be mobilized upon activation by 
phosphorylation of both factors (Figure 6). Specifically, targets of ATM include p53 and the 
effector kinase CHK2, resulting in the control of G1 to S cell cycle progression, whereas ATR 
primarily acts through CHK1 and controls DNA replication (intra-S checkpoint) and the G2/M 
checkpoint (Marechal and Zou 2013). One of the most important substrate of ATM and ATR 
is H2AX, a variant of histone H2A that is present in about 10-15% of the nucleosomes. 
Phosphorylation of H2AX on serine 139 (a modification known as γ-H2AX) by ATM or ATR 
induces chromatin structure alteration at the DSB site that act as scaffold for the recruitment 
of the DSB machinery (Kinner et al., 2008; Podhorecka et al., 2010). Notably, γ-H2AX can be 
observed as foci that persist until DNA repair has been achieved. The quantification of γ-H2AX 
levels is a sensitive marker for DSBs and has become crucial in research and clinical studies 
(Redon et al., 2011). Interestingly, ATM- and ATR-dependent signalling overlaps have been 
demonstrated at DNA double strand breaks (Jazayeri et al., 2006), illustrating the complexity 
and redundancy of the DDR. The cooperation of all these signalling factors compose the DDR 
and is crucial for the maintenance of genome integrity. Finally, in addition to ATM, a third 
kinase, the DNA-dependent protein kinase (DNA-PK) plays a particular role during the G1 
phase of the cell cycle in sensing DSB, phosphorylating -H2AX and promoting the repair of 
DSBs by end-joining  (Blackford and Jackson 2017; Burma and Chen 2004). 
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DNA lesions that accumulate due to defective or overwhelmed DNA repair can lead to 
increased mutational burden and/or genomic instability, which are driving forces in 
tumorigenesis (Curtin 2012; Hanahan and Weinberg 2011; Lengauer et al., 1998). Examples 
include dominant gain of function mutations in oncogenes and loss of tumor suppressor 
genes (including DNA repair genes) (Hanahan and Weinberg 2000). Analysis of the mutational 
landscape of different cancer genomes illustrates how variations in cancer risk result from 
tissue-specific vulnerabilities to DNA damage caused by specific defects in DNA repair 
pathways (Tubbs and Nussenzweig 2017).  
Figure 6. Description of the DNA damage response signalling pathway. The DNA damage response (DDR) pathway 
is composed of two main DNA damage sensors: the MRE11–RAD50–NBS1 (MRN) complex is able to detect DNA 
double-strand breaks (DSBs) and the RAD9–RAD1–HUS1 (9-1-1) complex recognizes exposed regions of single-
stranded DNA (ssDNA). Upon recognition of the lesion, these sensors recruit the ataxia-telangiectasia mutated (ATM) 
or ataxia telangiectasia and Rad3-related (ATR) kinases, respectively. In turn, these kinases will phosphorylate (P) 
the histone variant H2AX on Ser139 (a modification known as γ-H2AX) and trigger the recruitment of several 
mediators of DNA repair factors and the execution of essential cellular programs including transient cell cycle arrest 
followed by repair of DNA damage and resumption of proliferation, or when the DNA repair machineries are 
overwhelmed or DNA repair cannot occur, cellular senescence or cell death. See text for details (Sulli et al., 2012). 
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Yet, although DNA damage repair is paramount to prevent genetic instability and 
tumorigenesis, it is also required to counter the accumulation of endogenous damage 
occurring during DNA replication in highly-proliferative cancer cells (Hanahan and Weinberg 
2011; Hoeijmakers 2001) and constitutes the major defence wall against genotoxic anti-
cancer agents (Bartkova et al., 2005; Sawicka et al., 2004). This apparent paradox is explained 
by the notion that cancer cells defective in a given DNA repair pathway become “addicted” 
to other, partially redundant pathway(s) for survival/response to DNA damage (Nickoloff et 
al., 2017). Documented examples of DNA repair gene addiction include breast and ovarian 
cancers harbouring mutations in the tumor suppressor genes BRCA1/2, thus displaying a 
defect in the recombinational repair of DNA double-strand breaks and synthetic lethality with 
inhibition of the single-strand DNA break repair factor PARP1 (Turk and Wisinski 2018). These 
observations have fostered classical therapeutic strategies relying on mainstays of cancer 
therapies such as IR and genotoxicants to overwhelm highly proliferative tumor cells and 
trigger cell death (Chabner and Roberts 2005). They have also led to more recent strategies 
targeting components of the DNA damage response (DDR), including modulation of cell cycle, 
mitotic progression and genetic stability (Dominguez-Brauer et al., 2015; Lord et al., 2015), 
which have emerged as an important therapeutic approach against many cancers. 
Unfortunately, the multiplicity of DNA repair mechanisms, combined with inherent or 
acquired DNA lesion-tolerance mechanisms hamper the efficacy of the current genotoxic 
treatment strategies against cancer cells. Thus, identifying and characterizing novel 
therapeutic targets for DNA-repair based therapeutic strategies clearly remains a crucial 
challenge. 
2.2. Repair of chemoradiation-induced DNA lesions in GBM cells 
As discussed previously, the first-line treatment for GBM is composed of chemoradiation; 
specifically, the concomitant use of IR + TMZ.  
The impact of IR is mediated in part by the formation of ROS induced by water radiolysis 
that will ultimately create oxidative stress in tumor cells and affect cellular components like 
DNA, proteins and lipids. Guanines have a lower redox potential than other nucleobases (Xie 
et al., 2007) and are a frequent target for different reactive species, resulting in several 
oxidation products including 7,8-dihydro-8-oxo-2-deoxyguanosine (8-oxoG), the most 
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ubiquitous and best characterized product formed in DNA (Markkanen 2017). Because they 
are rich in guanine, telomeric repeats are particularly prone to ROS-induced oxidative base 
lesions (Cadet et al., 2008; Dizdaroglu and Jaruga 2012), which interferes with telomere 
homeostasis, a crucial hallmark of cancer (Hanahan and Weinberg 2011), whereas oxidative 
base damage can also promote mutation and DNA strand breaks elsewhere in the genome 
(Cooke et al., 2003; Ensminger et al., 2014; Jena 2012). Base excision repair (BER) is the 
predominant pathway for the repair of oxidative DNA base damage (Krokan and Bjoras 2013). 
However, the most deleterious DNA lesions inflicted by IR are DSBs, which can be repaired by 
two major mechanisms, homologous recombination (HR) and non-homologous end joining 
(NHEJ).  
On the other hand, TMZ is a mono-alkylating agent that forms methyl adducts at the N- 
and O- atoms in DNA bases via a SN-1 (first-order nucleophilic substitution) mechanism. 
Interestingly, TMZ is a prodrug whose conversion into its active form, the methyldiazonium 
cation, is mediated by spontaneous hydrolysis at physiological pH (Ramirez et al., 2013) 
(Figure 7A).  
Figure 7. Structure of TMZ and its activated products, and major methylation sites induced by TMZ. A. At 
physiological pH, TMZ is spontaneously hydrolysed to MTIC (5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide) and 
the powerful alkylating agent, methyldiazonium cation (adapted from Ramirez et al., 2013). B. Representation of the 
major DNA lesions induced by TMZ and respective methylation frequencies on adenine and guanine DNA bases 
(adapted from Yoshimoto et al., 2012). 
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The major lesions induced by TMZ are N7-methylguanine (N7-meG, 60-80%), N3- 
methyladenine (N3-meA, 10-20%) and O6-methylguanine (O6-meG, 5-10%) (Figure 7B) (Fu et 
al., 2012; Yoshimoto et al., 2012). N7-meG and N3-meA are repaired primarily by base 
excision repair (BER) (Bobola et al., 2012), with nucleotide excision repair (NER) proposed to 
also contribute to the repair of N7-meA and to a lesser extent of N3-meA (Plosky et al., 2002; 
Smith and Engelward 2000). In contrast, the most cytotoxic lesion induced by TMZ, O6-meG, 
is removed by a direct repair mechanism catalysed by the O6-methylguanine-DNA 
methyltransferase (MGMT), in a reaction where the methyl group is transferred from the 
damaged guanine to a cysteine residue present in the active site (C145) of MGMT (Sharma et 
al., 2009). This reaction is suicidal as the methyl-linked MGMT reaction is irreversible, 
promoting ubiquitination of the protein and subsequent degradation by the proteasome 
(Ramirez et al., 2013). When O6-meG is not repaired (for instance in tumors presenting a 
methylated MGMT gene promoter), it is mispaired with thymine during DNA replication which 
can eventually cause G:C to A:T transitions hence increase mutation rates (Warren et al., 
2006). The O6-meG:T mismatch is recognized by the mismatch repair (MMR) machinery 
(Kyrtopoulos et al., 1997). However, MMR cannot remove O6-meG, and its action leads 
instead to single-stranded DNA (ssDNA) gaps that are converted into DSBs during the next 
rounds of replication, when encountered by the replication fork (Fan et al., 2013; Gupta et 
al., 2018). TMZ can also induce minor DNA lesions like the N1-methyladenine (N1-meA) and 
the N3-methylcytosine (N3-meC) that are repaired through direct removal catalysed by the 
alpha-ketoglutarate (α-KG) and Fe(II) dependent DNA demethylase ALKBH2/3 (Fu et al., 2012; 
Wyatt and Pittman 2006) (described in Figure 9A right panel). Notably, up-regulation of 
ALKBH2 confers resistance to TMZ in GBM cells (Johannessen et al., 2013). Also relevant to 
GBM is the observation that the oncometabolite 2-hydroxyglutarate (2-HG) generated in IDH 
mutated tumor cells, is able to act as a competitive inhibitor of α-KG, thus impairing the repair 
activity of the ALKBH2/3 enzymes (Wang et al., 2015). Finally, in addition to causing base 
methylation, TMZ, also induces oxidative DNA damage (Lopes et al., 2013; Ozben 2007). An 
overview of the repair pathways responsible for the removal of TMZ- and IR-induced DNA 
lesion is provided in Figure 8.  
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2.3. The DNA repair pathways: their clinical impact in GBM patients and 
therapeutic targeting potential 
2.3.1. Repair of the O6-methylguanine lesion by MGMT and clinical 
relevance of the MGMT promoter methylation status in GBM 
 As discussed in the previous chapter, MGMT is the dedicated enzyme removing the 
most cytotoxic lesion induced by TMZ, the O6-meG adduct, using a suicidal enzymatic 
reaction that leads to degradation of the enzyme (Figure 9A left panel). Therefore, the levels 
of MGMT protein are a crucial determinant in the response of GBM cells to TMZ. Importantly, 
Figure 8. Schematic overview of the DNA repair pathways involved in the removal of IR- and TMZ-induced lesions.  
The top panel represents a non-exhaustive summary of the main DNA lesions induced by both TMZ and IR and the 
bottom panel describes the various DNA repair pathways involved in the repair of the mentioned lesions and their 
crosstalk. See text and Chapter 3 for more details on the different repair processes (Erasimus et al., 2016). 
 17 
 
 CHAPTER 1 
epigenetic silencing of MGMT through promoter CpG island methylation is observed in about 
45% of GBMs (Hegi et al., 2005). In this study, MGMT promoter methylation was recognized 
as a significant predictive marker for GBM patient response to TMZ, as nearly 50% of patients 
presenting a methylated MGMT promoter were still alive 2 years after concomitant radio- 
and TMZ-based chemotherapy, compared to only 14% of patients with an unmethylated 
MGMT promoter (Hegi et al., 2005) (Figure 9B). This observation is related to the fact that 
promoter methylation negatively regulates MGMT protein expression which directly 
sensitizes the tumor cells to TMZ therapy (Friedman et al., 1998; Younis et al., 2016).  The 
properties of MGMT and its impact on alkylated DNA damage repair and chemoresistance 
have led to substantial efforts in GBMs and other solid tumors to deplete the MGMT pool 
using pseudosubstrates like O6-benzylguanine (O6-BG). Unfortunately, patient treated with 
the combination of TMZ and O6-BG were faced with severe myelosuppression toxicity during 
clinical trials (Quinn et al., 2009; Ranson et al., 2006). Several approaches have attempted to 
overcome this drawback, including direct local administration of O6-BG (Koch et al., 2007) or 
the use of folate conjugates in order to target the tumor cells specifically (Javanmard et al., 
2007). Other approaches rely on the observation that the expression of a O6-BG-resistant 
MGMT gene construct (MGMT-P140K) in hematopoietic cells provided significant protection 
against toxicity from O6-BG treatment (Kramer et al., 2006).  
Figure 9. A. Direct repair of methylated DNA bases by MGMT and the ALKBH2/3 enzymes. MGMT removes the O6-
meG adduct via a suicide reaction that transfers the methyl group on its catalytic site. The resulting modified enzyme 
is thought to be targeted to ubiquitination-mediated degradation by the proteasome. ALKBH2 and ALKBH3 are 
Fe(II)/α-ketoglutarate-dependent dioxygenases that repair N1-meA and N3-meC in DNA by hydroxylation of the alkyl 
group thereby releasing formaldehyde (Fu et al., 2012). Of note, these enzymes are inhibited by 2-hydroxyglutarate 
produced by mutant IDH (Wang et al., 2015). B. Impact of MGMT promoter methylation status on GBM patient 
prognosis. Shown are Kaplan-Meier curves illustrating the effect of patient treatment (RT alone or RT+TMZ) on 
overall survival in relation to the MGMT promoter methylation status (methylated, unmethylated) of the tumor 
(Hegi et al., 2005).  
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Thus a clinical trial has been undertaken in which newly diagnosed MGMT-positive patients 
were transplanted with modified hematopoietic CD34+ cells expressing a MGMT-P140K 
which conferred chemoprotection to O6-BG/TMZ combination treatment (Adair et al., 2012).  
2.3.2. Mismatch repair (MMR) 
Mis-incorporations of bases during DNA replication in the newly synthesized strand 
are recognized and repaired by the mismatch repair (MMR) pathway thereby preventing 
mutations in dividing cells. The multi-step process is described in detail in Figure 10. 
Figure 10. Representation of the mismatch repair pathway. First, the DNA base mismatches can be recognized by 
different MutS complexes. Specifically, MutSα (composed of MSH2 and MSH6) recognizes simple base-base 
mismatches and small nucleotide insertions/deletions (1-2 bp) whereas MutSβ (composed of MSH2 and MSH3 (not 
represented here)) detects larger insertion/deletion loops (2-10 nucleotides). If a DNA nick is present at the 5’-end 
of the lesion, the replication clamp loader (RFC) and the proliferating cell nuclear antigen (PCNA) are loaded on the 
DNA. The MutLα complex (MLH1/PMS2) is then recruited at the site of the mismatch. The exonuclease 1 (EXO1, not 
depicted) will then excise the DNA surrounding and including the mismatch. Finally, replication protein A (RPA) 
protects the resulting single-strand DNA before filling of the gap by DNA polymerase delta (POLδ) takes place. Finally, 
DNA ligase 1 (LIG1) seals the nick (adapted from Hsieh and Yamane, 2008).  
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As seen before, active MMR contributes to the toxicity of O6-meG left unrepaired by 
MGMT, by inducing mutagenesis as well as potentially lethal DSBs. Importantly, The 
mutagenic impact of TMZ as a driving mechanism in tumor progression and the selection of 
TMZ-resistant clones through defective MMR is well documented in gliomas (van Thuijl et al., 
2015; Xie et al., 2016), as well as GBM (Cancer Genome Atlas Research 2008; Yip et al., 2009). 
In fact, MMR dysfunction leads to TMZ tolerance (Humbert et al., 1999), promoting cell 
survival at the expense of increased mutations rates (Hunter et al., 2006). Ultimately, the 
question arises if TMZ treatment is profitable in patients presenting low levels of MGMT 
coupled with deficient MMR. Nevertheless, novel treatment strategies in MMR deficient cells 
have emerged based on synthetic lethality by inhibition of either POLβ or POLγ leading to 
accumulation of oxidative DNA damage (Martin et al., 2010). 
 
Figure 11. Description of the base excision and single-strand break repair mechanisms. See text for details 
(adapted from Akbari et al., 2015). 
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2.3.3. Base excision repair (BER) 
The BER pathway operates to remove simple base lesions that do not significantly 
distort the DNA helix such as base alterations (e.g. oxidation, methylation) and SSBs (Kunz et 
al., 2009; Lindahl and Wood 1999). In mammalian cells, BER-mediated repair is subdivided in 
‘short-patch’ BER (SP-BER, single nucleotide) and ‘long-patch’ BER (LP-BER, several 
nucleotides) that are characterized by the size of the repair patch and the enzymes involved 
(Fortini et al., 1998; Frosina et al., 1996). BER enzymes are also involved in the repair of ssDNA 
breaks. The three processes are represented in Figure 11.   
During BER, the damaged base is removed and subsequently replaced with an undamaged 
one. Repair is initiated by the recognition and removal of the modified DNA base, through 
cleavage of the N-glycosidic bond, by a DNA glycosylase, to generate an apurinic/apyrimidinic 
site (AP-site). To note, spontaneous hydrolysis of the glycosidic bond of a nucleotide occurs 
at high frequency under normal aerobic conditions resulting in the generation of AP sites 
(Lindahl 1993). In mammalian cells, 11 different DNA glycosylases grouped in 4 structurally 
distinct categories have been identified: the helix-hairpin-helix (HnH) family, the 3-methyl-
purine glycosylase (MPG), the uracil DNA glycosylases (UDGs) and the endonuclease VII-like 
(NEIL) family (Jacobs and Schar 2012). This structural diversity reflects the substrate specificity 
of each enzyme as they all share the same common principle of action and only differ by the 
type of lesions and/or DNA context in which they operate. Moreover, further distinction can 
be made with mono-functional enzymes that only present a glycosylase activity, compared to 
bi-functional glycosylases that also possess an AP lyase activity allowing to cut the DNA 
phosphodiester bond, creating a SSB without the need for an AP endonuclease (Jacobs and 
Schar 2012). The different DNA glycosylase families, their substrate specificities and mode of 
action is summarized in Table 1. Some of these DNA glycosylases, including NEIL3 – a central 
player of the present thesis, remain poorly characterized (see later).  
AP sites are then incised at the 5’ end of the sugar moiety by the AP-endonuclease 1 
(APE1), generating a single nucleotide gap intermediate flanked by a 3’-OH and a 5’-
deoxyribose phosphate (dRP) end that blocks further processing of the site. In SP-BER, the 5’-
dRP residue is trimmed by the DNA polymerase β (Sobol et al., 1996) before gap filling 
synthesis and subsequent ligation of the repair intermediate by the XRCC1-DNA ligase 3α 
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complex (Tomkinson et al., 2001) in order to restore the original sequence. Alternatively, the 
AP site can be processed by the LP-BER sub-pathway, which is dependent on the proliferating 
nuclear antigen (PCNA), and relies on the combination of the DNA polymerases β/δ and ε 
which will fill the nick by strand displacement synthesis resulting in a flap of 2-10 nucleotides 
(Fortini et al., 1998; Frosina et al., 1996). Cleavage of the displaced DNA by the flap 
endonuclease 1 (FEN1) then takes place before sealing of the nick by DNA ligase 1. The choice 
between SP- and LP-BER is thought to be dependent on the specificity of the initiating DNA 
glycosylase (Fortini et al., 1999) and availability of BER factors, thus displaying important cell-
type specificity (Bauer et al., 2011; Tichy et al., 2011). 
Additionally, BER is also involved in the repair of SSBs (SSBR) in a sequence of events 
that involves recognition of the damaged termini by the poly(ADP-ribose) polymerase I 
(PARP1) factor (Caldecott 2008; Liu et al., 2017) and lesion processing by downstream 
proteins such as the polynucleotide kinase (PNK) that converts potentially improper 5’ or 3’ 
margins of the DNA break into 5’-phosphate and 3’-hydroxyl ends for further processing by 
SP-BER or LP-BER (Caldecott 2014). Thus, the SSBR mechanism is considered a related form 
of BER. 
 Direct modification of DNA bases such as methylation and oxidation are among the 
prominent lesions induced by the concomitant use of TMZ and IR. BER is the supported 
pathway for the repair of oxidized bases (detailed in section 3.3.1.) and the two major TMZ-
induced lesions, 7-meG which does not affect base pairing (Karran et al., 1982) and the more 
cytotoxic 3-meA adduct that blocks both replication and the transcription machineries (Larson 
et al., 1985). Of note, BER is a double-edged sword in the management of methylated base 
damage, since SSBs generated as repair intermediate during the repair process can induce 
DSBs if encountered by the replication fork (Ensminger et al., 2014) (detailed in chapter 
2.3.4.2.). Thus, these authors showed that MPG-defective cells which fail to remove N-
methylpurines from DNA and do not initiate BER, display strongly reduced levels of 
methylation-induced DSBs and chromosomal aberrations compared with wild-type cells. 
Interestingly, higher expression of the DNA glycosylase MPG has been shown to mediate TMZ 
resistance in GBM cells and associated to poor patient outcome (Agnihotri et al., 2014; 
Agnihotri et al., 2012; Liu et al., 2012). Although these and other authors have suggested that 
targeting BER factors might help potentiate TMZ cytotoxicity in GBM (Bobola et al., 2012), 
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inhibitors of DNA glycosylases are thus far restricted to small molecules targeting OGG1 
(Tahara et al., 2018) and NEIL1 (Jacobs et al., 2013), and their effect is still under investigation. 
Other BER targets include PARP1 for which several direct inhibitors (PARPi) have been 
developed (Michels et al., 2014).  
 
Table 1. Summary of the different subgroups of the mammalian DNA glycosylases and their main 
substrate specificity.  
Structural 
families 
Name Substrates DNA context 
Helix-hairpin-
helix (HnH) 
OGG1 
MYH 
8-oxoG DNA glycosylase 1 
MutY homolog  
8-oxoG, FaPy 
8-oxoG 
Opposite C and dsDNA 
Opposite A and dsDNA 
Uracil DNA 
glycosylase 
(UDG) 
UNG 
SMUG1 
 
MBD4 
TDG 
Uracil-N glycosylase 
Single-strand specific monofunctional 
uracil DNA glycosylase 1 
Methyl-binding domain glycosylase 4 
Thymine DNA glycosylase 
U, 5-FU 
 
 
T, U, 5-FU 
5-hmU, 5-fC 
 
ss and dsDNA 
 
opposite G and dsDNA 
Methyl-purine 
glycosylase 
MPG 3-methyl-purine glycosylase 3-meA, 7-meG, 
3-meG 
ss and dsDNA 
Endonuclease 
VIII-like (NEIL) 
glycosylase 
NTHL1 
 
NEIL1 
 
NEIL2 
NEIL3 
Endonuclease III-like 1 
 
Endonuclease VIII-like glycosylase 1 
 
Endonuclease VIII-like glycosylase 2 
Endonuclease VIII-like glycosylase 3 
Tg, 5-hC, 5-hU 
 
Tg, FapyG, Gh, 
Sh 
5-hU, 8-oxoG 
Gh, Sh, Tg 
dsDNA 
 
ss, bubble and G4 DNA 
 
ss and bubble DNA 
ds telomeric DNA and 
G4 structures 
5-fC, 5-formylcytosine; 5-FU, 5-fluorouracil; C, cytosine; ds, double strand; FaPy, 2,6-diamino-4-hydroxy-5-N-
methylformamidopyrimidinel; G4, G-quadruplex; Gh, guanidinohydantoin; h, hydroxyl; me, methyl; sh, 
spiroiminohydantoin; ss, single strand; T, thymine; Tg, thymine glycol; U, uracil. * M, monofunctonal; B, 
bifunctional. Adapted from (Jacobs and Schaer 2012, Dou et al., 2003 and Zhou et al., 2013). 
 
Their mode of action is based on the formation of persistent PARP1-SSB complexes that lead 
to replication fork collapse and the formation of DSBs requiring HR-mediated repair. Hence, 
PARPi are particularly effective in the context of synthetic lethality in tumors with defective 
HR components like BRCA1 or BRCA2, which are unable to repair DSBs induced by PARP 
inhibition (Lord and Ashworth 2017). Targeting of PARP1 in GBM appears appealing as several 
studies have highlighted the radio- (Lesueur et al., 2018) and TMZ chemotherapy (Carruthers 
and Chalmers 2012) sensitizing effect of different PARPi molecules on GBM cells in vitro and 
in preclinical settings (Jannetti et al., 2018). In addition, it has been suggested that the 
expression levels of both MPG and POLβ modulate the cytotoxic effect of TMZ in glioma cells, 
in combination with the inhibition of BER through PARPi and methoxyamine (Tang et al., 
2011). To date, phase I clinical trials combining standard-of care chemoradiotherapy and 
 23 
 
 CHAPTER 1 
PARPi (olaparib, veliparib) are under investigation in both newly diagnosed (Fulton et al., 
2018) and recurrent GBM patients (Robins et al., 2016). Unfortunately, the trial initiated by 
Robins et al did not unveil any significant improvement in the progression free survival (PFS) 
of recurrent GBM patients. Although patient stratification may facilitate the implementation 
of such trials and reveal PARPi-driven survival benefits, it should be noted that synthetic 
lethality with PARP inhibition can be mediated by various defects in a plethora of DNA repair 
pathways (Michels et al., 2014) and it is currently impossible to predict sensitivity to PARPi 
based on gene expression (McGrail et al., 2017). Other BER factors like APE1 and POLβ have 
been shown to be promising targets in tumor treatment strategies. Firstly, the use of 
molecules like lucanthone or methoxyamine, which bind to the abasic site thus preventing 
their processing by APE1, have been shown to potentiate TMZ cytoxicity in vitro (Abbotts and 
Madhusudan 2010; Luo and Kelley 2004). Interestingly, methoxyamine is currently tested in 
a phase II clinical trial in combination with TMZ in recurrent GBM patients (NCT02395692). 
Although POLβ is overexpressed in several human tumors (Albertella et al., 2005) and was 
proposed as a promising target for sensitization of tumor cells to TMZ, none of the small 
molecule inhibitors developed so far have demonstrated high specificity against this enzyme 
(Goellner et al., 2011).  
2.3.4. Double-strand break repair (DSBR)  
Double strand breaks (DSBs) are the most threatening forms of DNA lesions; if 
misrepaired or unrepaired, they can lead to chromosomal rearrangements, chromosomal 
loss, carcinogenesis or cell death. In order to preserve genome integrity, cells rely on two 
major pathways, non-homologous end-joining (NHEJ) and homologous recombination (HR). 
Importantly, the activity of HR and NHEJ is cell cycle dependent. HR is activated during the 
S/G2 phase when a homologous duplex (a sister chromatid) is present which can serve as 
template for repair. In contrast, NHEJ acts through most of the cell cycle but is most 
prominent in the G1 phase. In addition, HR is considered an error free mechanism whereas 
NHEJ, which simply apposes, processes and ligates the broken DNA ends, is an error-prone 
mechanism.  
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The following paragraphs detail NHEJ and HR, emphasizing those factors that have 
been shown to play a role in the response of GBM cells to TMZ. Figure 12 illustrates these 
pathways as well as additional DSBR pathways such as the micro-homology mediated sub-
pathway of NHEJ (alt-EJ or alt-NHEJ) and the SSA pathway, whose involvement in GBM 
remains undocumented.  
2.3.4.1. Non-homologous end-joining (NHEJ) 
DSBR mediated by NHEJ is based on the juxtaposition and direct ligation of the two 
DSB ends (Chiruvella et al., 2013). The repair process can be subdivided in the canonical NHEJ 
(c-NHEJ) and the alternative NHEJ (alt-NHEJ) sub-pathways (Figure 12A and B) that are both 
error-prone, frequently resulting in small genomic rearrangements at the break site or 
chromosomal translocations when DNA ends from different parts of the genome are joined 
(Lieber 2010). For instance, NHEJ plays a central role in mediating chromosome end-to-end 
fusions at telomeres with compromised structural integrity (details in section 3.3). 
Classical NHEJ (c-NHEJ) operates during the whole cell cycle. The core c-NHEJ 
machinery encompasses the DNA-dependent protein kinase (DNA-PK) complex formed of the 
DNA end-binding Ku70/80 heterodimer and the DNA-PK catalytic subunit (DNA-PKcs). The 
Figure 12. Overview of the major DNA double-strand break repair pathways. The extent of DNA end resection, 
incurred by the broken ends, which is under complex regulation, is a crucial parameter in determining the choice of 
DSBR pathway. A. In the absence of resection, repair through error-prone c-NHEJ will be favoured. B-D. End resection 
of the broken ends generates 3’OH-ended ssDNA tails that can be engaged by alt-NHEJ (B) or HR leading to strand 
invasion of a homologous, intact duplex DNA (C), or expose regions of complementary DNA allowing repair by SSA 
(D). See text for details (adapted from Ceccaldi et al., 2015).  
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repair process is divided into several sequential steps starting with the recognition of the DNA 
ends by the Ku70/80 heterodimer which protects the DNA ends from degradation, juxtaposes 
them, activates DNA-PKcs and serve as a scaffold for the recruitment of downstream NHEJ 
factors (Gottlieb and Jackson 1993; Hammel et al., 2010; Mari et al., 2006). This step is 
followed by DNA end processing in order to create ligatable ends and finally ligation of both 
DNA extremities by DNA ligase IV/XRCC4. Interestingly, inhibition of DNA-PKcs enhances TMZ 
therapy (Lan et al., 2016) and radiosensitizes GBM cells both in vitro and in vivo (Timme et al., 
2018). Moreover, the DNA-PK specific inhibitor CC-115 has been tested in a phase I trial 
(Munster et al., 2017) and is currently being tested in combination with TMZ in a GBM-specific 
phase II trial (NCT02977780). Other factors such as Artemis are involved in NHEJ, for instance 
for processing of the DNA ends when they are not clean (i.e. when they are generated by IR), 
to facilitate DNA ligation (Chang and Lieber 2016). 
On the other hand, alt-NHEJ is mostly active during the S/G2 phase of the cell cycle 
and is based on DNA end-joining facilitated by micro-homologies fortuitously exposed in the 
two DNA ends. The enzymatic mechanisms of alt-NHEJ are less well defined than for c-NHEJ. 
This pathway is independent of the c-NHEJ factors like DNA-PK, relying instead on the SSB 
sensor PARP1 (Audebert et al., 2004; Della-Maria et al., 2011), which can also recognize DSBs 
(Audebert et al., 2006; Yang et al., 2018). Interestingly alt-NHEJ is suppressed by the Ku70/80 
heterodimer, implying a competition between c- and alt-NHEJ for binding DSBs (Wang et al., 
2006). Also involved in alt-NHEJ are DNA ligase III  (Lig3 ) and DNA ligase I (Lig1) (Audebert 
et al., 2004). As PARP1 is required in alt-NHEJ, PARPi are thought to be an attractive target for 
therapy in cancer associated with increased alt-NHEJ capacity. PARPi under investigation in 
GBM are described in section 2.3.3. Of note, alt-NHEJ pathway components have also been 
proposed as therapeutic targets in high-risk neuroblastoma (Newman et al., 2015). In this 
context, specific DNA ligases such as Lig3α appear potentially attractive in the targeting of alt-
NHEJ proficient tumors and are currently under investigation (Tomkinson et al., 2013).  
2.3.4.2. Homologous recombination (HR) 
HR is the pathway of choice for the error-free repair of DSBs as it utilizes a 
homologous, intact DNA duplex as template for repair of the broken DNA (Figure 12C).  
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The process is more prevalent during DNA replication at the S/G2 phase, since 
identical sister chromatids are already available as template for repair (Beucher et al., 2009). 
Essential HR steps include DNA end resection to provide 3’-ended ssDNA strands on which 
the RAD51 recombinase will assemble filaments that initiate DNA strand invasion. DNA end 
resection is a highly regulated process that only occurs in the S and G2 phases of the cell cycle 
and involves several factors including the MRN complex (endonuclease activity), exonuclease 
1 (EXO1), and the helicase Bloom syndrome protein (BLM). This process generates 3’-OH 
ending single-stranded DNA tails that are initially bound by the heterotrimer ssDNA binding 
protein RPA. The RAD51 recombinase will then assemble filaments on RPA-coated ssDNA, in 
the presence of mediators such as BRCA2 and PALB2, and these “presynaptic” filaments 
initiate the search for homologous DNA on the sister chromatid and engages strand exchange. 
This step, called synapsis, leads to the formation of a displacement (D)-loop that can be 
subjected to different subpathways, with different genetic outcomes (Li and Heyer 2008). In 
one such mechanism, the D-loop is extended during elongation of the invading strand by DNA 
synthesis and captured by the second DNA end. Further DNA synthesis based on the 
complementary information present on the sister chromatid, followed by ligation, ensure 
error-free DNA repair. The two duplexes are connected by four-way DNA structures called 
Holliday junctions. Holliday junction resolution is mediated by two different nucleases, the 
MUS81/EME1 complex or GEN1, which process the structure differently with the possibility 
to induce DNA crossovers (Matos and West 2014). The repaired sequences are then ligated, 
restoring the two DNA strands (Wright et al., 2018). Additionally, a complementary repair 
process, named single-strand annealing (SSA), is also involved in DSBR but is independent of 
strand invasion and instead uses resected DNA ends to anneal exposed complementary 
sequences in order to complete repair (Bhargava et al., 2016) (see Figure 12D).  
Inhibition of the HR in cancer cells is enticing but the intricacy of the pathways involved 
and the complexity of its regulation mechanisms limit the therapeutic potential of HR 
targeting. Nevertheless, novel strategies emerge that exploit the synthetic lethality 
relationship between BRCA mutated tumor cells (HR-deficient) and their propensity to be 
more sensitive to PARPi as discussed in section 2.3.3. To date, very few direct inhibitors of HR 
factors have been developed. Interestingly, several RAD51 inhibitors have been shown to 
induce radiosensitization (Budke et al., 2012; King et al., 2017) and enhance the sensitivity of 
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GBM cells to the alkylating drug CCNU (Berte et al., 2016). Moreover, the use of histone 
deacetylase inhibitors (HDACi) like valproic acid or vorinostat was shown to radiosensitize 
tumor cells by indirect inhibition of the DSB repair machinery and are under clinical trials in 
different cancers (Groselj et al., 2013) including GBM (Kamrava et al., 2008).  
It is important to note that the collision of the DNA replication fork with single-
stranded DNA (ssDNA) gaps, for instance those generated during MMR processing of O6-meG 
left unrepaired by MGMT or during BER, gives rise to single-ended DSBs (seDSBs) as opposed 
to the classical two-ended DSBs generated by IR (Li and Heyer 2008). The repair of seDSBs 
also involves the HR and NHEJ machineries, including a mechanism of recombination-
dependent DNA replication called break-induced replication (BIR) (Anand et al., 2013; Sotiriou 
et al., 2016). 
In summary, the repair of both endogenous and exogenous DNA lesions involves 
multiple, often redundant DNA damage pathways that are under the control of complex 
regulatory mechanisms. In this context, it is important to note that several genetic and 
epigenetic alterations described in GBM have been shown to directly influence DNA repair, 
thus impacting treatment efficacy. For instance, IDH1 mutation and EGFRvIII have been 
shown to promote TMZ and radio-resistance by promoting RAD51-mediated homologous 
recombination (Ohba et al., 2014) and double strand break repair initiation by DNA-PKcs 
(Mukherjee et al., 2009), respectively. On the other hand, alterations seen mainly in pediatric 
GBMs such as the specific G34 mutation in H3.3 (Schwartzentruber et al., 2012) and its histone 
chaperone ATRX (Conte et al., 2012), sensitized GBM cells to DNA damage and thus are 
associated to better survival.  
The complexity of these processes represents a crucial challenge in the development 
of efficient therapeutic strategies and the care of GBM patients. DNA repair inhibition in 
combination with genotoxicants is still a fairly new approach in many cancers, thus 
identification of DDR factors involved in the response of GBM cells to the current therapy 
remains a crucial step towards the improvement of the standard-of-care for newly diagnosed 
and recurred GBM patients.  
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3. Telomere homeostasis and the immortal phenotype of cancer cells 
Telomeres, the physical ends of linear eukaryotic chromosomes, are constituted of duplex 
repetitive, non-coding TTAGGG sequences (between 9-15 kb in size) that terminate with a 
single-stranded, G-rich overhang (about 50 to 300 nt in size) (de Lange 2005). Telomeres act 
as disposable DNA buffers, which are truncated after each cell division, to circumvent the end 
replication problem (Wynford-Thomas and Kipling 1997), thereby preventing senescence and 
cell death that occur if telomere length falls below a critical threshold (the so-called Hayflick 
limit) (Shay and Wright 2005), and protecting upstream protein-coding regions.  
Responsible for the maintenance of proper telomere length is the nucleoprotein 
reverse transcriptase called telomerase, composed of a catalytic subunit (TERT) and a RNA 
component (TERC) which serves as template for the synthesis of TTAGGG repeats (Blackburn 
2005). Active in normal stem cells, telomerase undergoes strong negative regulation in all 
other cell types (Cifuentes-Rojas and Shippen 2012; Wright et al., 1996). However, 
reactivation of a telomere maintenance mechanism (TMM) is a crucial step during 
tumorigenesis in order to ensure telomere homeostasis and enable limitless replicative 
potential (Hanahan and Weinberg 2011). Importantly, telomerase reactivation is the TMM 
observed in 90% of cancers (Shay and Wright 2011) while telomerase-negative cancer cells 
use a recombination-based mechanism called Alternative Lengthening of Telomeres (ALT) to 
maintain telomere length (Reddel 2003). 
3.1. Telomere structure, function and maintenance  
Telomeres are bound by a protein complex named shelterin formed of TRF1, TRF2, POT1, 
TPP1, TIN2 and RAP1 (de Lange 2005) (Figure 13A). These proteins protect chromosome ends 
from DNA degradation and from being recognized as DNA ends by the DSB repair machinery, 
thus preventing end-to-end fusions (de Lange 2005). TRF1 and TRF2 are tightly bound to the 
duplex telomeric DNA (Hanaoka et al., 2005), whereas the TPP1-POT1 heterodimer binds the 
3’ single-stranded overhang (Wang and Lei 2011). RAP1 can also bind the telomeric sequence 
and interacts with TRF2 (Li et al., 2000) whereas TIN2 is the cornerstone of the complex as it 
interconnects TRF1/2 and TPP1/POT1 into a single entity (Ye et al., 2004). Finally, TRF2 can 
mediate the invasion of the 3’ single-stranded overhang into duplex telomere sequences, 
leading to a displacement (D)-loop which allows telomere looping into a lariat structure called 
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t-loop (telomere-loop) that protects the 3’-end (Griffith et al., 1999) (Figure 13B). Importantly, 
the t-loop prevents the activation of the ATM-dependent DNA damage signalling and end-
joining by the NHEJ machinery. In addition, POT1 bound to the t-loop prevents ATR-
dependent DNA damage signalling and, together with Rap1, negatively regulates the action 
of the HR machinery at telomeres (Schmutz and de Lange 2016). Although crucial for telomere 
capping, TRF1 and TRF2 also promote safe and efficient processing of telomeric DNA during 
replication (Sfeir et al., 2009; Ye et al., 2010) by orchestrating the dissolution of the t-loop 
mediated by the RTEL1 helicase (Sarek et al., 2015). 
Notably, telomeres are rich in guanine and it has been shown that consecutives runs of 
guanine, preferentially in the 3’ single-stranded overhang of telomeres can fold into a four-
stranded DNA structure known as G-quadruplex (G4) (Biffi et al., 2013). Importantly, G4 in 
telomeric DNA (Williamson 1994) inhibit the telomerase activity (Wang et al., 2011) (Figure 
Figure 13. Salient features of human telomeres. A. Schematic description of telomeres, the shelterin complex and 
telomerase. Shown are the various proteins composing the shelterin complex that protects telomeres, as well as the 
4 scaffold proteins (dyskerin, NOP10, NHP2, and GAR) associated with telomerase, itself composed of an RNA 
template (TERC) and a reverse transcriptase TERT subunit (adapted from Townsley et al., 2014). B. In a reaction 
mediated by TRF2, the G-rich 3’-overhang invades the telomeric duplex DNA to create a displacement (D)-loop that 
is stabilized by POT1, and the telomere folds back on itself forming a lariat structure known as the T-loop (adapted 
from de Lange et 2005). C. The 3’ G-rich overhang at the telomeres can form G-quadruplex structures involved in 
telomere end protection and regulation (adapted from Rhodes et al., 2015). D. Telomeres are transcribed into long 
non-coding RNAs called TERRAs which originate from the subtelomeric region. TERRA transcripts can be redirect and 
associated to the telomeres and regulate telomere homeostasis. See text for details. 
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13C). As will be seen below, G-quadruplex structures also influence the repair of oxidative 
DNA damage.  
For a long time, it was thought that telomeres were transcriptionally inactive due the 
presence of specific “silencing” histone modifications (like H3K9me3) typically found in 
heterochromatic regions (such as the pericentromeric regions), as well as the presence of 
methylated CpG islands in subtelomeric regions (Schoeftner and Blasco 2010). Nevertheless, 
long non-coding (lnc) telomeric repeat-containing RNAs (TERRAs) were found to be 
transcribed from telomeres throughout eukaryotes (Azzalin et al., 2007; Cusanelli and 
Chartrand 2015; Schoeftner and Blasco 2008) (Figure 13D). The transcription of TERRA 
molecules originates in the subtelomeric region. Thus, TERRAs consist of chromosome end-
specific subtelomeric sequences with telomeric repeats at their 3’ ends. These lncRNAs play 
several critical roles in telomere biology, including the regulation of telomerase activity and 
heterochromatin formation at chromosome ends (Deng et al., 2009). The emerging evidence 
indicates that a considerable fraction of the TERRAs are mostly present in non-chromatin-
associated RNA pools (Porro et al., 2010) and that they preferentially associate with their 
telomere of origin forming RNA:DNA hybrids known as R-loops (Balk et al., 2013; Cusanelli 
and Chartrand 2015). When bound to telomeres, TERRAs are thought to either affect 
telomere homeostasis, negatively by direct inhibition of the telomerase (Redon et al., 2010) 
or positively by promoting the lengthening of shortened telomeres they are associated to 
(Cusanelli et al., 2013). Moreover, TERRA expression has been proposed to participate in 
telomere protection by preventing activation of the DDR at the telomeres during replication. 
Interestingly, deregulation of TERRAs was shown to induce widespread telomere dysfunction 
(Lopez de Silanes et al., 2014). The function and regulation of TERRAs in cells remains a subject 
of intense investigation, especially in the context of cancer where TERRAs represent an 
appealing target for novel treatment strategies. 
3.2. Reactivation of a telomere maintenance mechanism (TMM) in cancer: 
specificities of glial tumors 
Reactivation of the telomerase is generally mediated by activating somatic mutation of 
the TERT gene promoter (TERTp) or amplification of both subunits of telomerase TERT/TERC 
(Gaspar et al., 2018). Notably, ectopic expression of the telomerase catalytic subunit alone is 
sufficient to immortalize normal human cells (Bodnar et al., 1998). In contrast, the modalities 
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and molecular details underlying the establishment of the ALT pathway remain largely 
unknown (Brosnan-Cashman et al., 2018; Nabetani and Ishikawa 2011), although its 
prevalence in specific cancer types such as sarcomas and low-grade gliomas is associated to 
mutations in the H3.3 chaperones ATRX and DAXX (Amorim et al., 2016; Brosnan-Cashman et 
al., 2018; Liau et al., 2015). These two different TMMs are thought to be mutually exclusive 
and their representation throughout all tumor types is very diverse. 
Compared to other high-grade solid tumors, GBM patients present the highest prevalence 
of TERTp mutations (about 80% of cases) (Boldrini et al., 2006; Killela et al., 2013). Intriguingly, 
reactivation of telomerase is predominant in adult GBMs (80%) and less so in low-grade 
gliomas and pediatric GBMs where ALT is more frequently observed (44%) (Killela et al., 2013; 
Sturm et al., 2014). Recent studies have examined the prognostic value of telomerase-
associated parameters like telomerase activity, telomere length and expression of its catalytic 
subunit, in relation to GBM. Expression of hTERT in GBM patients was found to be associated 
with higher telomerase activity and adverse prognosis (Boldrini et al., 2006). Additionally, in 
a cohort of GBM patients harboring TERTp mutations, poor prognosis was confined to the 
patients who also displayed a specific SNP (rs2853669) in the promoter region of hTERT 
(Simon et al., 2015; Spiegl-Kreinecker et al., 2015). Since overexpression of hTERT in normal 
human fibroblasts cells enhances their DNA repair capacity (Shin et al., 2004), it is possible 
that the increased hTERT expression observed in GBM tumors impacts their resistance to 
genotoxicants and thus patient survival. In line with this notion, several studies have 
demonstrated that targeting telomerase either by RNAi-mediated depletion of hTERT 
(Masutomi et al., 2005), direct inhibition using the antagonist imetelstat in GSCs (Marian et 
al., 2010)or in a murine orthotopic mouse model (Ferrandon et al., 2015), or indirect 
restriction of telomerase activity by stabilization of G-quadruplexes using G4-specific ligands 
(Merle et al., 2011), enhanced the sensitivity of GBM cells in vitro and in vivo to IR. 
Furthermore, a similar observation was made in an ALT-positive preclinical model of GBM 
treated with G4 ligands (Jeitany et al., 2015). These findings demonstrate that the reactivation 
of a TMM is not only important for telomere homeostasis but can also indirectly influence 
other cellular pathways important for the fitness of tumor cells.  
3.3. Impact of DNA damage at the telomeres and its repair  
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In addition to maintaining proper telomere length, ensuring telomere integrity by protecting 
against DNA lesions has evolved as a critical task in cancer cells. Telomeres are notably prone 
to oxidative stress (Kawanishi and Oikawa 2004) and represent preferential sites of persistent 
DNA damage (Coluzzi et al., 2014; Hewitt et al., 2012). Given the reactivity of guanine toward 
oxidative stress, their abundance in telomere repeats and their propensity to generate G4 
structures that modify their oxidation potential compared to duplex DNA (Fleming and 
Burrows 2013), protection at the telomeres is particularly required against oxidative guanine 
damages. Thus, 8-oxoG, the major lesion induced by oxidative stress on DNA, present in the 
telomere sequence or within the dNTP pool, regulates telomerase activity (Fouquerel et al., 
2016) and disrupts the shelterin complex (Opresko et al., 2005). In addition, the low redox 
potential of 8-oxoG makes it a target for further oxidation into DNA modifications like the 
hydantoins guanidinohydantoin (Gh) and spiroiminohydantoin (Sh) (Luo et al., 2000; Luo et 
al., 2001) which have been shown in vitro to destabilize DNA replication substrates (i.e. primer 
extension substrates) to a much greater extent than 8-oxo-G (Kornyushyna et al., 2002). 
Furthermore, compared to 8-oxoG, these lesions are more mutagenic (Henderson et al., 
2003) and have been shown to impede transcription by blocking RNA polymerase II 
(Kolbanovskiy et al., 2017). Whereas 8-oxoG is efficiently removed by BER when present in 
duplex DNA (David et al., 2007), it is poorly repaired when present in single-stranded or G4 
contexts and causes significant distortion of the G4 structure (Jia et al., 2015; Zhou et al., 
2015). Likewise, Gh and Sh lesions were not a substrate for BER DNA glycosylases when 
present in G4 structures formed at specific gene promoters (i.e., MYC, VEGF) (Fleming et al., 
2017). 
However, recent studies using telomere G4-related oligonucleotides with an additional 
repeat, as well as similar substrates mimicking G4 structures forming at gene promoters, have 
uncovered a novel mechanism whereby a fifth G-track located a few nucleotides distant from 
the guanine tracks forming the G4 structure could act as a spare tire, facilitating extrusion of 
the damaged track to preserve intact G4 folding (in case of 8-oxoG lesions) (An et al., 2016) 
or facilitate BER (in case of Gh and Sh lesions) (Fleming et al., 2015).  
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Under normal conditions, DNA repair needs to be harnessed at telomeres to prevent 
activation of the DDR resulting in end-to-end fusions. This role is devoted in part to the 
shelterin component TRF2 which can repress ATM-mediated DNA damage signalling 
(Karlseder et al., 2004) as well as NHEJ at telomeres (Bae and Baumann 2007). However, 
telomere uncapping can result from critical shortening of telomeres or loss of telomere-
protective factors such as TRF2 (Takai et al., 2003) (see Table 2). Due to their resemblance 
with damaged DNA, uncapped telomeres might become associated with DNA damage 
response factors such as 53BP1, phosphorylated H2AX and ATM, and the co-localization of 
these factors at the chromosome ends is termed telomere dysfunction induced foci (TIF) 
(Takai et al., 2003). To note, unlike genomic breaks, deprotected telomeres do not induce 
direct DDR-dependent proliferation arrest signalling but instead are passed on to the 
daughter cells to induce p53-dependent growth arrest in stable diploid G1 phase cells to 
Figure 14. Telomere dysfunction, activation of the DDR and end-to-end fusion. A. “Healthy” telomeres are fully 
protected from DNA damage signalling and the action of NHEJ through proper capping by the shelterin complex. 
Progressive telomere shortening (e.g., following DNA replication) or loss of telomere integrity activates the DDR 
resulting in the formation of TIFs. Depending on the extent of deprotection, such telomeres may still able to prevent 
NHEJ. However, exacerbation of telomere deprotection ultimately triggers not only DNA damage signalling but also 
NHEJ-mediated telomere fusions. NHEJ, non-homologous end joining (adapted from Price 2012). B. Representative 
image of telomere fusions in metaphase spreads of TIN2-deficient MEFs. Green, C-rich telomere PNA probe; red, 
DAPI DNA stain (adapted from Frescas and de Lange, 2014). C. Example of telomere dysfunction induced foci (TIF) 
by co-localization (white arrows) of 53BP1 (immunofluorescence, red) and telomeres (FISH, green) in TIN2-deficient 
MEFs (adapted from Frescas and de Lange, 2014). 
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ensure proper repair before genome instability can occur (Cesare et al., 2013).  Severe loss of 
telomere integrity results not only in TIFs but also in the activation of the DSBR machinery, 
notably c-NHEJ, at telomeres leading to chromosome end-to-end fusions (Smogorzewska et 
al., 2002) (Figure 14).  
Interestingly, sister chromatid fusions might promote tumorigenesis by initiating gene 
amplification processes frequently observed in human tumors (Lo et al., 2002). Recent 
findings also indicate that both TERRA downregulation and their unplanned accumulation at 
telomeres is associated with activation of DDR at the chromosome ends (Deng et al., 2009; 
Lopez de Silanes et al., 2010). Moreover, TERRA transcripts promote structural changes in the 
chromatin of uncapped telomeres (Porro et al., 2014) thus participating actively in the DDR 
response at dysfunctional chromosome ends.  
 
Table 2. Representative gene alterations impacting telomere homeostasis. 
Gene Alteration Global effect Impact at telomeres References 
NTHL1 Deletion Defective 
repair of 
oxidative base 
lesions 
Telomere fragility in 
mice and length 
attrition in telomerase 
negative cells 
Vallabhaneni 
et al., 2013 
OGG1 Deletion  
(S. cerevisae) 
 
 
Deletion  
(M. musculus) 
 
Increase in 
oxidized guanine 
levels 
 
Telomere lengthening 
and reduction of 
telomere bound proteins 
 
Telomere shortening in 
mouse embryonic 
fibroblasts in normoxia 
conditions 
Lu et al., 2010 
 
 
Wang et al., 2010 
POT1 
 
Deletion NA DDR activation and 
aberrant HR 
Wu et al., 2006 
 
TERRA Upregulation 
 
Accumulation 
 
NA 
 
NA 
In the absence of active 
TMM induces telomere 
shortening 
In the absence of 
telomerase and presence 
of HR induces telomere 
lengthening 
Maicher et al., 2012 
Yu et al., 2014 
TERC Deletion  
(M. musculus) 
Abnormalities in 
mutiple organs 
Shortened telomeres 
after several generations 
of terc-/- intercrosses 
Argilla et al., 2004 
TRF2 Deletion Induction of 
apoptosis or cell 
senescence 
Telomere uncapping 
Activation of DDR 
inducing TIFs and 
telomere end-to-end 
fusions 
Karlseder et al., 1999 ; Takai 
et al., 2003 
DDR, DNA damage response; HR, homologous recombination; NA, not available; TIF, telomere dysfunction-
induced foci; TMM, telomere maintenance mechanism.  
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3.3.1. The NEIL3 DNA glycosylase: its function in the repair of telomeric 
DNA damage and tumor development  
As stated before, BER is the predominant pathway for the repair of oxidative DNA base 
damage (Krokan and Bjoras 2013). To date, five mammalian DNA glycosylases are specialized 
in the repair of oxidative DNA damage: the 8-oxoguanine-DNA glycosylase (OGG1) which acts 
mostly on purines (8-oxoG lesions), the endonuclease three homolog 1 (NTHL1) that 
processes mainly pyrimidine lesions (5-hydroxy lesions) and finally the three members of the 
Nei Endonuclease VIII-Like (NEIL) family, NEIL1, NEIL2 and NEIL3. The substrate specificities 
and the DNA context in which these DNA glycosylases operate, is detailed in Table 1. 
In contrast to OGG1 and NTHL1, the NEIL DNA glycosylase family is specialized in the 
removal of the more complex oxidative DNA lesions in specific DNA contexts. Specifically, 
NEIL1 is preferentially involved in the removal of oxidized purines such as Gh and Sh in duplex 
DNA (Krishnamurthy et al., 2008; Zhao et al., 2010) as well as in the replication-dependent 
repair of oxidized pyrimidines (5-hydroxyuracil, formamidopyrimidines) in single-stranded, 
bubble, and forked DNA structures (Dou et al., 2003). Meanwhile, NEIL2 primarily intervenes 
in the transcription-coupled repair of oxidized pyrimidines, removing lesions present in single-
stranded and bubble DNA structures (Dou et al., 2003). Contrasting with NEIL1 and NEIL2 
which show very similar substrate specificity, NEIL3 displays distinct properties that translate 
into a preference for DNA damage present in specific DNA regions, as detailed in the next 
section. 
3.3.1.1. NEIL3 structure and activity towards oxidized guanine lesions  
The NEIL3 gene sequence encodes a protein of 605 amino acids that is composed of 
an N-terminal Nei-like glycosylase domain (GD), a DNA-binding domain (DB) of the helix-two-
turn-helix type (H2TH), two zinc finger domains, as well as a nuclear localization sequence 
(NLS) that allows its translocation into the nucleus. What distinguishes NEIL3 from its family 
members is a long intrinsically disordered C terminal domain (CTD) (Liu et al., 2010; Liu et al., 
2013) (Figure 15A). The biochemical characterization of NEIL3 glycosylase domain revealed a 
distinct preference for the removal of oxidative DNA lesions like Gh and Sh (Krokeide et al., 
2013). Furthermore, NEIL3 preferentially removed Gh and Sh guanine lesions in G4 
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quadruplex DNA structures present at the telomeres and in promoter regions (Zhou et al., 
2015; Zhou et al., 2013). Intriguingly, in the same study, NEIL1 was also found to be involved 
in the removal of oxidized lesion in G4 structures but showed a preference for Gh lesions 
compared to NEIL3 which excised Tg, Gh and Sh with higher efficiency in the telomere 
sequence context (Zhou et al., 2013). Importantly, a recent study unveiled that NEIL3 could 
be directly mobilized to the telomeres through its disordered CTD domain (Zhou et al., 2017). 
Specifically, the authors made the important observation that the shelterin subunit TRF1 was 
able to actively recruit the enzyme to the telomeres by direct protein-protein interaction in 
order to initiate BER-mediated repair of telomere damage during the S phase of the cell cycle 
(Zhou et al., 2017). Moreover, siRNA-mediated knockdown of NEIL3 in human colorectal 
carcinoma (HCT116) cells induced dysfunctional telomeres with an increase in telomere loss 
and sister chromatid fusions, thus correlating the in vitro functional studies and supporting a 
Figure 15. Structure of NEIL3, its substrates and role in the unhooking of ICLs. A. Schematic overview of the 
structural features of NEIL3 and the other NEIL glycosylase family members (NEIL1/2). The three enzymes present a 
similar N-terminal sequence with the presence of a large glycosylase domain (grey), a conserved N-terminus (black), 
a helix-2-turn-helix DNA binding motif (red), a Fpg/Nei family specific DNA binding Zinc finger motif present in NEIL1 
and NEIL3 (green square) while NEIL2 displays a zincless finger motif (green sphere). Compared to its family 
members, NEIL3 has a large disordered C-terminal sequence that harbors two more zinc finger motifs (blue and 
yellow) whose functions are not  characterized to date (adapted from Liu et al., 2013). B. Summary of the DNA lesions 
recognized and processed by NEIL3. Top panel: oxidized guanine lesions guanindinohydantoin (Gh) and 
spiroiminohydantoin (Sh). Bottom panel: Exogenous psoralen-induced inter-strand crosslink (ICL) and endogenous 
abasic site ICL generated after spontaneous depurination or the action of DNA glycosylases during the BER-mediated 
repair of a damaged base (adapted from Semlow et al., 2016). C. NEIL3 is involved in the replication-coupled 
unhooking of ICLs. The process involves cleavage of the N-glycosyl bond at the lesion site, releasing an abasic site on 
one strand and the crosslinked bases on the other strand. The replication fork is then free to resume replication and 
the remaining lesions are subsequently repaired (adapted from Semlow et al., 2016).  
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direct role of NEIL3 in telomere homeostasis in vivo. It must be noted that the DNA 
glycosylases NTHL1 and OGG1 have also been indirectly implicated in the protection of 
telomere integrity. Intriguingly, OGG1 loss in S. cerevisae induced telomere lengthening 
through increased oxidative DNA damage (Lu and Liu 2010), meanwhile OGG1 deletion in 
mouse embryonic fibroblasts (MEFs) had opposite effects in normoxia and hypoxia conditions 
with the observation of telomere shortening and lengthening (Wang et al., 2010), 
respectively. Moreover, NTHL1 knockout mouse cells displayed telomere fragility due to 
defective repair of oxidative base lesions and telomere shortening (Vallabhaneni et al., 2013), 
further implying the peculiar role of BER-mediated repair of oxidative telomere DNA damage. 
Alterations in several representative DNA repair and telomere factors, and their impact on 
telomere homeostasis are summarized in Table 2.  
Finally, a BER-independent function has also been identified for NEIL3. Indeed, NEIL3 
was described as a primary unhooking mechanism for specific DNA interstrand cross-links 
(ICLs) associated with psoralen and abasic sites (Figure 15B), through its DNA glycosylase 
activity (Semlow et al., 2016) (Figure 15C). For instance, NEIL3 was found to incise psoralen-
induced ICLs in four-stranded DNA structures (Martin et al., 2017).   
3.3.1.2. NEIL3 expression signature and function in normal and tumor 
cells 
High expression of NEIL3 seems to be confined to cells with a high proliferative 
potential, such as neural and hematopoeitic stem cells (Hildrestrand et al., 2009; Reis and 
Hermanson 2012), while it appears to be repressed in non-dividing cells (Neurauter et al., 
2012). In newborn mice, expression of Neil3 was specifically observed in subregions of the 
brain where neurogenesis takes place, such as the subventircular zone, and decreased during 
development (Hildrestrand et al., 2009). This study was further correlated with the 
observation that homozygous depletion of the gene induced defects in adult progenitor cell 
populations (Regnell et al., 2012). Although the in vivo function of NEIL3 remains unclear, it 
was shown to regulate neurogenesis after a hypoxic-ischemic event in mice (Sejersted et al., 
2011) and promote cardiac fibroblast proliferation after myocardial infarction (Olsen et al., 
2017). Moreover, a recent study demonstrated that triple negative Neil DNA glycosylase 
deficient mice (Neil1-/-, Neil2-/- and Neil3-/-) showed no increased propensity to cancer or 
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higher mutation frequencies and that MEFs did not accumulate oxidative DNA damage and 
neither telomere length was affected (Rolseth et al., 2017). 
In addition, NEIL3 was shown to be significantly upregulated in a panel of 16 different 
tumor tissues (Hildrestrand et al., 2009). Particularly, analysis of the TCGA database revealed 
the upregulation of NEIL3 and concomitant downregulation of NEIL1 and NEIL2 in a subset of 
different cancer types. Deregulation of the whole NEIL glycosylase family was further 
associated with increased somatic mutation load (Shinmura et al., 2016). Of note, this study 
covered 13 cancer types but not GBM. However, a study on GBM patients in the Han Chinese 
population found that a specific single nucleotide polymorphism in NEIL3 (rs12645561) was 
associated with the occurrence of GBM (Jin et al., 2013). Furthermore, NEIL3 knockdown was 
shown to reduce cell proliferation and increase sensitivity to the oxidative stress inducer 
paraquat and the DNA crosslinking agent cisplatin in mouse embryonic fibroblasts (Rolseth et 
al., 2013) and to ATR inhibitors in GBM cells (Klattenhoff et al., 2017).  
Although the available evidence pinpoints NEIL3 as a potential target in cancer cells, 
its role in telomere homeostasis, specifically in relation to glioma development and 
chemoresistance, remains vastly unexplored. 
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Today still, most anti-cancer treatments rely heavily on genotoxicants or IR to induce 
tumor cell death through accumulation of DNA damage. Because tumor cells respond to these 
insults by engaging the DNA damage response and executing complex DNA repair pathways, 
targeting components of these mechanisms has emerged as an important therapeutic approach 
against many cancers. At the same time, predicting tumor response to DNA damaging agents 
remains a challenge that is exacerbated by the multiplicity and intricacy of the DNA repair 
pathways. In addition to MGMT, complex DNA repair pathways and DDR components contribute 
to resistance to TMZ and IR in GBM, thus mediating its poor outcome. The management of newly 
diagnosed GBM patients has not changed since the introduction of TMZ in 2005 and no novel 
approach tested in the context of clinical trials has yet demonstrated encouraging benefits.  
As exposed in Chapter 1, DNA repair factors are under intense scrutiny in order to identify 
novel targets for the sensitization of GBM cells to the current therapy or the development of 
altogether new treatment strategies. As an approach to identify novel DNA repair and DDR 
factors involved in the response of GBM cells to chemoradiation, shRNA/siRNA-based in vitro 
screens have revealed several hitlists of potential targets that may translate to the clinic, whilst 
also contributing to our understanding of DNA repair in GBM (Agnihotri et al., 2014; Luo et al., 
2009; Svilar et al., 2012). Nevertheless, despite these advantages, RNA interference screens are 
inherently limited by the nature/properties of the cells they are using, which adapt to the in vitro 
environment and may not fully recapitulate the complexity of GBM observed in patients. 
The heterogeneity of GBM tumors adds to the complexity of this disease and increasing 
studies have aimed to stratify patients into clinically-relevant prognostic subgroups based on 
specific molecular alteration profiles (Verhaak et al., 2010; Brennan et al., 2013; 
Schwarzentruber et al., 2013; Wang et al., 2017). Such studies have mainly focused on whole 
transcriptomic/genetic data generated in primary GBM specimens. Although various molecular 
alterations were discovered and associated to patient prognosis, methylation of the MGMT 
promoter remains the only marker proven to effectively predict TMZ efficacy in the clinic (Hegi 
et al., 2005). Thus, although these studies have shed light into the complexity of  GBM, it may be 
argued that they have failed to grasp the determinants behind chemo- and radioresistance in 
part because of the huge span of genes they are analysing. In addition, the use of cohorts of 
paired GBM specimens (i.e., biopsies from the same patient obtained at the time of primary 
tumor operation and at recurrence) to explore DNA repair and the impact of chemoradiation has 
not been considered. Indeed, although the use of paired biopsies is gaining momentum, their 
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availability, especially specimens predating the introduction of TMZ in the clinic, is still limited in 
part by the speed of progress in the biobanking of reliable and clinically annotated specimens. 
Yet, such paired biopsies offer the possibility to examine, through comparison of primary and 
matched recurrent samples, the impact of chemoradiation on crucial parameters such as tumor 
phenotype, activation of the DDR, mobilization of DNA repair factors, and changes in the 
expression of DNA repair/DDR factors.  
In this context, the general aim of the project was to undertake a novel approach to 
understand how DNA repair mechanisms contribute to the resistance of GBM tumor cells to 
chemoradiation therapy and propose improved strategies to undermine DNA repair or exploit 
specific vulnerabilities associated with GBM cells. Specifically, we decided to focus on a cohort 
of paired GBM samples from patients treated with RT or RT plus TMZ with the aim of exploring 
alterations in DNA repair and cell cycle gene expression in primary GBMs and their recurrences. 
By doing this, we were hoping to combine the benefits of using GBM specimens and a targeted 
gene expression analysis focusing only on the major factors in the DNA damage response and -
related cell cycle genes. In addition, the uniqueness of our patient cohort, would allow different 
comparisons to be made, in order to unravel the DNA repair makeup of tumor cells during 
glioblastomagenesis and examine the possible effect of TMZ and IR on the DDR and DNA repair. 
Consequently, my research project was divided in two axes with specific aims: 
1) Analyze the expression of selected components of the DDR, DNA repair and cell cycle 
machineries in a cohort of paired primary and recurrent GBM biopsies in order to uncover 
and characterize gene expression alterations associated with chemoradiation. This 
research led to the proposal of a novel clinically applicable gene signature that exposes 
specific vulnerabilities against genotoxicants and inhibitors of the cell cycle and DDR, with 
the prospect of personalized therapeutic strategies (Chapter 4) 
2) Exploit the gene expression data obtained in (1) to identify key molecular players of the 
DNA damage response in GBM for further functional characterization using patient-
derived cell lines. This research led to the identification of the NEIL3 DNA glycosylase as a 
novel factor involved in tumor development, response to TMZ and telomere integrity in 
GBM cells (Chapter 5) 
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RATIONALE 
 
 
This first part of the result section represents a comprehensive review of the DNA 
repair mechanisms driving chemoradiation resistance and tumor relapse in GBM, including 
DNA damage response-related biomarkers. In particular, we introduce the most prominent 
cellular systems as well as the animal models currently available for the study of DNA repair 
in the context of glioblastoma. Moreover, we summarize recent progress in the knowledge of 
the major pathways and factors involved in the removal of IR- and TMZ-induced DNA lesions. 
In line with these observations, we introduce current therapeutic strategies relying on DNA 
repair inhibitors tested in vitro or in clinical trials, and present the main challenges in drug 
delivery to the brain as well as the strategies developed to circumvent this major hurdle. 
Finally, we review the novel genetic and epigenetic alterations that were found to shape the 
DNA repair makeup of GBM in both adult and pediatric patients, and discuss their potential 
implications for personalized therapy.  
Personal contributions: I am first co-first author of this review and my main significant 
contributions were to address and investigate novel DNA-damage response-related 
biomarkers of GBM in the literature (Chapter 6) and the design, including the 
conception/drawing, of the Figure representing the main pathways involved in the repair of 
IR- and TMZ-induced DNA lesions (Figure 1), as well as the depiction of the molecular basis of 
small molecule inhibitors (Figure 4). Finally, I was involved in the establishment and 
description of the list of alterations affecting DNA repair and chromatin factors in both adult 
and pediatric GBMs (Table 2).   
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Despite surgical resection and genotoxic treatment with ionizing radiation and the DNA alkylating agent
temozolomide, glioblastoma remains one of the most lethal cancers, due in great part to the action of
DNA repair mechanisms that drive resistance and tumor relapse. Understanding the molecular details of
these mechanisms and identifying potential pharmacological targets have emerged as vital tasks to
improve treatment. In this review, we introduce the various cellular systems and animal models that are
used in studies of DNA repair in glioblastoma. We summarize recent progress in our knowledge of the
pathways and factors involved in the removal of DNA lesions induced by ionizing radiation and
temozolomide. We introduce the therapeutic strategies relying on DNA repair inhibitors that are
currently being tested in vitro or in clinical trials, and present the challenges raised by drug delivery
across the blood brain barrier as well as new opportunities in this ﬁeld. Finally, we review the genetic and
epigenetic alterations that help shape the DNA repair makeup of glioblastoma cells, and discuss their
potential therapeutic impact and implications for personalized therapy.
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Glioblastoma (GBM, grade IV glioma)2 represent the most
frequent and aggressive malignant primary brain tumors in
humans. GBMs encompass secondary GBMs (about 5% of the
cases) which develop from lower-grade diffuse astrocytoma (WHO
grade II) or anaplastic astrocytoma (WHO grade III), and primary
GBMs (about 95% of the cases) which arise rapidly de novo without
clinical or histological evidence of a less malignant precursor.
GBMs display very poor prognosis and lack therapeutic options,
further complicated by the presence of the blood brain barrier
(BBB). Current management of GBMs usually consists of surgical
resection, followed by radiotherapy (RT) with concomitant and
adjuvant chemotherapy with the DNA alkylating agent temozo-
lomide (TMZ) [1], both treatments inducing DNA damage.
Although TMZ displays antitumor activity and limited toxicity,
its survival beneﬁt remains unsatisfactory  a mere 2.5 months [1],
due to rapid occurrence of resistance and tumor relapse.
GBMs are characterized by an important intertumor and
intratumor heterogeneity both at the cellular and genomic levels
[2,3]. Signiﬁcant progress has been made in our characterization of
the molecular alterations found in GBM biopsies, leading to a
comprehensive landscape of somatic genomic alterations in
glioblastoma and reﬁning the list of putative GBM driver genes
[4]. Adult and pediatric GBM subtypes with different presentation
and/or progression courses as well as therapeutic responses have
been proposed based on molecular analyses [5]. Likewise,
advances in surgical sample collection, integrated genomic
analyses and single-cell technology have shed new light on the
(regional) intratumor heterogeneity within GBM patients, reveal-
ing patterns of cancer evolution at the single-patient level [6,7].
Although what drives such dynamic heterogeneity at the cellular
level remains unclear ([8], and references therein), it may hold
important keys to understanding the response of GBM cells to
genotoxics and tumor recurrences [9,10].
Sophisticated cellular mechanisms have evolved to detect,
signal and repair the various DNA lesions inﬂicted in our
chromosomes by endogenous or exogenous genotoxics. The
robustness of the DNA repair mechanisms composing this DNA
damage response (DDR) is ensured in part by the inherent
redundancy of the many pathways that can remove a speciﬁc
lesion and also by the fact that DNA repair pathways function in
complex networks, with DNA-repair intermediates produced by a
given pathway oftentimes forming substrates for another pathway
[11]. In non-neoplastic cells, accurate DNA repair is essential to
prevent genetic instability, a driving force in tumorigenesis. Thus,
cancer cells often display genetic or epigenetic alterations that
affect DNA repair factors [12]. Paradoxically, DNA repair mecha-
nisms are also paramount to the removal of lesions induced by
genotoxic anti-cancer agents, and a crucial factor contributing to
the development of resistance and tumor relapse. Furthermore,
tumorigenic cells experience greater dependence on residual DNA
repair mechanisms that help them cope with exacerbated DNA
damage resulting from increased cellular metabolism (i.e., oxida-
tive DNA damage) as well as replication and/or mitotic stress [13],
whereas conditions imposed by the tumor microenvironment (e.g.,2 The abbreviations used in this review are deﬁned in Table 1.hypoxia) can profoundly alter the expression and function of DNA
repair genes. Understanding the molecular details underlying the
response of tumor cells to genotoxics and deciphering the
exploitable cancer-speciﬁc genetic alterations in the DNA damage
response are recognized as crucial steps in the development of
strategies that will improve cancer management. In recent years,
several therapeutic strategies and DNA repair inhibitors have been
elaborated to take advantage of defective DNA repair or saturate
altogether the DNA repair capacities in cancer cells [12,14].
The main DNA lesions induced by ionizing radiation (IR) and
TMZ, together with the major factors involved in their repair are
recapitulated in Fig. 1. The most severe DNA lesion inﬂicted by IR
are double-strand breaks (DSBs), which are repaired by two
mechanisms each composed of several pathways  homologous
recombination (HR) and non-homologous end joining (NHEJ)
[15,22]. Other forms of DNA damage induced by IR include base
damage and single-strand breaks (SSBs), which are repaired,
respectively by base excision repair (BER) and SSB repair. The major
lesions induced by TMZ are N7-methylguanine (N7-meG) and N3-
methyladenine (N3-meA), which are primarily repaired by BER,
and O6-methylguanine (O6-meG), a highly cytotoxic lesion which is
removed by the O6-methylguanine-DNA methyltransferase
(MGMT) product of the MGMT gene [16]. MGMT is a notable
exception to the multi-protein DNA repair pathways, as it works
single-handedly in a suicidal reaction that transfers the alkyl group
from guanine to an internal cysteine residue. Loss of MGMT by
promoter hypermethylation is commonly observed in colorectal
carcinomas, gliomas, non-small cell lung carcinomas, lymphomas
and head and neck carcinomas [29]: in colorectal cancer, such
inactivation is an early event associated with mutagenic con-
sequences [30]. MGMT promoter CpG methylation is observed in
about 45% of patients presenting with GBM and is associated with
increased sensitivity to TMZ and prolonged survival [31]. In the
absence of MGMT, unrepaired O6-meG can pair with cytosine or
thymine leading to O6-meG/T mispairs that are recognized by the
mismatch repair (MMR) machinery. However, MMR action leaves
the O6-meG intact, introducing instead SSBs that are converted to
potentially lethal DSBs at replication forks. TMZ-induced muta-
tional inactivation of MMR genes has been observed in recurrent
GBM tumors [9,32], consistent with the notion that loss of MMR
contributes to resistance to TMZ. Repair of DSBs generated as a
result of MMR activity involves the DSB repair machineries as well
as proteins belonging the Fanconi Anemia (FA) pathway involved in
the recombinational repair of perturbed or broken replication forks
[33,34].
2. Scopes of this review
Various reviews have addressed genetic, biochemical and
molecular aspects of DNA repair and therapy in glioblastoma
[35–37]. Here, we focus on recent developments in the following
ﬁelds of primary GBM research: i) the experimental and pre-
clinical models used in studies of DNA repair in GBM, ii) the
regulation/inhibition of MGMT expression and activity, iii) novel
insights into the DNA damage response and DNA repair inhibitors
for the treatment of GBM, and iv) DDR-relevant genetic and
epigenetic alterations identiﬁed in primary GBMs.
Throughout this review, we will also emphasize how strategies
driven by RNA interference have contributed to the identiﬁcation
Fig. 1. DNA repair pathways involved in the removal of IR- and TMZ-induced lesions. Schematic overview the lesions induced in DNA by IR and TMZ, as well as the repair
mechanisms that have been implicated in their removal in GBM. Only those factors that are discussed in the review have been indicated. The reader is referred to Ciccia [15] for
the mechanistic details of each pathway and the molecular composition of the various DNA repair machineries. Removal of TMZ-induced alkylated bases: Direct reversal of O6-
meG is mediated by MGMT. In the absence of MGMT, O6-meG can direct misincorporation of T during DNA synthesis, resulting in mismatch repair (MMR)-driven futile cycles
that lead to the generation of DNA single-strand breaks (SSBs), double-strand breaks (DSBs) and replication-associated DSBs. Removal of N7-meG and N3-meA, which is
mediated by Base Excision Repair (BER), is initiated by the DNA glycosylase MPG. Repair of the resulting apurinic/apyrimidinic (AP) site can involve the replacement of either a
single nucleotide (short-patch BER) or several nucleotides (long-patch BER). TMZ can also generate N1-methyladenine (N1-meA) and N3-methylcytosine (N3-meC) [16,17].
These lesions may be removed by the oxidative demethylases ALKBH2 and ALKBH3 which are capable of directly reversing N1-meA and N3-meC in DNA [18,19]. ALKBH2 was
found to confer resistance to TMZ in GBM cells [20]. Repair of oxidative DNA damage: TMZ- and IR-induced oxidative DNA damage includes oxidized bases (such as 8-Oxo-7,8-
dihydroguanine (8-oxoG)) that are recognized and excised by a variety of DNA glycosylases that initiate BER [21]. SSB repair: SSBs generated by IR and Reactive Oxygen Species
(ROS) or during processing of TMZ-induced DNA lesions are recognized and bound by poly(ADP-ribose) polymerase family members such as PARP1, leading to the recruitment
of the scaffold protein XRCC1. Repair is then achieved through short- or long-patch BER repair. DSB repair: Repair of DSBs can be achieved by two major pathways, homologous
recombination (HR) and non-homologous end joining (NHEJ) DNA repair, each composed of several sub-pathways [15,22]. HR pathways act upon 30-extended single-stranded
DNAs produced by DSB resection. Homology-directed strand invasion, mediated by RAD51 ﬁlaments, provides a major mechanism for the recombinational repair of DSBs in
GBM cells. When resection exposes complementary sequences (blue segments), repair can occur via RAD52-mediated single-strand annealing. Although this mechanism is
involved in the repair of IR-induced DSBs, its relevance in the context of TMZ-induced lesions has thus far not been reported. Recombinational repair of replication-associated
DSBs involves the Fanconi Anemia (FA) pathway and HR factors [23]. Recognition of DSBs by either KU70/KU80 or PARP leads respectively, to canonical NHEJ and alternative
NHEJ (A-NHEJ, itself composed of sub-pathways), a backup pathway that has been described in GBM cells [24,25]. Finally, translesion synthesis polymerases (not represented)
that allow bypass of TMZ-induced lesions during DNA replication have been implicated as a mechanism to tolerate TMZ-induced DNA lesions [26–28].
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mechanisms underlying the cellular response of GBMs to IR and
TMZ (hereby referred to as chemoradiation).3
3. Experimental and pre-clinical models for the study of DNA
repair in GBM
3.1. Cellular models
Established GBM cell lines (such as U87, U251 etc.) and low-
passage primary cell lines grown in monolayer cultures in serum–
complemented media have commonly served as in vitro models of
GBM. More recently, GBM cell cultures have also been established
from tumor-derived single-cell suspensions grown in serum-free
medium containing EGF and FGF (neurobasal medium). Under
these conditions, the cells generate spheres and display stem cell
properties, including self-renewal and the ability to differentiate
into multiple cell types resembling central nervous system (CNS)
cell lineages [41] and are often referred to as GBM stem cells
(GSCs). GSCs are sometimes isolated based on the expression of
speciﬁc markers (such as CD133, CD44 and A2B5) although
expression of these markers in patients is highly heterogeneous [7]
and their relevance as stem-cell markers is controversial. It
remains to be determined whether GSCs represent a genetically
deﬁned, stable subpopulation of cells or an adaptive cellular state
responding to microenvironmental changes. Yet, several studies
suggest that GCSs are more resistant to DNA damage than their
non-GSCs counterparts [10,42] and are able to mediate tumor cell
repopulation during recurrence [43–45]. GSCs can be maintained
in adherent cultures when the serum-free culture system is
adjusted [46], which greatly facilitates their experimental study
and in particular ensures the uniform distribution of genotoxics
during cell cytotoxicity experiments or high-throughput genetic
screens.
3.2. In vivo animal models
Transgenic and knockout mice for DNA repair functions have
provided invaluable knowledge on spontaneous and genotoxic-
induced carcinogenesis, as well as the deleterious consequences of
defective DNA repair [47,48]. Mouse models have revealed the
importance of DSB repair mechanisms during brain development
and in neurological diseases [49]. Chemically-induced rodent
models have been used to investigate glioblastomagenesis
whereas genetically-engineered mouse models (GEMMs) harbor-
ing selected GBM driver mutations offer unique contexts to
investigate GBM development driven by speciﬁc alterations and
test potential therapeutics [47,50]. Unlike medulloblastoma [51],
the impact of selective DNA repair gene knockout on tumorigenesis
and DNA repair in GEMMs of GBM still awaits to be analyzed (see
Section 6.2.1 for a description of the epigenetic factor SETD2).
Xenograft models developed from human GBM-derived cells
provide another preclinical model to investigate glioblastoma-
genesis and test therapeutic strategies using genotoxics. Although3 The chloroethylnitrosourea alkylating agents 1,2-bis[2-chloroethyl]-1-nitro-
sourea (BCNU, carmustine) and 1-[2-chloro-ethyl]-3-cyclohexyl-1-nitrosourea
(CCNU, lomustine) are also part of the arsenal against GBM although, since the
advent of TMZ they have been more generally administered as second line agents,
when recurrence occurs. Removal of DNA lesions induced by these compounds
involves most of the mechanisms mediating repair of TMZ-induced lesions,
including MGMT. However, as bi-functional agents, BCNU and CCNU are also able to
induce interstrand crosslinks [16] whose removal also involves factors from the FA
and nucleotide excision repair pathways [38,39]. Other genotoxics that have been
considered for the treatment of GBM, such as the DNA topoisomerase inhibitor
irinotecan [40] are not addressed here.a great number of publications report observations made on
tumors grown from subcutaneous implants of GBM-derived cells,
stereotactic intracranial implantation in immunodeﬁcient rodents
provides clinically more relevant and experimentally reproducible
models. Notable in the context of treatment with genotoxics is that
the BBB and also DNA repair-relevant features of the tumor
microenvironment (including tumor-stroma interactions and the
impact of hypoxia) are recapitulated in these models. Xenograft
models can be generated from established GBM cell lines or, more
relevantly, obtained from patient-derived xenografts (PDX) where
human GBM tissue is transplanted in the animal following limited
in vitro processing [47].
Currently, most animal experiments designed to assess the
response of GBM cells to genotoxics expose the animal to the DNA-
damaging agent for some time during tumor development,
without prior tumor resection. The time selected for genotoxic
treatment is usually chosen based on tumor mass analysis by in
vivo imaging (e.g., magnetic resonance imaging or biolumines-
cence analysis) or predetermined time course of tumor appearence
[7]. In such cases, the entire tumor mass is challenged with the
drug (Fig. 2, panel A). Genotoxic treatment can also be carried out
in vitro, prior to implantation of the surviving cells in the animal
(Fig. 2, panel B). This latter strategy has been used, for instance, to
investigate the effect of combined treatment with the PARP
inhibitor olaparib and IR on tumor formation by GSCs [52]. One
idea behind this approach is that the in vitro treatment might lead
to the selection of a subpopulation of surviving cells with increased
DNA repair capacity, that may reﬂect in part the features/
properties of the invasive cells that have migrated away from
the tumor mass at the time of resection and chemoradiation.
Although neither strategy accurately reﬂects the clinical situation
with regard to tumor recurrence, the development of surgical
resection models for GBM is still in its infancy [53]. Thus, attempts
to assess the effects of genotoxics in animals that have been
subjected to tumor micro-resection, and possibly also IR, (Fig. 2,
panel C) have to our knowledge not been reported.
4. Novel insights into the regulation of MGMT expression and its
inhibition
MGMT provides the main mechanism for removal of the
cytotoxic O6-MeG lesion. Identifying the factors that orchestrate
MGMT expression as well as therapeutic means to debilitate this
line of defense against TMZ is thus the object of intense efforts. The
main features of MGMT regulation and inhibition are recapitulated
in Fig. 3.
A thorough review on the regulation of MGMT expression,
including its epigenetic silencing and value/use as a biomarker and
clinical target, has recently been published [36]. Here, we focus on
the molecular progress in this ﬁeld as well as aspects that are most
relevant to genotoxic chemotherapy.
4.1. Transcriptional regulation of MGMT
The tumor suppressor gene TP53 encodes a transcriptional
activator that orchestrates fundamental cellular responses to a
variety of stress signals including DNA damage [65]. TP53
mutations and loss of heterozygozity are frequently observed in
GBM [66], as is the case with the ampliﬁcation or overexpression of
its negative regulators MDM2 and MDM4 [67]. Overexpression of
p53 has been proposed to negatively regulate MGMT transcription
by sequestering Sp1 transcription factor [63], thereby sensitizing
tumor cells to alkylating agents in vitro. In glioma cells, p53
overexpression can be induced by interferon beta (IFN-b), which
was shown to sensitize cells to TMZ [68]. However, IFN-b has also
been reported to induce sensitization of GSCs to TMZ, independent
Fig. 2. Assessing GBM tumor response to genotoxics using orthotopic xenograft models. The response of GBM tumors (derived from established cell lines/GSCs/patient-
derived GBM cells) to genotoxics can be tested in various xenograft settings. A. Xenotransplantation followed by treatment is the most commonly used orthotopic model. In
this case, tumor growth can be monitored by MRI or bioluminescence analysis, followed by treatment and its evaluation. B. Cells are treated in vitro and the surviving cell
population is implanted, followed by monitoring of tumor formation. C. Same as in A., except that tumor formation is followed by surgical resection, leaving resection margins
as well as inﬁltrating cells that have migrated from the tumor mass. The animal is then treated and tumor recurrences are monitored. This model best reﬂects the current
clinical situation in the setting of GBM.
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the underlying mechanisms, Motomura et al. [70] have proposed
IFN-b as a good candidate for adjuvant GBM therapy, especially for
patients with an unmethylated MGMT promoter, based on a
retrospective study of 68 newly diagnosed primary GBM patients
showing that treatment with IFN-b increased the median survival
time from 12.5 (TMZ alone) to 17.2 months (TMZ + IFN-b).
A long list of microRNAs (miRs) has been shown to target MGMT
for downregulation (Fig. 3). Some miRs modulate TMZ sensitivity
in vitro [59,64,71–73] and have been proposed to predict either the
response to chemoradiation in GBM patients [73,74] or patient
outcome in different GBM subtypes [75].
MGMT expression is induced by c-MYB and appears to be
positively regulated by the transcription factor ZEB1 (zinc ﬁnger E-
box binding homeobox 1), which operates through inhibition of
miR-200c, a negative regulator of c-MYB [59]. Thus, ZEB1 was
found to modulate TMZ chemoresistance in GBM cells and the
authors have suggested that it could be a target for future
therapeutic approaches.
4.2. MGMT inhibition: pseudosubstrates and genetic therapy
MGMT operates by stoichiometrically transfering the methyl
group of O6-MeG to a cysteine residue within its active site. This
reaction is irreversible as it is followed by the ubiquitination and
degradation of MGMT. Such a suicide reaction has been exploited
in therapeutic strategies aiming at decreasing the pool of MGMT
molecules in MGMT-positive patients (Fig. 4, panel A). However,
attempts to sensitize GBMs and other solid tumors to TMZ through
pharmacological depletion of MGMT levels using the pseudosub-
strates O6-benzylguanine (O6-BG) or O6-(4-bromothenyl) guanine
(O6-BTG, also known as lomeguatrib or PaTrin-2) have been facedwith severe myelosuppression toxicity, forcing the use of
decreased doses of TMZ which proved inefﬁcient in clinical trials
[76,77]. A number of approaches have been considered to
overcome these adverse effects whilst targeting tumor cells more
efﬁciently, including local administration of O6-BG [78] or the use
of glucose- [79] or folate-conjugates [80] of O6-BG and O6-BTG that
target tumor cells through highly-expressed transporters or
receptors. However, these early efforts have not been fruitful.
More recently, expression of the O6-BG-resistant MGMT
(P140K) mutant by hematopoietic cells was shown to provide
signiﬁcant protection against toxicity from O6-BG/alkylator
chemotherapy [81], leading to a prospective phase I/II clinical
trial in which newly diagnosed MGMT-positive GBM patients were
transplanted with autologous MGMT(P140K) gene–modiﬁed
hematopoietic CD34+ cells [82]. Gene therapy increased tolerance
to the O6-BG/TMZ combination as well as patient survival,
supporting further development of chemoprotective gene therapy
in GBM patients treated with O6-BG and TMZ [83].
Other molecules that might in the future be considered to
sensitize MGMT-positive patients to TMZ, include the direct
inhibitor disulﬁram [61,84], as well as various epigenetic drugs that
sensitize MGMT-positive GBM cells to TMZ by down-regulating
MGMT gene expression. Examples include the histone deacetylase
inhibitors levetiracetam and valproic acid [85], and the DNA
methylation inhibitor decitabine [56].
5. Inhibition of IR- and TMZ-induced DNA damage repair in GBM
5.1. DNA damage signaling and its inhibition
Various forms of DNA damage activate key sensor kinases such
as ATM and ATR, triggering the phosphorylation of downstream
Fig. 4. Molecular basis of DNA repair inhibition by O6-benzylguanine, methoxyamine and PARP inhibitors. See text for details.
Fig. 3. MGMT regulation and inhibition. Depicted are the activating factors (green boxes) and repressing factors (peach boxes) of MGMT expression as well as direct inhibitors
that affect MGMT activity (violet boxes). Various epigenetic mechanisms have been shown to modulate MGMT expression, including CpG methylation of MGMT promoter and
gene body, histone H3K4 methylation and H3K9 dimethylation, acetylation of histones H3K9 and H4K20, and binding by the methyl-CpG binding protein MeCP2. MGMT
Expression can also be controlled by a variety of transcription factors, as well as numerous miRs. Note that miR-648 interferes with MGMT protein translation whereas
miR200 impacts MGMT through targeting of cMYB (see Section 4.1). At the post-translational level, MGMT can be stabilized by binding of the NDRG1 protein. Following
binding of a methylated guanine or O6-BG, MGMT becomes a substrate for ubiquitin conjugation, leading to its subsequent degradation by the proteasome. Direct inhibitors of
MGMT include the pseudosubstrates O6-BG and O6-BTG, as well as disulﬁram. PDB structure references: 1EH6 (native MGMT), 1EH7 (O6-MeG-bound MGMT) and 1EH8 (O6-
BG-bound MGMT) [54]; 1T38 (O6-MeG-DNA) [55]. This ﬁgure is inspired from [36,57,58,60,62].
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and ATR are activated, respectively, by DSBs and single-stranded
DNA (ssDNA) structures. Key targets of ATM include p53 and the
effector kinase CHK2, resulting in the control of the G1/S and intra-
S checkpoints, whereas ATR acts primarily through CHK1 and
controls the intra-S and G2/M checkpoints. However, there are
overlaps between ATM- and ATR-dependent signaling [86].
Based on the characterization of genetically-engineered mouse
models, Squatrito et al. [87] provided evidence that the ATM/
CHK2/p53 pathway operates as a tumor suppressor in the brain.
Chk2-/- mice exhibited increased GBM resistance to IR and failed to
activate DNA-damage-induced cell-cycle checkpoints. The authors
also showed that crucial DDR components were constitutively
activated in primary GBM biopsies from patients not previously
exposed to chemoradiation. Robust activation of the ATM/CHK2/
p53 cascade in GBM specimens was also observed by Bartkova et al.
[88] who identiﬁed oxidative DNA damage and replication stress as
the underlying sources of endogenous genotoxic stress. Constitu-
tive activation of the DDR has led to the suggestion that its
inhibition might have potential application in the management of
GBM. Thus, in contrast with the observations made in the Chk2 null
glioma mouse model [87], dual inhibition of CHK1 and CHK2 [43]
or ATM [89] sensitized GSCs to IR in vitro. Likewise, the ATM
inhibitor KU-60019 has been described as an efﬁcient radio-
sensitizer of GBM cells both in vitro [90] and, when administered
intratumorally by convection-enhanced delivery or osmotic pump,
in orthotopic GBM mouse models [91]. Importantly, the authors
showed that p53 mutant GBM cells were much more sensitive to
KU-60019 radiosensitization than their isogenic wild-type coun-
terparts. The IR-induced synthetic lethality between p53 and ATM
likely reﬂects the inability of DNA damage-ridden cells to execute
functional cell cycle checkpoints, leading to mitotic catastrophe
[92]. Other molecules that may show promise include AZ32, an
orally-bioavailable, BBB-penetrant ATM inhibitor which has been
reported to radiosensitize GBM cells in xenograft models [93].
The stimuli that activate ATM and ATR can also be generated
during processing of the major lesions elicited by TMZ. BER-
mediated removal of N7-meG and N3-meA  a process that is
independent of MGMT and MMR, leads to the early phosphoryla-
tion/activation of CHK1 driven by ssDNA repair intermediates [94].
Although ssDNA and DSB stimuli are not produced when the O6-
MeG lesion is processed by MGMT, its handling by MMR in the
absence of MGMT results in SSBs and DSBs that trigger the DDR and
late activation of CHK1 and CHK2 [94,95]. Eich et al. [95] have
shown that both ATM and ATR contribute to the resistance of GBM
cells to TMZ in vitro; however, cells depleted of ATR by small
interfering RNAs (siRNA) showed a more pronounced sensitivity to
the drug compared to ATM-depleted cells, and knockdown of ATR,
but not ATM, abolished phosphorylation of the DSB marker H2AX,
as well as CHK1 and CHK2.
Litman-Flynn et al. [96] have shown that GBM cells relying on
the alternative lengthening of telomere (ALT) pathway to
overcome cell senescence (about 11% of adult GBM and 44% of
pediatric GBM [97], see Section 6.1) were hypersensitive to ATR
inhibitors. Such inhibitors appeared highly speciﬁc for ALT cells
and may therefore offer a useful treatment approach in ALT-
positive GBMs.
Aghinotri et al. [98] recently uncovered a novel function for
ATM as an important regulator of BER in pediatric GBM, through
modulation of MPG (3-methylpurine-DNA glycosylase, also known
as alkylpurine–DNA-N-glycosylase (APNG)) glycosylase activity.
The authors demonstrated direct phosphorylation of MPG by
activated ATM, and showed that combined depletion of ATM and
MPG resulted in increased TMZ-induced cytotoxicity in vitro and
prolonged survival in mice with intracranial GBM xenografts. It
was therefore suggested that ATM inhibition, in addition topreventing DSB repair, may sensitize cancer cells to TMZ through
inhibition of BER, and that the combination of ATM and BER
inhibitors may improve GBM treatment. The nature of the signals
triggering ATM-mediated phosphorylation of MPG is currently
unknown.
In summary, ATM and ATR appear to be attractive targets in
combination with chemoradiation treatment.
5.2. Strategies to inhibit base excision repair
In 2012, Agnihotri et al. reported a positive correlation between
the expression levels of the BER factor MPG and the TMZ IC50 in
adult GBM cells, where MPG was found to promote TMZ resistance
[99]. Later, the authors identiﬁed a similar correlation in pediatric
GBM lines and also uncovered MPG and the apurinic/apyrimidinic
(AP) endonuclease 1 (APEX1) amongst TMZ sensitizers in a siRNA
screen with TMZ-resistant pediatric GBM cell lines [98]. Targeting
MPG together with non-BER genes, or multiple targeting of BER
genes in pediatric cells caused additive sensitivity to TMZ, whereas
re-introduction of MPG in TMZ-sensitive cells conferred resistance
to TMZ in orthotopic mouse models of pediatric and adult GBM
[98].
MPG catalyzes the cleavage of N7-meG and N3-meA, generating
abasic sites that are substrates for APEX1, and the MPG-APEX1 axis
in GBM cells could serve as target for therapeutic strategies with
methoxyamine (Fig. 4, panel B). This small molecule inhibitor
binds the abasic sites generated by MPG, thereby preventing
further processing. Compared to treatment with either molecule
alone, the combination of methoxyamine plus TMZ dramatically
increased survival of mice injected intracranially with SJG2 cells, as
well as in an orthotopic PDX mouse model generated from
pediatric GBM primary cells [98,99].
Other strategies targeting BER to sensitize GBM cells to TMZ
include inhibition of DNA polymerase b whose lyase activity is
required for excising 50-deoxyribose phosphate (50dRP) residues
generated by APEX1 (Fig. 1) [100].
5.3. DSB repair pathways and their inhibition
Little or no sensitization towards IR was observed when the
RAD51 recombinase was inhibited in LN-229 cells, whereas
inhibition of the NHEJ factor DNA-dependent protein kinase
(DNA-PK) resulted in increased sensitivity to IR irrespective of
RAD51 knockdown [101]. Hypersensitization of GBM cells to IR was
also observed following depletion of 53BP1, a positive regulator of
NHEJ, in U87, U251 and T98G cells [102]. However, targeting HR in
T98G [103] and GSCs [104] resulted in sensitization to IR, suggesting
that HR can also contribute to IR-induced DSB repair in GBM.
The importance of the major DSB repair pathways in the
response of GBM cells to alkylating agents was addressed by Quiros
et al. [101], who described the impact of inhibiting HR or NHEJ on
the response of LN-229 to TMZ. RNA interference (RNAi)-mediated
depletion of the HR factors RAD51 or BRCA2 speciﬁcally sensitized
GBM cells to TMZ in MGMT-negative backgrounds, underlining O6-
meG as the crucial lesion leading to DSBs in the absence of MGMT.
That RAD51 knockdown resulted in increased sensitivity to TMZ in
the absence of MGMT was conﬁrmed by Short el al [103]. In
contrast, hampering NHEJ through pharmacological inhibition of
DNA-PK did not sensitize LN-229 cells signiﬁcantly to TMZ [101].
Likewise, depletion of 53BP1 had no signiﬁcant effect on the
response of U87, U251 and T98G cells to TMZ [102]. It should be
mentioned, however, that the NHEJ factors LIG4 and XRCC4 were
identiﬁed as TMZ-sensitizers in pediatric GBM cell lines [98] whilst
siRNA-mediated depletion of LIG4 sensitized A172 cells to TMZ
[105]. Several alternative NHEJ pathways (A-NHEJ) have been
described [22]. LIG4 and XRCC4 mediate the ultimate step of the
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intermediates are repairable by several alternative routes until
the ﬁnal ligation step which, once engaged through canonical
NHEJ, can only be carried out by LIG4/XRCC4.
Recently, gene expression analysis using The Cancer Genome
Atlas (TCGA) database by Rivera et al. [106] showed that
components of the meiotic HR machinery are expressed in GBM.
In addition, increased levels of the meiotic recombinase DMC1
were found in a battery of GBM cell lines compared to non-
neoplastic brain. In vitro, siRNA-mediated depletion of DMC1
resulted in increased genomic instability and replication stress,
and decreased proliferation in the absence of exogenous genotoxic
stress, whereas it inhibited IR-induced activation of the DDR and
radiosensitized GBM cells. Intracranial implantation of DMC1-
depleted U87 in mice decreased tumor growth and prolonged
survival. Pharmacological inhibition of DMC1 has hitherto not been
reported.
5.4. Endogenous and chemoradiation-induced oxidative DNA damage
in GBM: extra burden of DNA damage
Elevated rates of reactive oxygen species (ROS) production are a
hallmark of most cancer cells where they are associated with
tumor development and progression [107]. In GBM, increased ROS
levels, DNA damage and genetic instability were observed in cells
overexpressing EGFRvIII, a common oncogenic variant of EGFR
amongst GBM patients [108], leading to a DNA repair pathway
addiction phenotype that was exploited by Nitta et al. [109]. In this
textbook illustration of the framework of non-oncogene addiction
[110], the authors carried out a siRNA screen of 240 DDR genes,
identifying BER genes involved in oxidative DNA damage repair, as
well as poly(ADP-ribose) polymerase 1 (PARP1) (see Section 5.5)
amongst those gene silencings that sensitized U87MG cells
overexpressing EGFRvIII, but not the parental U87MG cell line,
to IR. Of note, overexpression of EGFRvIII has also been linked to
increased radioresistance in U87 cells, through the upregulation of
DNA-PK [111].
In addition to causing base alkylation, TMZ, like IR, also induces
oxidative DNA damage [112,113] which further mobilizes the BER
machinery. Thus, Svilar et al. [114] showed that TMZ induced the
production of ROS in GBM and validated the involvement of
oxidative DNA glycosylases that do not recognize alkylated bases,
but instead act upon oxidative DNA lesions, in a siRNA screen
targeting “druggable” targets (5520 genes) for depletions confer-
ring TMZ hypersensibility in T98G cells.
It therefore appears that BER and DSB repair mechanisms play a
crucial role in the repair of oxidative DNA damage from
endogenous and exogenous sources, which could be exploited in
therapeutic approaches.
5.5. Strategies using PARP inhibitors
PARP1 is a sensor of SSBs involved in several forms of DNA
repair (Fig. 1) [115]. Small molecule PARP inhibitors (PARPi),
administered as monotherapies or in combination with genotoxic
chemotherapeutics, have showed encouraging results against
tumors harboring DNA repair defects, in which they induce
synthetic lethality (a thorough review of the use of PARP inhibitors
in the treatment of cancer is provided by [116]). Well characterized
examples include the sensitivity of BRCA1 and BRCA2 deﬁcient
breast cancer cells defective in homologous recombination, to
inhibition of PARP via small molecule inhibitors [117].
PARPi are thought to mediate their cytotoxic effects by trapping
PARP1 enzymes (as well as the other PARP family member PARP2)
on SSBs formed by endogenous cellular metabolism or as
intermediates of crucial DNA repair pathways (Fig. 4, panel C).In addition, they prevent auto-PARylation (an activity required for
dissociation of PARP from DNA and completion of repair) as well as
PARylation of chromatin proteins that mediate the recruitment of
DNA repair factors. Thus, by blocking pathways such as SSB repair,
BER and A-NHEJ, persistent PARP-SSB complexes ultimately lead to
replication collapse and the formation of DSBs that require HR for
accurate repair.
The therapeutic potential of PARPi is not conﬁned to cells
deﬁcient in HR. Thus, synthetic lethality was uncovered between
deﬁciency in XRCC1 (involved in SSB repair, BER and A-NHEJ, Fig.1)
and PARP inhibition [118,119]. More recently, Horton et al. [120]
showed that Polb-/- and Xrcc1-/- mouse ﬁbroblasts were
hypersensitive to PARPi. In these defective cells, endogenous
DNA damage led to unrepaired BER intermediates sufﬁcient to
trigger increase in PARP binding sites in the presence of PARPi,
leading to replication fork disruption and DSB. The authors
therefore suggested that BER deﬁciency could represent a
therapeutic opportunity for PARPi single-agent therapy.
Several reports suggest that PARPi may also synergize with
genotoxic therapeutics, including IR and TMZ, two treatments
which bear direct relevance to GBM. Thus, Quiros et al. [101],
presented evidence that MGMT-deﬁcient LN-229 cells were
hypersensitive to TMZ-induced DNA damage following treatment
with the PARPi olaparib, which was exacerbated upon depletion of
RAD51 recombinase. Dungey et al. [121] reported that olaparib
sensitized the GBM cell lines T98G, UC373-MG, UVW and U87-MG
to IR in vitro. A similar observation was made by Russo et al. [122]
with U251 cells and the PARPi E7016. In both cases, treatment with
PARPi was found to inhibit the repair of IR-induced DSBs. In
addition, compared to IR plus TMZ, the trimodal combination of IR,
TMZ and E7016 resulted in delayed tumor growth of U251
subcutaneous xenografts [122]. The sensitizing effect of another
PARPi, ABT-888, in combination with IR and TMZ was also observed
in various GBM cell lines [123].
Understanding the determinants of PARPi sensitivity and the
mechanisms of resistance to PARPi is crucial to identify the cancer
patient populations that may beneﬁt from treatment with PARPi.
Resistance to PARPi can occur via i) secondary mutations restoring
BRCA1/2 open reading frame, ii) overexpression of the RAD51
recombinase and/or loss of PARP1 expression, iii) upregulation of
drug efﬂux pumps, and iv) loss of the DNA repair factor 53BP1
[124]. In a recent study, Venere et al. [52] provided additional
support for GBM clinical trials with PARPi, showing that, compared
with non-GSCs, GSCs exhibited higher levels of ROS, increased
oxidative base damage and SSBs, and exacerbated dependence on
PARP1 activity, which could be exploited in vitro and in vivo. Thus,
inhibition of PARP sensitized GSCs to IR, hampered growth, self-
renewal and DNA repair, and inhibited tumor initiation in
orthotopic xenotransplantation experiments [52]. The sensitivity
of GSCs to PARPi was also reported by Majuelos et al. [125] using
olaparib. In addition, the authors tested the effect of PARPi in U87
(PTEN-deﬁcient) and LN229 (PTEN-proﬁcient) GBM cells. PTEN-
deﬁcient cells were more sensitive to olaparib than the proﬁcient
cells, and this sensitivity was not increased in combination with IR
or TMZ. Microarray analysis of U87 cells following treatment with
PARPi revealed the down-regulation of HR factors, which was
corroborated by the observation that HR is impaired in PTEN-
deﬁcient cells treated with PARPi.
Taken together, these studies suggest that conditions of
increased ROS levels (e.g., cells expressing EGFRvIII), as well as
defective BER or HR may provide contexts in which GBM patients
might be amenable to PARPi-based therapeutic strategies. Single-
agent and combination clinical trials involving PARPi have been
reviewed [116]. A phase I clinical trial is underway to test the
combination of olaparib and TMZ in patients with relapsed GBM
(clinicalTrials.gov identiﬁer: NCT01390571).
Table 1
List of abbreviations.
Abbreviation Deﬁnition
2-HG 2-hydroxyglutarate
ALT alternative lengthening of telomeres
A-NHEJ alternative non-homologous end-joining
AP site apurinic/apyrimidinic site
BBB blood brain barrier
BCNU bis-chloroethylnitrosourea, carmustine
BER base excision repair
CCNU 1-(-2-chloroethyl)-3-cyclohexyl-1-nitrosourea, lomustine
CED convection-enhanced delivery
CNS central nervous system
CRISPR clustered regularly-interspaced short palindromic repeats
DDR DNA damage response
DSB double-strand break
FA fanconi anemia
GBM glioblastoma
G-CIMP glioma CpG island methylator phenotype
GEMM genetically-engineered mouse model
GSC glioma stem cell
HDAC histone deacetylase
HR homologous recombination
IR ionizing radiation
MMR mismatch repair
N1-meA N1-methyladenine
N3-meA N3-methyladenine
N3-meC N3-methylcytosine
N7-meG N7-methylguanine
NHEJ non-homologous end-joining
O6-BG O6-benzylguanine
O6-BTG O6-bromothenylguanine, lomeguatrib
O6-meG O6-methylguanine
PARPi PARP inhibitor
PDB protein database
PDX patient derived xenograft
PRC2 polycomb repressive complex 2
RNAi RNA interference
ROS reactive oxygen species
RT radiotherapy
shRNA short hairpin RNA
siRNA small interfering RNA
SNP single nucleotide polymorphism
SSB single strand break
ssDNA single-stranded DNA
TALEN transcription activator-like effector nuclease
TCGA The Cancer Genome Atlas
TMZ temozolomide
a-KG a-ketoglutarate
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Table 2 summarizes the DDR- and DNA repair-relevant features
of well-established molecular alterations that have been used in
clinical diagnosis and prognosis of adult and pediatric GBMs, as
well as recently-described alterations that impact the DDR, some
of which are proving valuable as markers to improve the
classiﬁcation of gliomas and/or as therapeutic targets [155,156].
Here, we focus on telomere-maintenance mechanisms and DNA
repair changes associated with epigenetic alterations in pediatric
and adult GBM. Speciﬁcally, we address alterations affecting
histone H3 variants, the histone chaperones ATRX and DAXX, the
histone methyltransferases EZH2 and SETD2, and also isocitrate
dehydrogenase IDH1 (including its impact on the glioma-CpG
island methylator phenotype (G-CIMP)).
6.1. Telomere-maintenance mechanisms
Telomeres are nucleoprotein structures that protect the ends of
chromosomes and prevent their recognition as DSBs. Althoughmaintenance of telomeres requires the taming of DSB repair
pathways (NHEJ and HR), other DNA repair factors collaborate with
telomere-speciﬁc factors and epigenetic mechanisms to protect
chromosome ends [157]. Central to the synthesis of telomeric DNA
sequences is telomerase, a specialized ribonucleoprotein reverse
transcriptase. In most cells, telomerase activity decreases as cells
differentiate and telomeres gradually shorten after each round of
cell division, resulting in DNA instability, cellular senescence and
ultimately cell death. In order to maintain viable telomere length,
tumor cells rely either on the re-expression of telomerase or a
telomerase-independent, HR-dependent mechanism called alter-
native lengthening of telomeres (ALT). Reactivation of telomerase
is largely limited to adult GBMs (80% vs 3–11% in pediatric GBM),
whereas, a reverse pattern is observed for ALT (pediatric GBMs
(44%), adult GBMs (11%)) [158].
In recent years, several studies have examined the prognostic
value of telomerase-associated parameters like telomere length,
telomerase activity and expression of its catalytic subunit, hTERT,
in relation to GBM. Expression of hTERT is associated with high
telomerase activity and adverse prognosis in GBM patients [146].
Induction of hTERT expression through mutations in the promoter
core region of hTERT is responsible for the reactivation of the
telomerase in various cancer types including GBM. In a cohort of
GBM patients, where 80% were found to carry hTERT promoter
mutation, a bad prognostic value was conﬁned to those patients
who also harbored the G-allele of a SNP in the promoter of hTERT
(rs2853669) [149,159].
Overexpression of hTERT in normal ﬁbroblasts led to enhance-
ment of DNA repair capacity [148]. Whether a similar situation
occurs in GBM tumors might explain why increased hTERT
expression confers resistance to genotoxics and poorer patient
survival. In line with the observation that RNAi-mediated
depletion of hTERT resulted in impaired DNA damage response
and sensitivity to IR [160], direct inhibition of telomerase activity
in GSCs using the antagonist imetelstat [162], or treatment of
telomerase-reactivated GBM cells with quadruplex-selective
ligands that stabilize G-quadruplex structures present in telomeric
DNA [161,162], inhibited cellular proliferation and sensitized cells
to IR in vitro. A similar observation was made with ALT-positive
GBM cells [163], although these cells were naturally more resistant
to IR than GSCs with reactivated telomerase [164].
6.2. DNA repair changes associated with epigenetic alterations in
pediatric and adult GBMs
6.2.1. Driver mutations in histone H3 variants and histone chaperones
Recent analyses have underlined the unique molecular features
of pediatric GBMs [5,165,166]. Speciﬁcally, driver mutations in the
H3F3A gene encoding the histone variant H3.3 as well as in the
H3.3 histone chaperones ATRX and DAXX were uncovered at high
frequency in pediatric GBMs [136,137]. The point mutations in H3.3
resulted in the amino acid substitutions K27M or G34R/V, which
were mutually exclusive and heterozygously expressed. K27M
substitutions were also observed in the HIST1H3B gene encoding
H3.1. Residues K27 and K36 (close to H3G34) in H3/H3.3 are critical
sites for post-translational modiﬁcations, and the epigenetic
impact of the observed mutations was seen at the level of gene
expression and chromatin dynamics. Thus, K27M and G34R/V
mutations showed distinct gene expression proﬁles and DNA
methylation patterns. Importantly, nearly all tumors bearing G34R/
V mutations also exhibited mutations in ATRX/DAXX and displayed
the ALT-phenotype [136,167], in line with the documented
requirement of these chaperones for the deposition of H3.3 at
normal telomeres [168,169]. The H3.3K27M mutation resulted in
reduced levels of H3K27me3, a repressive mark deposited by EZH2,
the catalytic subunit of polycomb repressive complex 2 (PRC2). In
Table 2
Established and newly described alterations affecting DNA repair and chromatin factors in primary adult and pediatric GBMs.
Gene Function Alteration type* General effect Impact on DDR Drug** Ref.
Established markers in primary adult GBMs
MGMT Removal of O6-meG in
DNA
CpG-island promoter
methylation
Increased overall survival in
patients presenting
alteration
Reduced O6-meG removal; increased
response to TMZ treatment
O6-BG [4,31,126]
IDH1 TCA cycle enzyme Gain-of-function
mutation: R132H (5%)
Alteration of metabolic, DNA
methylation and gene
expression proﬁles
Increased RAD51-mediated HR; 2-HG
mediated inhibition of ALKBH2/3
AGI-5198 [4,19,126–
128]
EGFR Cell surface tyrosine
kinase receptor
Focal ampliﬁcation
(50%) as well as
activating, intragenic
deletions (i.e: EGFRvIII
variant)
Tumor growth stimulation by
activation of downstream
RAS/MAP, mTOR and PI3K/
Akt signaling pathways
EGFRvIII variant is associated to
increased ROS production and DNA
damage, as well as activation of DNA-
PKCs and NHEJ-mediated DSB repair
Erlotinib
Cetuximab
[4,109,111,126]
PDGFRA Cell surface tyrosine
kinase receptor
Focal ampliﬁcation (11%)
and activating,
intragenic deletion
(De8-9)
Stimulation of tumor growth *** Sorafenib
Imatinib
[4,126,129]
PTEN Tumor suppressor,
inhibitor of oncogenic
Akt signaling pathway
Focal deletion (10%),
mutation (30%)
Re-activation of Akt pathway
signaling
Impaired DNA repair in GBM cells;
compromised HR in normal astrocytes
/ [4,126,130–
132]
TP53 Tumor suppressor, DDR
factor involved in cell
cycle regulation and
apoptosis modulation
Mutation and LOH Loss of cell cycle checkpoint
control, tumor proliferation
See Section 4.1 / [4,126,133]
CDKN2A/
B
Tumor suppressor,
negative regulator of cell
cycle, regulator of p53
Focal/Homozygous
deletion (60%), promoter
hypermethylation
Dysregulation of cell cycle
control
*** / [4,126]
Established alterations in primary pediatric GBMs
H3F3A/B Histone variant H3.3 Mutations (K27M, G34V/
R, K36M)
Epigenetic changes and
alteration of gene expression
proﬁles
See Section 6.2.1 / [134–136]
HIST1H3B Histone variant H3.1 Mutation (K27M) Epigenetic changes and
alteration of gene expression
proﬁles
See Section 6.2.1 / [137]
ATRX Histone H3.3 chaperone Mutation Decreased H3.3 deposition at
telomeres, epigenetic
changes, ALT-phenotype
Increased sensitivity to DNA damaging
agents; increased DNA damage
/ [136,138]
SETD2 H3K36 speciﬁc tri-
methyltransferase
Mutation (15%) Defective H3K36 tri-
methylation
Defective HR-mediated DSB repair;
impaired MMR
/ [139–142]
Recently described alterations in primary GBMs
EZH2 Mono-, di- and tri-
methylation of H3K27
Up-regulation Epigenetic changes and
alteration of gene expression
proﬁles; tumor proliferation
Inhibition associated with increased
expression of HR genes, including
RAD51
GSK126
DZNeP
[143–145]
hTERT Catalytic subunit of
telomerase
Overexpression through
activating mutation in
promoter core region
(80%)
Cellular transformation,
immortalization
Improved DNA repair capacity GRN163L
Telomestatin
[146–149]
ID1 Transcription factor High expression (50%) Increased tumor growth Deﬁcient DDR; downregulation of LIG4
and ATM
Cannabidiol [150,151]
PGRN Secreted growth factor Overexpression Tumor progression Increased DDR and resistance to TMZ / [152]
XRCC6BP1 DNA dependent
protein kinase
Ampliﬁcation (14%) Increased proliferation Improved DSB repair / [153,154]
Abbreviations: ATRX, a-thalassemia/mental retardation syndrome X-linked; CDKN2A/B, Cyclin-dependent kinase inhibitor 2A/B; EGFR, Epidermal growth factor receptor;
EZH2, Enhancer of zeste homolog 2; H3F3A/B, H3.3 histone; HIST1H3B, histone cluster 1, H3b; hTERT, human telomerase reverse transcriptase; ID1, Inhibitor of DNA binding
1; IDH1, Isocitrate dehydrogenase 1; MGMT, O6-methylguanine-DNA methyltransferase; PDGFRA, platelet-derived growth factor receptor; PGRN, Progranulin; PTEN,
phosphatase and tensin homolog; SETD2, SET domain containing 2; TP53, tumor protein p53; XRCC6BP1, XRCC6 binding protein 1; 2-HG, 2-hydroxyglutarate; a-KG,
ketoglutarate.
* Incidence when available, unless quoted in the text.
** Example of drug.
*** These important markers have been included although the association between the indicated alterations and DNA repair has not been reported in GBM.
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inhibit PRC2 activity [170].
The oncogenic mechanisms associated with the H3.3K27M and
H3.3G34R/V mutations in pediatric GBMs have been reviewed by
Yuen [166]. Remarkably, a recent report by Gallo et al. [171]
identiﬁed mixed lineage leukemia 5 (MLL5)-mediated repression
of H3F3B, the second gene encoding human H3.3, as a mechanism
that phenocopies the DNA methylation proﬁles of pediatric GBMs
with H3.3 mutations, in adult GSCs. Moreover, the authors
demonstrated that MLL5 action impacts chromatin structure, thusmodulating gene expression to maintain the tumorigenic and self-
renewal properties of adult GSCs.
Whether H3.3 mutations or expression alterations result in
altered DNA repair capacities in pediatric GBM remains to be
investigated. However, studies of the phenotypes associated with
EZH2 depletion suggest a strong connection between epigenetic
remodeling and DNA repair in pediatric as well as adult GBM. EZH2
is overexpressed in adult and pediatric GBM [172]. This observa-
tion led de Vries et al. [143] to target EZH2 via inducible short
hairpin RNAs (shRNA) in mouse-derived GSCs. Prolonged EZH2
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yielding highly proliferative and undifferentiated tumors and
resulting in increased tumor progression. Importantly, gene
ontology analysis identiﬁed DNA Repair as a major enriched term
in EZH2-depleted GBMs where key HR factors including RAD51
were upregulated. In vitro and in vivo experiments indicated that
enhanced DNA repair resulting from EZH2 inhibition decreased the
sensitivity of GBM cells to TMZ, highlighting a crucial role for
RAD51-mediated DSB repair in this process. The authors suggest
that concomitant inhibition of EZH2 and HR (e.g., RAD51) might
potentiate TMZ toxicity in GBM [143].
Although they may operate more indirectly, the H3.3G34R/V
mutations, like H3K27M, could also affect DNA damage response
activities in GBM. Indeed, point mutations in H3.3G34 decrease the
levels of H3K36me3 on the same and nearby nucleosomes, and the
evidence suggests that the G34R/V mutant histones disrupt the
activity of SETD2, the only methyltransferase that mediates
trimethylation of K36me2 in H3 and H3.3 [166]. H3.3 variant
histones are enriched at telomeres and pericentromeres. Thus, it
remains to be seen how H3.3G34R/V-induced local perturbations
of H3K36me3 and H3.3K36me3 might affect DNA repair and
genetic instability. However, the documented role of H3K36me3, a
mark associated with transcription elongation in active genes, as
an important modulator of MMR [141] and HR-mediated DNA
repair [142,173] suggests that depletion of SETD2 may impact the
response of GBM cells to genotoxics. Importantly, point mutations
in SETD2 have been identiﬁed in pediatric and adult GBMs [174].
6.2.2. IDH1 and the glioma-CpG island methylator phenotype (G-
CIMP)
Mutations in isocitrate dehydrogenase (IDH) 1 and 2 (metabolic
enzymes which convert isocitrate into a-ketoglutarate (a-KG, also
called 2-oxoglutarate)) occur predominantly as driver mutations in
low grade gliomas and secondary high grade gliomas, although
IDH1 mutations have been observed in 6% of GBM [4,175–177].
IDH1 mutations are associated with longer patient survival and
improved response to TMZ. The most frequent mutation in IDH1 is
R132H, a gain-of-function mutation that confers the ability to
convert a-KG into 2-hydroxyglutarate (2-HG). Because 2-HG
inhibits Fe(II)- and 2-oxoglutarate-dependent oxygenases such
as histone lysine demethylases [178] and DNA demethylases [179],
its accumulation in IDH1R132H tumors has the potential to
generate global epigenetic defects and alter gene expression [180].
The R132H mutation in IDH1 is closely associated with the glioma-
CpG island methylator phenotype (G-CIMP) deﬁned as the
concerted hypermethylation of a large number of loci [181].
Although it is more prevalent among low- and intermediate-grade
gliomas, this phenotype appears to be also enriched in a subset of
primary GBMs belonging to the proneural subtype (one of 4 GBM
subtypes  proneural, neural, classical, mesenchymal  proposed
by Verhaak et al. [66]) where it is associated with a younger age at
diagnosis and better survival [181]. Expression of a G-CIMP
phenotype, which could be obtained by the sole introduction of
exogenous IDH1R132H into primary astrocytes was suggested to
result from 2-HG-mediated inhibition of DNA demethylating
enzymes such as TET2, and probably also from DNA-methylation
promoting alterations in H3K9me2 and H3K27me3 [182]. Recently,
a reﬁned classiﬁcation of gliomas based on G-CIMP status, DNA
methylation proﬁles and IDH mutation has been proposed [183].
The impact of mutant IDH1 on the cellular response to TMZ was
investigated by Ohba et al. [127], using MGMT-deﬁcient human
astrocytes immortalized by expression of virally-encoded E6, E7
and hTERT, and infected with lentiviral constructs encoding wild-
type or mutant IDH1 (which in both cases led to cellular
transformation). Compared with wild-type cells, IDH1R132H cells
displayed more efﬁcient processing of TMZ-induced DSB lesionsand increased survival. Furthermore, mutant IDH1-driven trans-
formation resulted in enhanced RAD51-mediated HR, and siRNA-
mediated depletion of RAD51 reduced the TMZ resistance
conferred by overexpression of mutant IDH1. Thus inhibitors of
HR may offer an efﬁcient therapeutic options in IDH1 mutant GBM
tumors.
In addition to an indirect effect resulting from the impact of
global epigenetic and gene expression alterations, mutations in
IDH1 have recently been shown to also exert a direct effect on
alkylated DNA repair enzymes in GBM cells. Thus, Wang et al. [19]
found that 2-HG produced by IDH1 mutants inhibited, in vitro,
puriﬁed recombinant forms of the Fe(II)- and a-KG-dependent
DNA demethylases ALKBH2 and ALKBH3, the major enzymes
involved in the removal of N1-meA and N3-meC (Fig. 1). Further-
more, characterization of GBM cells engineered to express wild-
type or R132H mutant IDH1, together with manipulation of
heterozygous IDH1+/R132C ﬁbrosarcoma cells and ALKBH2/3-over-
expression experiments indicated that mutant IDH1 sensitize cells
to DNA alkylating agents through 2-HG-mediated inhibition of
ALKBH2 and ALKBH3. The clinical relevance of these ﬁndings are
supported by a previous report that ALKBH2 confers resistance to
TMZ in GBM cells [20].
IDH1-mediated oxidative decarboxylation of isocitrate to a-KG
is accompanied by production of NADPH from NADP+. IDH1
mutant cells are thought to display lower production of NADPH, an
important player in the cellular defense against oxidative damage,
which was proposed to sensitize GBM to chemoradiation [184]. Shi
et al. [185] showed that the decreased intracellular NADPH levels
elicited by overexpression of the IDH1R132H mutation were
associated with glutathione (GSH) depletion and ROS generation.
However, conﬂicting data have been obtained when the impact of
IDH1R132H overexpression on the response of GBM cells to
genotoxics was tested. Thus, one study found that, compared with
control cells and cells overexpressing wild-type IDH1, over-
expression of IDH1R132H sensitized U87 and U251 cells to TMZ
[186]. Another study found that overexpression of IDH1R132H
conferred sensitivity to IR, but not TMZ in U87 and U373, whereas
overexpression of wild-type IDH1 increased resistance to TMZ
compared to control cells [141]. It should be noted that IDH1-
overexpressing cell lines most likely do not recapitulate the
endogenous IDH1 mutant status of glioma cells (see Section 7.2).
Although MGMT promoter methylation is more prevalent in G-
CIMP GBMs than in non-G-CIMP GBMs (79% vs 46%, respectively),
MGMT promoter methylation correlated with patient response
only in the classical subgroup but not in the proneural subgroup
[4]. Furthermore, analysis of hypermethylated and downregulated
genes within proneural G-CIMP positive tumors [181], did not
show signiﬁcant enrichment in DNA damage signaling and DNA
repair. These observations suggest that the impact of the G-CIMP
phenotype on DNA repair in GBMs might be limited.
7. Discussion
7.1. Integrative strategies that must be considered for genotoxic-based
therapeutic management of GBM
Elucidating the DNA repair pathways and factors activated by
GBM cells in response to IR and TMZ-induced lesions, identifying
selective DNA repair inhibitors that can be used as monotherapy or
in combination with chemoradiation, and deﬁning the (epi)genetic
features that shape the DNA-repair makeup of GBM cells, are
crucial steps to tackle the development of resistance currently seen
in GBM patients whilst tailoring treatment to the patient’s tumor.
Signiﬁcant progress has been made in our understanding of the
molecular details of the DNA repair mechanisms that operate in
GBM, leading to the discovery of novel, druggable DNA repair axes,
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studies are expanding the list of pathways that could be targeted by
a given inhibitor. In addition, several studies have helped reﬁne the
molecular settings in which speciﬁc DNA repair inhibitors, such as
PARPi, can be used. Most relevant in this respect is the fact that
GBM cells have to cope with pervasive oxidative DNA damage
resulting from ROS production, rendering them more dependent
upon the BER machinery.
GBM driver mutations have recently been described in genes
encoding (e.g., H3.3, ATRX, DAXX) or affecting (e.g., IDH1)
epigenetic factors, raising the issue of whether drugs capable of
reprogramming abnormal epigenomes may compose part of the
therapeutic arsenal against glioblastoma [187]. Although driver
mutations in histone H3 variants have been discovered in pediatric
GBMs, the evidence suggests that at least some of their phenotypic
consequences might also be recapitulated in adult GBMs, through
MLL5-mediated repression of H3.3 expression. Moreover, it is
notable that the resulting amino-acid changes in H3.3 mutants
affect post-translational modiﬁcations that can also be impacted
by alterations in epigenetic writers such as EZH2 and SETD2, as
such alterations are also found in adult GBMs. Thus, future lessons
learned from the characterization of pediatric GBMs might, to
some extent, serve in the management of adult GBMs as well. The
changes in gene expression and chromatin dynamics induced by
such mutations/alterations appear to impact the DNA repair
capacity and response of GBM cells to chemoradiation. Based on
the documented effect of histone deacetylase (HDAC) inhibitors
[188,189] and DNA methyltransferase inhibitors [190,191] on DNA
repair, it is tempting to speculate that epigenetic drugs may help
reverse the adverse effects (e.g., resistance to genotoxics)
associated with altered DNA repair in GBM, in part by impacting
the expression of DNA repair factors or perturbing DNA repair-
associated chromatin modiﬁcations. Moreover, HDAC inhibitors
have been shown to trigger not only widespread changes in histone
acetylation but also, by mechanisms that remain obscure, the
production of ROS [188], thus imposing an extra burden for DNA
repair that might be exploited in therapeutic strategies.
How speciﬁc GBM driver mutations/alterations affecting other
processes than epigenetics impact DNA repair remains a matter of
investigation that would greatly beneﬁt from the characterization
of DNA repair genes and pathways in GEMMs. Likewise, knocking
down selected DNA repair genes in these models may help
elucidate the contribution of speciﬁc DNA repair defects (for
instance, caused by downregulation of DNA repair factors) to
glioblastomagenesis and response to genotoxics.
7.2. Considerations on the cellular and animal models used to study
DNA repair in GBM
The great variety of GBM-derived cells currently used both in
vitro and in preclinical studies with animal models raises issues
that are of paramount importance in DNA repair and chemothera-
py. Indeed, preservation of the genetic and epigenetic alterations of
the original tumor is crucial to maintain the “DNA repair makeup”
of the tumor cell and study its impact on DNA repair and cellular
response to genotoxics. Although they commonly serve as in vitro
model, established GBM cell lines (such as U87, U251, T98 etc.)
suffer the limitation of having incurred genetic alterations,
changes in DNA ploidy, clonal selection and novel gene–gene
interactions during adaptation to and prolonged passages in
monolayer cultures. The inability of these models to preserve
genetic and epigenetic features of the original tumor is also
reﬂected in their failure to recapitulate the pathohistological GBM
phenotypes in xenografts [47,192]. Thus, tumor invasion, inﬁltra-
tion, necrosis, and vascular proliferation in these models are
usually not comparable to a GBM in patients. The questionablepertinence of such cellular models for the study of DNA damage
also stems from the conﬂictual results to which they can give rise,
as illustrated, e.g., by two studies of the response to TMZ conferred
by mutant IDH1 expressed in U87 cells ([141,186], see Sec-
tion 6.2.2). Although the observed discrepancies might be due to
inter-laboratory variations within U87 lines, it may be argued that
U87 cells, which were established from an adult GBM, do not
represent an adequate model to investigate the impact of mutant
IDH1 since, unlike the astrocyte-derived model generated by Ohba
[127], expression of the IDH1 mutation played no role in their
genesis. Thus, extrapolating conclusions from studies involving
established GBM cell lines must be done with caution. Organotypic
spheroids formed from patient-derived GBM biopsies better
preserve the original tissue architecture, the genomic proﬁle
and DNA ploidy of the parental tumor [7,193]. Importantly, such
spheroids do not undergo passaging and selection in vitro and,
instead, can be maintained by serial transplantation in vivo, which
maintains the original genetic and phenotypic heterogeneity of the
biospy [194]. Similarly, GSC sphere cultures partially reiterate the
molecular features of the original tumor and we have recently
shown that such cell lines establish similar histological phenotypes
as organotypic spheroid-based xenografts [194]. Nevertheless, GSC
cultures also undergo in vitro selection and changes in DNA ploidy
[7].
GBM cell lines are often preferred tools because they can be
engineered to express a transgene or subjected to RNA interfer-
ence-mediated gene silencing using shRNAs. In the case of PDXs
based on organotypic spheroids, efﬁcient gene silencing is
challenging but can be obtained with lentiviral vectors without
selection, which minimizes the risks of genetic drift. In principle,
xenograft models should also be amenable to gene knockout
through genome-editing technologies such as TALEN (Transcrip-
tion Activator-Like Effector Nucleases) or CRISPR (Clustered,
Regularly Interspaced, Short Palindromic Repeats), although the
cellular manipulations and time constraints associated with these
techniques will lead to selection processes and possibly genetic
drift.
7.3. Non-coding RNAs in the response of GBM tumors to
chemoradiation
Targeting of miRs regulating DNA repair is associated with a
therapeutic potential [195]. With the exception of the miRs that
affect MGMT expression, this review has not addressed the roles
played by miRs in glioblastomagenesis and response to genotoxics.
Other non-coding RNAs known as long non-coding RNAs have
emerged as essential elements involved in GBM development and
progression [196]. The roles of non-coding RNAs in DNA repair as
well as their potential as biomarkers and potential therapeutic
targets in the management of GBM remains largely to be
elucidated.
7.4. Improving the delivery of chemotherapeutic agents to the brain
The need for chemotherapeutic agents that cross the BBB
efﬁciently and maintain an effective steady state concentration
remains a serious challenge in the management of GBM. With the
exception of TMZ, most of the anti-cancer agents that have been
tested for the management of GBM fail to cross the BBB efﬁciently
[197]. Due to a short half-life in plasma, TMZ itself must be
administered in high systemic doses to achieve therapeutic levels
in the brain, leading to undesired side-effects, whereas the TMZ/
O6-BG combination results in hematopoietic toxicity.
Local intracerebral administration of drugs or macromolecules
has been regarded as desirable in order to bypass the obstacle of
the BBB and eliminate the potential undesired toxicity. Delivery
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polymers (Gliadel1 Wafer) [198]), Ommaya reservoir, or convec-
tion-enhanced delivery (CED) systems, make it possible to use
drugs that do not necessarily cross the BBB or whose adverse
systemic effects are too unsafe for the patient [199]. CED, for
instance, delivers drugs, macromolecules or nanoparticules
through one to several catheters placed stereotactically directly
within the resection cavity. Its safety was established in a study
investigating the delivery of a MGMT-siRNA/cationic liposome
complex in normal rat and pig brains treated or not with TMZ
[200]. Animal studies have also shown that CED-mediated
distribution of O6-BG via nanoparticles, in parallel with TMZ
treatment resulted in a 3-fold increase in median overall survival
compared with TMZ-only control animals [201].
Although such delivery techniques should greatly widen the
pipeline of genotoxic agents and DNA inhibitors that could be used
to treat GBM, the invasive nature of these procedures remains an
obstacle. Thus, the design of novel anti-cancer agents, including
DNA repair inhibitors, with better CNS bioavailability and the
ability to be administered intravenously or orally remains a crucial
challenge in the management of GBM.
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investigating changes in the expression of DNA repair and cell cycle genes in a cohort of paired 
biopsy samples (primary and recurrent tumor of the same patient) from patients treated with 
RT or RT+TMZ as a step to unravel the impact of chemoradiation on the DDR and identify 
potential targets for improving GBM therapy. In this manuscript, we identify and describe a 
27-gene signature that classified our patient cohort into two main groups which displayed 
inverse expression profiles. Interestingly, the tumor at relapse frequently display a gene 
expression profile different from that of its matched primary biopsy. Moreover, within the 
two main groups, the expression pattern at relapse was associated to progression-free 
survival. Finally, we demonstrate experimental evidence of group-specific vulnerabilities 
against genotoxicants and inhibitors of the cell cycle and DDR, with the prospect of 
personalized therapeutic strategies based on patient profiling using our gene signature.   
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9 Abstract
11 Inevitable tumor recurrence and a poor median survival are
12 frustrating reminders of the inefﬁcacy of our current standard
13 of care for patients with newly diagnosed glioblastoma
14 (GBM), which includes surgery followed by radiotherapy and
15 chemotherapy with the DNA alkylating agent temozolomide.
16 Because resistance to genotoxic damage is achieved mainly
17 through execution of the DNA damage response (DDR) and
18 DNArepair pathways, knowledge of the changes inDNA repair
19 and cell-cycle gene expression that occur during tumor devel-
20 opment might help identify new targets and improve treat-
21 ment. Here, we performed a gene expression analysis targeting
22 components of the DNA repair and cell-cycle machineries in
23 cohorts of paired tumor samples (i.e., biopsies from the same
24 patient obtained at the timeof primary tumor operation and at
25 recurrence) from patients treated with radiotherapy or radio-
26 therapy plus temozolomide. We identiﬁed and validated a 27-
27 gene signature that resulted in the classiﬁcation of GBM speci-
28 mens into three groups, two of which displayed inverse
29 expression proﬁles. Each group contained primary and recur-
30 rent samples, and the tumor at relapse frequently displayed a
31 gene expression proﬁle different from that of the matched
32 primary biopsy. Within the groups that exhibited opposing
33 gene expression proﬁles, the expression pattern of the gene
34 signature at relapse was linked to progression-free survival.We
35 provide experimental evidence that our signature exposes
36 group-speciﬁc vulnerabilities against genotoxicants and inhi-
37 bitors of the cell cycle and DDR, with the prospect of person-
38 alized therapeutic strategies.
39 Signiﬁcance: Findings suggest that classiﬁcation of GBM
40 tumors based on a DNA repair and cell-cycle gene expres-
41 sion signature exposes vulnerabilities to standard-of-care
42 therapies and offers the potential for personalized thera-
43 peutic strategies.
44
45 Introduction
46 Despite surgical resection and genotoxic treatment with
47 ionizing radiation (IR) and the DNA alkylating agent temozo-
48 lomide, glioblastoma (GBM) remains one of the most lethal
49 cancers. Although occasional long-term survivors are
50 reported (1), patients with GBM have a poor median survival
51 (<1 year; refs. 2, 3), and all patients ultimately succumb due to
52 treatment resistance and tumor relapse. Resistance to chemor-
53 adiation is promoted by complex DNA repair mechanisms,
55including O6-methylguanine-DNA methyltransferase (MGMT),
56which mediates the direct removal of O6-methylguanine (O6-
57meG), the most cytotoxic lesion induced by temozolomide. In
58the absence of MGMT, processing of O6-meG by the mismatch
59repair (MMR) pathway ultimately leads to perturbations of the
60replication fork and double-stranded DNA breaks (DSB) that
61require complex machineries for their repair. The other lesions
62induced by temozolomide are repaired mainly through base
63excision repair (BER) or direct removal mechanisms catalyzed
64by the DNA demethylases ALKBH2/3 (reviewed in ref. 4).
65Concurrent andmaintenance temozolomidewas introduced to
66ﬁrst-line treatment for GBMs in 2005 (2). Prior to this date,
67temozolomide and other alkylating agents were mainly used as
68second-line therapy inpatientswith recurrent tumors (5, 6). In the
69clinic, two populations of patients can be distinguished on the
70basis ofmethylation of theMGMTgenepromoter-associated CpG
71island. Although patients with MGMT promoter–unmethylated
72GBM do not beneﬁt from temozolomide, epigenetic silencing of
73MGMT (observed in about 40% of patients with GBM) confers a
74small but signiﬁcant survival beneﬁt (2.5 months) in patients
75exposed to temozolomide and IR compared with patients treated
76with IR only (7). However, improved therapeutic strategies are
77clearly needed in all cases.
78Targeting components of the DNA damage response (DDR),
79including modulation of cell cycle and mitotic progression and
80genetic stability (8, 9), has emerged as an important therapeutic
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83 approach against many cancers. As a step toward improved
84 strategies to undermine DNA repair or exploit speciﬁc vulner-
85 abilities associated with GBM cells, we quantiﬁed the mRNA
86 expression levels of a selection of genes covering the major DNA
87 repair pathways, as well as important regulatory proteins and cell-
88 cycle control genes, in GBM specimens and control, nontumor
89 tissues. To this end, we exploited a cohort of paired GBM samples
90 (i.e., matched primary and recurrent tumor from the same
91 patients) that would allow us to address treatment-induced
92 changes in gene expression, including biopsies obtained from
93 patients treated with radiotherapy only (pre-2005) or with radio-
94 therapy plus temozolomide (post-2005) so that the impact of
95 temozolomide could be investigated.
97Materials and Methods
98Study cohort and validation datasets
99The K€oln cohort is described in Table 1. The expression data
100(Illumina microarray) pertaining to the 27 DNA repair and cell-
101cycle gene signature together with the relevant clinical data of the
102Heidelberg cohort (46 GBM pairs) are presented in Supplemen-
103tary Table S1. Ethical guidelines were followed for patient sample
104collection and all samples were anonymized. Written informed
105consents were received from the patients, and the project was
106approved by local ethical committees in Cologne (K€oln cohort,
107Application No. 03-170) or Heidelberg (Heidelberg cohort,
108Application No. 207/2005). Research was conducted according
Table 1. Clinical and relevant molecular features of the K€oln cohortQ5
Patient features
Male 32
Female 13
Mean age at diagnosis (y) 56.7 ! 10
Median 58 (30–73)
<50 12
50–70 30
>70 3
Clinical features Initial Recurrence
Karnofsky performance score >90% 3 1
70%–90% 28 22
<70% 3 8
NA 9 4
Resection Gross total 16 13
Partial 10 18
NA 10 12
Tumor locationa Frontal 9 5
Temporal 12 9
Parietal 4 3
Occipital 2 3
Multiple 15 14
NA 1 1
Histopathologic features
GBM (grade 4) 78
Tumor content >80%
Ki-67 (mitotic index) <10% 24
10%–30% 26
>30% 9
NA 19
IDH1 mutation status Negative 78 (100%)
Patient biopsies TMZ-na€"ve TMZ-treated
Unique samples Primary 11 32
Recurrence 10 25
Sample pairsb 9 24
MGMT promoter statusc (patients)
Unmethylated 20
Methylated 20
NA 3
PFS (months)
Mean 14.2
Median 9.8 (3.5–79)
OS (months)
Mean 21.8
Median 18.1 (4.6–87.9)
Abbreviation: TMZ, temozolomide.
aIn all paired biopsies (33 samples) of cohort, the recurrence is found at the same location as the primary tumor.
bPrimary and recurrent samples from same patient.
cMGMT status was assessed in primary samples.
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111 to the principles expressed in the Declaration of Helsinki. The
112 Wang cohort is composed of 61 GBM pairs from three individual
113 RNA-seq datasets (Korean_SMC, HF_MDA, TCGA_GBM) ana-
114 lyzed by RNA sequencing and described in (10), and which are
115 publicly available in the GlioVis database (http://recur.bioinfo.
116 cnio.es).
117 Biopsy procedure and characterization
118 All patients with GBM of the K€oln cohort underwent surgical
119 resection using standard craniotomy. The extent of resection was
120 evaluated through pre- and postoperativeMRI. Snap-frozen biop-
121 sies were used for analysis only if examination of their formalin-
122 ﬁxed parafﬁn-embedded counterpart by 2 independent neuro-
123 histopathologists revealed >80% tumor cells. MGMT promoter
124 methylation and IDH1 mutation status were assessed by DNA
125 pyro-sequencing as described previously (11, 12). IHC stainings
126 for Ki-67, PTTG1, AURKA, AURKB, and CENPA were performed
127 on representative tissue sections from selected cases of primary
128 and recurrent tumors fromG1andG3groups. IHCwasperformed
129 on an automated immunostainer (DAKO) using the UltraVision
130 Quanto horseradish peroxidase detection system with 3,30-dia-
131 minobenzidine tetrahydrochloride as chromogen (ThermoFisher
132 Scientiﬁc) and pretreatment of the sections by heating them in
133 citrate buffer pH 6.0. The following primary mouse mAbs were
134 used: anti-Ki67 (clone MIB-1, DAKO), anti-PTTG1 (clone DCS-
135 280, MBL Co., 1:50), anti-AURKA (clone JLM28, Leica Biosys-
136 tems, 1:50), anti-AURKB (clone mAbcam 3609, Abcam, 1:30),
137 and anti-CENPA (clone 3-19, MBL Co., 1:100). The expression of
138 Ki-67 was estimated using the following categories: <5%, 5%–
139 10%, 10%–20%, 20%–30%, 30%–40%, 40%–50%, and >50%
140 labeled nuclei.
141 RNA preparation and gene expression analysis
142 Total RNAwas extracted using themiRNeasy RNA Isolation Kit
143 (Qiagen) according to the manufacturer's instructions. Samples
144 with RNA integrity number (RIN) >7 and A260/280 1.8–2.2 were
145 sent to the VIB Nucleomics Core Facility for gene expression
146 analysis using the direct multiplexed nCounter technology
147 (NanoString; ref. 13) analysis and 154 gene probes (including
148 2 control, housekeeping genes) designed in silico.Gene expression
149 data are available in the ArrayExpress database (https://www.ebi.
150 ac.uk/arrayexpress) under accession number E-MTAB-6425.
151 Characterization of the GBM patient–derived spheroid cell
152 lines
153 GBMpatient–derived spheroid cell lines fromG1andG3group
154 tumors were obtained from the Heidelberg cohort, at the Depart-
155 ment of Neurosurgery (University Clinic Heidelberg, Heidelberg,
156 Germany). The cell lines were controlled for potential cross-
157 contamination using short tandem repeat DNA typing and tested
158 free ofMycoplasma. Cellswere cultured in serum-freeCSCmedium
159 (DMEMF-12 (Biowest L0093-500), supplementedwith 20%BIT-
160 100 (Provitro 204/3100), 1 U/mL Heparin (Sigma H3149-
161 25KU), 4 mmol/LQ6 Ultraglutamine (Lonza BE17-605E/U1),
162 100U Pen-Strep (Lonza DE17-603E), 20 ng/mL EGF (Provitro
163 1325950500), and 20 ng/mL FGF (Miltenyi Biotec 130-093-841)
164 in a humidiﬁed 37"C incubator under normal conditions
165 (5% CO2).
166 TheG1orG3 status of the two cell lineswas ascertained by qRT-
167 PCR analysis of the following genes from the signature: CCNA2,
168 CDC25, EME1, and TOP2A. To this end, RNAwas prepared using
170TRIzol reagent (Ambion 15596018) followed by retrotranscrip-
171tion using the iScript cDNA Synthesis Kit protocol (Bio-rad
1721708891). cDNA was then subjected to qPCR reaction in a ViiA7
173Real-time PCR system (Applied Biosystems), using the FastSYBR
174green mix (Applied Biosystems 4385612) and the following
175primers: CCNA2 (Forward (F): AAGACGAGACGGGTTGC,
176Reverse (R): GGCTGTTTACTGTTTGCTTTCC), CDC25C (F: GAC-
177ACCCAGAAGAGAATAATCATC, R: CGACACCTCAGCAACT-
178CAG), EME1 (F: CTCCATGATACCCCAGAGAGG, R: CCTGG-
179ACCTTCTGACTCGG, TOP2A (F: ACAAGACATCAAAGTGAAG-
180TAAAGCC, R: GCAGACTCAAAACACAGACAAAGC). The house-
181keeping genes used for normalization were GAPDH (F:
182CATGAGAAGTATGACAACAGCCT, R: AGTCCTTCCACGATAC-
183CAAAGT) and Ezrin (F: TGCCCCACGTCTGAGAATC, R: CGGC-
184GCATATACAACTCATGG). Comparison of the relative expression
185of each gene in the G1 and G3 cell line was carried out using the
186
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2(# DDCU)method.WesternblotanalysisofKi-67expression levels
in total cellextractswas carriedoutusing the followingmAbs:
anti-Ki67 (clone MIB-1, DAKO, 1:100), anti-GAPDH (clone
5174S,CellSignalingTechnology,1:1,000).
Forcytotoxicityassays,4,000cells/wellwereseeded in tripli-
cates in a 96-well plate format (Greiner 655101) followed by
incubationwiththeselecteddrugsfor48or72hours.Cytotoxicity
wasassayedusingtheWST-1reagent(Roche11644807001)and
absorbancesweredeterminedusing theClariostarreader(BMG
Labtech).
Statisticalanalysis
Differential gene expression analysis. Differentially expressed
geneswereidentiﬁedfollowingrawRNAcountsnormalization,
using theDESeq2package(rawRNAcounts; ref.14)or limma
package(15).Signiﬁcantgeneswere identiﬁedusingFDRand
foldchange.Functionalannotationofthegeneswascarriedout
usingthe topGORpackage.Pvalues in thefunctionalenriche-
mentanalysiswerecorrectedformultiplehypothesistestingby
FDR.
Genesignatureestablishmentandpatientclustering.A thorough 
coexpression analysis was used to assess a gene expression
patternabletosegregatetheK€olncohort.First,weidentiﬁeda
clusterofgeneswithhighly correlatedproﬁles as determined 
by calculation of the coefﬁcients of determination (R2)
observedbetween log-transformedgeneproﬁles.Second, this
cluster of 52 highly correlated genes was considered for the
classiﬁcationoftheclinicalsamplesusingnonnegativematrix
factorization (NMF; ref.16).After1,000-foldNMF iterations
with different initial estimations, the samples that clustered
togetherin90%oftherunswereassignedtotwoindependent
groups (G1 or G3), whereas samples showing less concor-
dance were assigned to an "undeﬁned"G2group.Reﬁnement
of the original 52-gene signature was achieved using the
method developed by Hein€aniemi and colleagues (17). In
this analysis, gene pairs are randomly assigned, tested for
speciﬁcity to our signature, and sorted according to their
potential to participate in the patient clustering determina-
tion.This resulted ina reﬁnedsignaturewith27geneswhich
have the same capacity to segregate our cohort in 2 distinct
groupsastheinitial52-genesignature,asdeterminedbyNMF
analysis.Therobustnessofthepatientgroupingobtainedwith
bothsignatureswasassessedbyleave-one-outcrossvalidation
(LOOCV)cross-validationand5-foldcrossvalidation.Forthe
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231 validation of the signature in the Heidelberg, Wang and Murat
232 cohorts, and The Cancer Genome Atlas (TCGA) GBM RNA
233 expression dataset, NMF was used to group GBM specimens
234 based on the expression of the 27 gene signature, as described
235 above.
236 Univariable Cox regression analysis.Univariable Cox proportional
237 hazards models were built using the R package survival (18), to
238 investigate thepotential impact of the following clinical factors on
239 survival: gender, age, MGMT status and Karnofsky Performance
240 Scale (KPS). Of these, age and KPSwere considered as continuous
241 variables, while others as categorical.
242 Signature reproducibility performance. Correlation between the
243 gene expression levels pertaining to the 27 gene signature among
244 the K€oln cohort and the validation datasets (Heidelberg and
245 Wang cohorts) was assessed by calculating the logFC for each
246 gene, followed by linear regression analysis.
247 Results
248 To investigate DNA repair and cell-cycle control gene expres-
249 sion inGBM,weusednCounter technology, a robust and sensitive
250 method allowing multiplexed analysis of a panel of selected
251 genes (19), to analyze RNA extracted from the K€oln cohort
252 (Table 1) composed of samples from paired GBM biopsies
253 (n ¼ 66, of which 18 from temozolomide-na€"ve patients and
254 48 from temozolomide-treated patients) as well as unpaired
255 biopsies (n ¼ 12) and control, tumor-adjacent tissues (n ¼ 9).
256 All patients received radiotherapy and harbored wild-type IDH1,
257 as determined by DNA sequencing. Because of the nCounter gene
258 expression format, we focused on 154 genes encompassing the
259 major DNA repair pathways: base excision repair (BER), nucle-
260 otide excision repair (NER), mismatch repair (MMR), homolo-
261 gous recombination (HR), nonhomologous end joining (NHEJ),
262 direct repair enzymes (e.g., MGMT), Fanconi anemia (FA), as well
263 as a selection of genes encoding effectors and regulators of cell
264 cycle, DNA replication, DDR, centromere, and centrosome
265 dynamics (Supplementary Table S2). These genes were chosen
266 based on the available literature on the response of GBM cells to
267 chemoradiation and in particular to temozolomide (4).
268 Crucial alterations inDNA repair and cell-cycle gene expression
269 distinguish subsets of GBM tumors
270 In preliminary comparisons of tumor samples with control,
271 tumor-adjacent tissues, detailed in Supplementary Data S1, we
272 identiﬁed lists of differentially expressed genes (DEG) associated
273 with primary (72 genes) and recurrent GBM tumors (71 genes).
274 These lists displayed extensive overlap, with 67 genes in common
275 that exhibited comparable fold change direction and intensities.
276 Accordingly, no DEGs were identiﬁed upon direct comparison of
277 primary and recurrent GBM samples. Notably, no temozolomide-
278 associated changes in gene expression were observed when temo-
279 zolomide-na€"ve and temozolomide-treated recurrent biopsies
280 were compared.
281 Failure to identify temozolomide-associated gene expression
282 changes using global DEG analysis of unstratiﬁed specimens
283 prompted us to examinewhether stratiﬁcationwould help uncov-
284 er such genes in a subset of patients. To address this issue andwith
285 the aim of relating our ﬁndings to tumor recurrence, we ﬁrst
286 subjected the gene expression data from the paired biopsies (66
288specimens) to a coexpression analysis and obtained a set of 52
289genes associated with highly correlated proﬁles (Supplemen-
290tary Fig. S1A). We then used this set of genes for the stratiﬁ-
291cation of our specimens using NMF. The resulting heatmap
292(Supplementary Fig. S1B) revealed that this 52-gene signature
293segregated the biopsies into 2 well-deﬁned groups (hereafter
294called G1 and G3) that displayed an inverse expression pattern
295of the gene signature, leaving 10 samples with a more neutral
296proﬁle in a separate group called G2. Our 52-gene signature was
297robust, as evaluated by 2 forms of cross-validation [mean
298sample misclassiﬁcation error: 0.0606 (LOOVC), 0.087 (5-fold
299cross-validation)].
300The signature contained 2 subsets of genes [component A (n ¼
30127) and B (n ¼ 25) of Supplementary Fig. S1C] characterized by
302inverse expression in G1 and G3. Furthermore, component A was
303found to contain all the cell cycle–associated genes in the
304signature.
305A 27 DNA repair and cell-cycle gene signature in primary and
306recurrent GBM
307Inspired byHein€aniemi and colleagues (17), we reﬁned the 52-
308gene signature by analyzing the predictive power of all gene pairs
309able to reproduce the initial classiﬁcation. We identiﬁed a subset
310of 27 geneswithinwhich each gene pair displayed high prediction
311ability [meanmisclassiﬁcation error: 0.0758 (LOOCV), 0.086 (5-
312fold cross-validation)] and, interestingly, highly positive coex-
313pression (Fig. 1A). Notably, 21 of those 27 genes belonged to
314component A (Supplementary Fig. S1C) of the original signature.
315The resulting heatmap generated by NMF clustering is presented
316in Fig. 1B, again revealingG1 andG3 groups presenting an inverse
317gene expression pattern, and a third less-deﬁned group (G2), as
318observed with the original signature (Supplementary Fig. S1B).
319All 3 groups contained both primary and recurrent samples.
320Indeed, stratiﬁcation into 3 groups was also obtained when
321primary and recurrent biopsies were considered separately, and
322when an independent cohort of primary GBMs (20) was exam-
323ined (see below). However, whereas some patients (13/33) had
324both their primary and recurrent biopsies in the same group, in 20
325of 33 patients, the recurrence was traced to a group distinct from
326that of the primary tumor (Fig. 1C), a notion hereafter referred to
327as group migration. These observations indicate that relapse was
328often associated with signiﬁcant alterations in DNA repair and
329cell-cycle gene expression. The degree of alteration culminated in
330patients whose paired biopsies showed inverse gene expression of
331the signature (Fig. 1B). Similar group migrations were observed
332with the original 52-gene signature (Supplementary Fig. S1D).
333Description of the 27-gene signature
334Our 27-gene signature contains important effectors and reg-
335ulators of the cell cycle, centromere and centrosome dynamics,
336chromosome segregation, andmitosis (AURKA, AURKB, CCNA2,
337CCNB1, CDC25C, CDC6, CDK1, CENPA, CENPF, MKI67,
338PCLAF, PLK1, PTTG1, TOP2A), as well as genes encoding crucial
339HR factors such as the RAD51 recombinase, the chromatin remo-
340delers RAD54B and RAD54L, and enzymes involved in Holliday
341junction resolution (EME1/MUS81 complex) and/or NER
342(ERCC3(XPB), ERCC4(XPF)). Also in the signature were genes
343encoding the DNA glycosylase NEIL3, Fanconi Anemia factors
344(FANCD2, UBE2T), the ubiquitin protein ligase UBE3B and 2
345specialized DNA polymerases, POLM, and POLQ, involved in
346NHEJ pathways of DSB repair. None of these genes have been
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349 associated to sites of frequent copy number alterations (21) or
350 found to be signiﬁcantly mutated (22) in GBM.
351 Given the inverse gene expression proﬁle displayed by the G1
352 and G3 groups and the large number of genes involved in cell
353 cycle and mitosis regulation in our signature, including MKI67
354 encoding the proliferation marker Ki-67, we further investigat-
355 ed the expression of this marker at the protein level. IHC
356 staining of Ki-67 revealed that 95% of the G1 samples exhibited
357 a low Ki-67 index (<10%), whereas 72% of G3 samples dis-
358 played a high Ki-67 index (>30%; Fig. 2), in line with the gene
359 expression data and suggesting that the net effect of the
360 observed upregulation of the cell-cycle genes in G3 was
361 increased proliferation. Additional immunostainings for
362 PTTG1, AURKA, AURKB, and CENP-A were carried out using
363 selected primary and recurrent tumors from the G1 and G3
364 groups (Fig. 2), globally validating the expression of these
365 genes at the protein level.
366 Validation of the 27 DNA repair and cell-cycle gene signature
367 We next sought to validate our signature by challenging two
368 datasets: the Heidelberg cohort (biopsy pairs n ¼ 46) and a
369 heterogenous collection described in ref. 10, hereby referred to
370 as the Wang cohort (biopsy pairs n ¼ 61).
372NMF clustering of the Heidelberg cohort generated 3 groups
373that exhibited proﬁles reminiscent of the G1, G2, and G3 groups
374(Supplementary Fig. S2A) and displayed signiﬁcant group migra-
375tion (Supplementary Fig. S2B). Similar observations were made
376with the Wang dataset (Supplementary Fig. S2C and S2D). Fur-
377thermore, although the heatmaps generated by NMF suggested
378that, when considered individually, not all the genes of our
379signature performed equally well in the validation datasets, the
380behavior of the gene signaturewas concordant among all datasets,
381as revealed by linear regression analysis (P values: 0.0019 for K€oln
382and Heidelberg; 6.1 % 10# 6, for K€oln and Wang; Supplementary
383Fig. S2E and S2F). Thus, our 27-gene signature allowed classiﬁ-
384cation of GBM tumors based on DNA repair and cell-cycle gene
385expression, and performed equally well with datasets generated
386by different RNA analysis platforms.
387We next asked whether the stratiﬁcation afforded by our sig-
388nature now allowed temozolomide-associated changes to be
389uncovered in speciﬁc subsets of samples. Comparable numbers
390of recurrences from temozolomide-na€"ve and temozolomide-
391treated patients were found within each group (Fig. 1B), suggest-
392ing that the clustering was independent of temozolomide treat-
393ment. Moreover, within-group comparisons of the recurrences
394from temozolomide-na€"ve and temozolomide-treated patients
Figure 1.
A 27 gene signature of DNA repair and cell-cycle expression in primary and recurrent GBM.A,Coexpression heatmap of the 27 genes identiﬁed following gene
pair-combination analysis. B,Expression heatmap of the 66 GBM specimens from the K€oln cohort obtained with the 27-gene signature. Genes were sorted by
hierarchical clustering, as shown on the left of the heatmap. Standardized expression values are depicted using a red (high) to green (low) color key. Neon green
and yellow squares mark temozolomide-na€"ve and -positive patients, and blue and red squares denote primary and recurrent samples, respectively. NMF
clustering groups are shown in light green (G1), gray (G2), and light red (G3). C,Sankey diagram illustrating the changes in gene expression groups (G1, green;
G2, grey; G3, red) observed at relapse among the tumor pairs stratiﬁed by the 27-gene signature. The total number of samples in each group is indicated.Q7
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397 did not uncover DEGs among the whole gene set, indicating that
398 the initial failure to observe temozolomide-associated genes in
399 our cohort was not due to lack of patient stratiﬁcation. Finally,
400 when we considered the 31 of 33 patients with known MGMT
401 methylation status of the primary tumor, we found no statistically
402 signiﬁcant differences in the representation ofMGMT-methylated
403 and -unmethylated specimens among the 3 groups. The lack of
404 annotations on MGMT promoter methylation status in the Hei-
405 delberg and Wang cohorts led us to ascertain this observation
406 using the cohort of primary GBM specimens with well-deﬁned
407 MGMT status described by Murat and colleagues (20). NMF
408 clustering of the 84 samples of this cohort using our 27-gene
409 signature again identiﬁed 3 groups, including well-deﬁned G1
410 and G3 groups (Supplementary Fig. S3A). In these 2 groups, the
411 relative distribution of specimens withmethylated and unmethy-
412 lated MGMT promoter was identical (Supplementary Fig. S3A),
413 indicating that the clustering was independent of MGMT pro-
414 moter methylation status.
415 Speciﬁc alterations of DNA repair and cell-cycle gene
416 expression at relapse correlate with prognosis
417 We next examined progression-free survival (PFS) and
418 overall survival (OS) in the 3 groups. When only primary
419 tumors were considered, analysis of these endpoints showed
420 no signiﬁcant differences between the groups, neither in the
421 paired GBM cohorts, nor in two independent cohorts of
422 primary GBMs (Murat and colleagues; Supplementary Fig.
423 S3B; ref. 20), and the TCGA GBM RNA expression dataset
424 (Supplementary Fig. S4). In contrast, when only the recurrent
426biopsies of the K€oln cohort were analyzed, we found a
427signiﬁcant difference in PFS between patients with G1 and
428G3 biopsies: PFS was longer among patients with a G3
429recurrence (12.3 months), compared with those with a G1
430recurrence (6.05 months, Fig. 3A). A similar trend was
431observed with OS, although not statistically signiﬁcant (inset
432in Fig. 3A). Importantly, univariable Cox analysis of the K€oln
433dataset interrogating age, gender, MGMT promoter status,
434KPS, and grouping identiﬁed the recurrence association with
435a speciﬁc group as the sole parameter inﬂuencing PFS (P ¼
4360.019; Supplementary Table S3).
437Group migration analysis in the K€oln dataset revealed that all
438transitions were possible (Fig. 1C), and this was corroborated in
439the other datasets (Supplementary Fig. S2B and S2E). To further
440explore the impact of group migration on the survival para-
441meters, we assembled patients of the K€oln cohort based on the
442migration behavior of their recurrence, thus creating 4 categories
443(A–D) corresponding, respectively, to those patients with altered
444recurrence in G1 (A), G2 (B), G3 (C) or with unaltered recur-
445rence (D). Pairwise analyses revealed that the worst PFS and OS
446were associated with category A (i.e, progression to G1; Fig. 3B).
447These ﬁndings were reinforced by the observation that both PFS
448(Fig. 3C) and OS (Fig. 3D) were signiﬁcantly worse in patients
449with G1 recurrences (rG1) originating from G3 primaries (pG3;
450deﬁned as pG3-rG1, red line) than in patients with G3 recur-
451rences originating from either G1 or G3 primaries (pG1-rG3,
452black line and pG3-rG3, green line), suggesting that these
453patients contributed the major determinant behind the poor
454prognosis associated with category A. Taken together, our data
Figure 2.
Immunostaining for Ki-67, PTTG1,
AURKA, AURKB, and CENPA in
sections of G1- and G3-group
tumors. Shown are selected primary
and recurrent GBM specimens
representative of the G1 and G3
groups from the K€oln cohort. Note
the high and low nuclear Ki-67
positivity in G3 and G1 tumors,
respectively. In addition, little or no
expression of PTTG1, AURKA,
AURKB, and CENPA is detected in
G1 tumors as compared with their
clear detection in G3 tumors. All
sections are counterstained with
hemalum. Brown staining indicates
immunopositivity. Magniﬁcation of
each picture was % 400 (scale bars,
50 mm).
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457 suggest that alterations of the DNA repair and cell-cycle gene
458 expression signature at relapse are associated with signiﬁcant
459 changes in prognosis, with a transition to G1 translating into the
460 poorest prognosis. Finally, the G1 and G3 groups presented
462similar proportions of recurrent tumors from temozolomide-
463treated and -na€"ve patients (Fig. 1B), indicating that the observed
464difference in survival between G1 and G3 was not related to
465temozolomide treatment.
Figure 3.
Prognostic values associated with the 27 DNA repair and cell-cycle gene signature in the K€oln (A–D) and Heidelberg (E and F) cohorts.A,Kaplan–Meier plots of
the PFS and OS (inset) associated with patients displaying a recurrent GBM tumor in the G1 (rG1, blue line) or G3 (rG3, black line) expression group. B,PFS
associated with the following migration categories: cat. A (migration to G1, purple line), cat. C (migration to G3, orange line) and cat. D (nomigration, black line).
C and D,Kaplan–Meier plots of the PFS (C) and OS (D) associated with the indicated comparisons. E,Kaplan–Meier plots of the PFS and OS (inset) associated
with patients displaying a recurrent GBM tumor in G1 (rG1, blue line) or G3 (rG3, black line). F,Kaplan–Meier plots of the OS associated with the indicated
comparisons.
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468 That aG1-type expressionpattern at relapsewas associatedwith
469 worse survival parameters was also observed in the Heidelberg
470 cohort where statistically signiﬁcant differences in PFS and OS
471 were seen bothwhen all recurrences were considered (Fig. 3E) and
472 when group migration was highlighted (Fig. 3F).
473 Having shown that a recurrent G1 tumor was associated with
474 worse prognosis (Fig. 3C, D, and F), we next examined whether it
475 was themigration toward theG1groupor themere presence inG1
476 that was associated with poor prognosis, by comparing pG1-rG1
477 and pG2/G3-rG1 patients. As only one patient of the K€oln cohort
478 belonged to the ﬁrst category, we focused on the Heidelberg
479 cohort. Although pG1-rG1 patients (n ¼ 3) had worse prognosis
480 than pG2/G3-rG1 patients (n ¼ 14; PFS: 6 vs. 15.5months;OS: 17
481 vs. 25.4 months), the differences were not statistically signiﬁcant.
482 Noassociation couldbe establishedbetween gene expression at
483 relapse and survival parameters in the Wang cohort. Based on
484 published work (23), we considered differences in the age dis-
485 tribution as a potential explanation for this ﬁnding. Indeed, while
486 there was no statistical difference in age between the K€oln cohort
487 (median age: 58 years, range: 30–73) and the Heidelberg cohort
488 (59 years, range: 32–81; P ¼ 0.73, Wilcoxon test), the difference
489 was signiﬁcant between the K€oln andWang cohorts (median age:
490 52 years, range: 29–74; P ¼ 1.2 % 10# 5, Wilcoxon test), with the
491 age distribution in the Wang cohort being shifted towards youn-
492 ger patients. In addition, unlike the K€oln and Heidelberg cohorts,
493 Cox regression analysis indicated that age had an impact on
494 survival of patients in the Wang cohort (P ¼ 1.04 % 10# 6). Age
495 is a strong prognostic factor among patients with GBM, with
496 younger age correlating with improved survival (24). Thus,
497 although the contribution of other clinical factors cannot be
498 excluded, our observations suggest that our failure to validate
499 the prognostic impact of our signature in theWang cohort may in
500 part be due to the increased proportion of younger patients in this
501 cohort, which obscures the impact of our patient stratiﬁcation.
502 GBM transcriptional subtypes associated with the DNA repair
503 and cell-cycle gene signature
504 Recent reﬁnement of the gene expression subtypes associated
505 with GBMs has led to three subtypes: proneural, classical, and
506 mesenchymal (10). Having validated our signature using cohorts
507 from this study, we used its annotations to probe the association
508 between our groups and the transcriptional subtypes. Notably,
509 when all the biopsies were considered (i.e., primary and recurrent
510 specimens), we observed speciﬁc enrichment of mesenchymal-,
511 classical- and proneural-type tumors in group G1 (49%, P ¼
512 0.06), G2 (52%, P ¼ 0.01), and G3 (42%, P ¼ 0.01), respectively
513 (Supplementary Fig. S2D).
514 Biological processes associated with the G1 and G3 groups
515 Wenext investigated the biological processes that distinguished
516 theG1andG3groups displaying inverse expressionproﬁles of our
517 gene signature, using the RNA expression dataset from the Wang
518 cohort whose stratiﬁcation is shown in Supplementary Fig. S2.We
519 identiﬁed 2061 DEGs between the two groups (FDR < 0.001;
520 |logFC| >1), ofwhich 253were upregulated inG3 and1808 inG1
521 (Supplementary Fig. S5A; Supplementary Table S4). Gene Ontol-
522 ogy (GO) enrichment analysis (Supplementary Fig. S5B) indicat-
523 ed that GO terms corresponding to biological processes related to
524 cell cycle and cell division, chromosome organization and seg-
525 regation, DNA replication and repair, and chromatin assembly
526 and dynamics predominated among the DEGs upregulated in the
528G3 group. These results are in full agreement with the initial
529distinction of the G1 and G3 groups obtained with our gene
530signature. In contrast, the list of biological processes signiﬁcantly
531enriched among the DEGs upregulated in the G1 group included
532terms related to vesicle-mediated transport, apoptosis and autop-
533hagy, cellular adhesion, response to (chemical) stimulus, and
534response to stress. These results are consistent with the notion that
535G3 group tumors develop cellular programmes to sustain high
536proliferation, in contrast to G1 tumors which engage critical
537survival cellular processes.
538Mutations and copy number alterations underlying the groups
539identiﬁed by the DNA repair and cell-cycle gene signature
540As a step to determine whether speciﬁc genetic aberrations
541were associated with tumor development and/or progression
542within the groups identiﬁed by our signature, we took advantage
543of the availability of exome sequencing and copy number data
544for a subset of paired tumors of theWang cohort characterized by
545Kim and colleagues (25). We generated an oncoprint where the
546grouping assigned by NMF based on our signature was super-
547imposed on the panel of genetic aberrations related to frequent-
548ly ampliﬁed, deleted and mutated gene components of the
549major signaling pathways involved in the pathogenesis of GBM,
550previously determined for these samples (Fig. 4A). Notable
551differences between the G1 and G3 group tumors are schemat-
552ically summarized in Fig. 4B. Unlike G3 tumors, all G1 tumors
553displayed deletion of PTEN and also a high frequency of EGFR
554and PDGFRA ampliﬁcation, strongly implicating growth factor
555tyrosine kinase receptor pathways and the PI3K/PTEN/AKT
556pathway in the etiology of these tumors (26). In contrast, G3
557tumors were characterized by an increased number of cases with
558RB1 deletion, as well as a high frequency of mutations in TP53,
559PTEN, and NF1, suggesting that PI3K/PTEN/AKT, RB/CDKN2A-
56016, and TP53 pathways contributed to the development of G3
561tumors. Tumors from the G2 groups presented a composite
562pattern, for instance displaying increased frequency of TP53
563mutations compared with G1 tumors, but also higher frequency
564of PTEN deletion compared to G3 tumors (Fig. 4A). Finally,
565when groupmigrationswere considered in this small cohort, the
566majority of cases did not associate withmutations/alterations in
567the genes characterized by Kim and colleagues (25). In addition,
568no group migration involving pG3-rG1 was observed in this
569cohort. However, we noted that one case of pG1-rG3 migration
570involved transitions in the clonal status of TP53 and PTEN
571mutations, from subclonal in the initial G1 tumor to clonal in
572the recurrent G3 tumor.
573Experimental validation of the therapeutic vulnerabilities
574exposed by the DNA repair and cell-cycle gene signatures
575We next wanted to know whether our 52- and 27-gene
576signatures exposed group-speciﬁc vulnerabilities against clini-
577cally relevant genotoxics agents as well as inhibitors of the DDR
578and perturbators of the cell cycle. Indeed, increased expression
579of TOP2A in the G3 group suggested that G3 tumors might be
580more sensitive to topoisomerase II inhibitors such as etopo-
581side (27). Likewise, the downregulation of NER genes ERCC3/
582XPB and ERCC4/XPF in this group suggested that agents such as
583cisplatin that cause interstrand crosslinks requiring NER for
584their repair (28, 29), might be more efﬁcient against G3 tumors.
585We also considered inhibition of RAD51, involved in the
586recombinational repair of DSBs (30), which was upregulated
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589 in group G3 compared to G1, as well as inhibitors of mitotic
590 kinases, given the strong expression of AURKA, AURKB, CDK1
591 and PLK1 in G3.
592 Having successfully established two cell lines, NCH741f and
593 NCH481, from clinical biopsies obtained fromG1- andG3-group
594 patients, respectively, of the Heidelberg cohort, we ﬁrst veriﬁed
595 their G1 andG3 status by RT-qPCR analysis of selected genes from
596 the 27-gene signature, including CCNA2 and CDC25C, which
597 together form a gene pair with high predictive ability (mean
598 misclassiﬁcation error: LOOCV ¼ 0.07576; 5-fold cross validation
599 ¼ 0.09774 ! 0.0015; Fig. 5A, left). We also performed Western
600 blot analysis of Ki-67 showing increased Ki-67 levels in theG3 cell
601 line compared with the G1 cell line (Fig. 5A, middle), consistent
602 with the calculated doubling times for these cell lines (NCH481:
603 ca. 57 hours; NCH741f: ca. 104 hours). Importantly, these cell
604 lines were obtained and maintained in serum-free medium con-
605 ditions, which is crucial to preserve the biological status and
606 behavior of GBM cells, including their response to therapeu-
607 tics (31). Under these conditions, the cells grew as spheroids
608 (Fig. 5A, right).
609 We next treated the 2 cell lines with the DNA-damaging
610 agents etoposide and cisplatin, as well as inhibitors of RAD51
611 (i.e., RI-1) and mitotic kinases [i.e., anti-AURKA (alisertib) and
612 pan-AURK (tozasertib)] to which we expected cells from the G3
613 group to be more sensitive compared with G1 cells. Given that
614 inhibitors of the DNA repair factor PARP (PARPi; ref. 9) are
615 currently in clinical trials against GBM (32), we also tested the
616 PARPi olaparib. In this case, however, we could not predict
617 differences in sensitivity to the PARPi among G1- and G3-group
619tumor cells based on the expression of our gene signature
620components because synthetic lethality with PARP inhibition
621can be mediated by various defects in a plethora of DNA repair
622pathways (33, 34). The data from WST-1 cytotoxicity assays
623illustrated in Fig. 5B, show the statistically signiﬁcant increase
624in sensitivity of G3-group derived cells relative to G1-group
625cells, to all tested compounds with the exception of olaparib,
626for which no signiﬁcant differences were observed, in line with
627our gene expression data.
628Taken together, these data provide experimental evidence to
629suggest that analysis of GBM biopsies using our DNA repair and
630cell-cycle gene signature may help identify novel therapeutic
631strategies against subsets of GBM tumors.
632Discussion
633Previous studies sought to identifymolecular proﬁles speciﬁc to
634resistance to chemoradiotherapy by interrogating clinical out-
635come data and gene expression data generated from primary
636GBM specimens (i.e., collected before treatment; ref. 20). In this
637study, we focused on a cohort of paired GBM samples from
638patients treated with radiotherapy or radiotherapy plus temozo-
639lomide with the aim of exploring alterations in DNA repair and
640cell-cycle gene expression in primary GBMs and their recurrences.
641Although the use of paired biopsies is gaining momentum, their
642availability is still limited by the speed of progress in the biobank-
643ing of reliable and clinically annotated specimens. For GBM,
644paired biopsies predating the introduction of temozolomide in
645the clinic represent a scarce resource.
Figure 4.
A,Mutations and copy number alterations associated with the GBM groups identiﬁed by the DNA repair and cell-cycle gene signature.A,Oncoprint showing the
group status (G1, G2, G3) of the analyzed samples (ﬁrst panel) and cooccurrence with the indicated mutations and copy-number alterations, as determined by
Kim et al. (25). Second panel: clinical features [MGMT promoter methylation (mMGMT), mutated IDH1 (R132H or R132G), MMRmutations]; third panel: EGFRvIII
mutation; fourth panel: copy number alterations in the indicated genes; bottom panel: clonal/subclonal somatic mutations. B,Schematic summary of the
aberrations that distinguish G1 and G3 group tumors and their involvment in the GBM oncogenic pathways. Genes harboring signiﬁcant aberrations in G1 and G3
tumors are highlighted in yellow, with the percentage of mutations or copy number alterations found in each group speciﬁed in a pie chart; mutated and wild-
type genes are depicted in purple and striped, respectively; copy number alterations (deletion, ampliﬁcation, neutral) affecting these genes are presented in blue,
red, and white pie charts, respectively. Representation of the oncogenic pathways is based on Crespo et al. (26).
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648 Our analysis did not reveal temozolomide-related alterations
649 in the studied genes, or expression patterns predictive of response
650 to temozolomide. This observation suggests that the dynamics of
651 mRNAexpression in response to temozolomide treatment cannot
652 be assessed in clinical samples collected at the time of second
653 surgery, most likely due to the delay between the cycles of
654 temozolomide administration, tumor relapse, and sampling of
655 the recurrent biopsy. Experiments to investigate this question
656 would beneﬁt from patient-derived xenograft models where time
657 courses of gene expression in response to treatment can be carried
658 out, as underlined by studies in ovarian (35) or breast (36)
659 cancers. The mutagenic impact of temozolomide as a driving
660 mechanism in tumor progression and the selection of temozo-
661 lomide-resistant clones through defective MMR is well documen-
662 ted in gliomas (37–39) and GBM (40, 41). Future work should
663 focus on the mutational status of the MMR genes and other
664 mutations induced by temozolomide in our cohorts.
665 Our 27-gene signature clustered primary and recurrent GBMs
666 according to DNA repair and cell-cycle gene expression. Perfor-
667 mance comparison with other signatures is hampered by the
669current paucity of studies on paired biospies. Thus, a 412-gene
670classiﬁer has been described that segregated paired GBM speci-
671mens into 2 groups, revealing cases of group migration; however,
672no association between patient grouping and survival was
673reported (42). Although our gene signature could not be used
674to predict relapse-free survival based on the proﬁling of primary
675GBM samples, its expression pattern at the time of recurrence
676correlated with prognosis. As our signature contains 14 cell cycle
677genes that display high positive coexpression, it is striking that
678decreased expressionof these genes at relapse inG1was associated
679with shorter PFS. It is possible that the high Ki-67 proliferation
680index seen in the G3 recurrent tumors is associated with exacer-
681bated genetic and/or chromosomal instability, leading to
682increased mitotic catastrophe and cell death. Increased chromo-
683somal instability has been described in recurrentGBM(25, 43). In
684addition, deregulation of CENPA and CENPF, present in our
685signature, could contribute to the observed phenotype, because
686misregulation of centromere and kinetochore function leading to
687chromosomal instability contribute to tumor development and
688response to chemoradiation (44). Alterations in the division
Figure 5.
In vitro validation of the therapeutic vulnerabilities exposed by proﬁling of GBM tumors using the DNA repair and cell-cycle gene signature. A,Characterization of
the G1 (NCH741f) and G3 (NCH481) GBM patient-derived cell lines. Left, plot of the expression levels obtained by quantitative RT-PCR of the indicated genes
conﬁrming their expected upregulation in the G3 group relative to the G1 group (P < 0.05). Expression data were normalized against the GAPDH and ezrin
housekeeping genes. Middle, Western blot analysis of Ki-67 in total cell extracts. Right, optical microscopy images illustrating the two spheroid cultures (scale
bar, 1 mm). B,Effect of etoposide and cisplatin, as well as the indicated inhibitors [RI-1 (RAD51i); alisertib (AURKAi); tozasertib (pan-AURKi)] on the viability of
NCH741f (green line) and NCH481 cells (red line), as assessed using theWST-1 reagent. Differences in sensitivity between the two cell lines were analyzed by
direct t test comparisons and their signiﬁcance are indicated by P values.
Gobin et al.
Cancer Res; 2019 Cancer Research10
691 mode and differentiation status of the tumor cells and their
692 subpopulations may also affect chromosomal instability and
693 proliferation in ways that remain to be explored. As no standard
694 second-line treatment of GBM has yet been determined, patients
695 with recurrent GBM often receive complex modalities (5, 6).
696 Because the survival outcome of these patients may beneﬁt from
697 second-line therapy, in depth analysis of these modalities may
698 help determine the extent to which the improved OS of patients
699 with a G3-group recurrence reﬂects the impact of DNA repair and
700 cell-cycle gene expression on the tumor cell response to second-
701 line treatment. Such an analysis was not possible in our cohorts,
702 due to the lack of documented patient records and the large panel
703 of drugs that were considered as second-line treatment, resulting
704 inmultiple subgroups of patients whose small size precluded any
705 statistically signiﬁcant analysis.
706 It is notable that the G1 group from the Wang cohort was
707 enriched in mesenchymal-type specimens, since this subtype has
708 been shown to be associated with worse PFS in recurrent GBM
709 (ref. 45 and references therein). Furthermore, analysis of key
710 molecular alterations that underlie GBM in a small subset of
711 tumors from this cohort suggests that there are distinct molecular
712 drivers behind the groups identiﬁed by our signature. However,
713 extensive molecular characterization of the paired biopsies of our
714 cohorts, for example, by large-scale next-generation sequencing
715 approaches, will be required to understand the full impact of
716 chemoradiation on genomic alterations and reveal the molecular
717 drivers behind the groups detected in our studies and their
718 associated prognosis. Such comprehensive analyses are currently
719 pursued in large collaborative efforts such as the one undertaken
720 by the Glioma Longitudinal Analysis (GLASS) consortium (46).
721 Our gene signature exposes vulnerabilities against speciﬁcDDR
722 inhibitors, perturbators of mitosis, and/or genotoxic agents,
723 including several mainstream chemotherapeutics (etoposide, cis-
724 platin, carboplatin) previously considered, either alone (47–49)
725 or in combination (50, 51) against GBM. It is tempting to
726 speculate that the heterogeneity of the cohorts used in these
727 studies contributed to the limited efﬁciency attributed to these
728 compounds and that future studies might beneﬁt from patient's
729 tumor stratiﬁcation based on our signature. Potential modalities
730 also involve the targeting of crucial components of the DNA
731 damage response including RAD51 (9), which our data suggest
732 could prove an attractive target to undermineHR-mediated repair
733 of replication fork-associated DSBs in highly proliferative cells
734 (e.g., in G3-group tumors) or to sensitize these cells to IR and
735 genotoxic agents known to induce DSBs. The identiﬁcation of
736 patients that are likely to beneﬁt from PARP inhibition remains a
737 challenge (33, 34), and we could not predict differences in
738 sensitivity to the PARPi olaparib used as a single agent based on
739 the expression of our gene signature components. Future experi-
740 ments will need to consider PARPi in combination with DNA-
741 damaging agents or otherDDRi. Our data also lend support to the
742 use of mitosis perturbators against GBM. Indeed, our signature
743 contains crucial regulators of this process, including PTTG1/
744 securin and themitotic kinases AURKA, AURKB, CDK1 and PLK1,
745 which have gained recent attention as therapeutical targets in
747GBM. Thus, in vitro and xenograft animal model studies have
748advocated the use of AURK inhibitors in combination with
749radiotherapy and temozolomide against GBM cells (52–55). Our
750data suggest that, when used as single agents, mitotic kinase
751inhibitors may be particularly effective against G3-group tumors.
752Finally, although our experimental data, obtained with genotox-
753icants and inhibitors used in monotherapy formats, suggest that
754G3-group tumor cells are particularly amenable to DNA repair–
755based strategies, future experiments using combination therapy
756may unveil modalities targeting speciﬁcally G1-group cells. How
757our gene signaturemay contribute to precisionmedicine for GBM
758is summarized in Supplementary Fig. S6. We are aware that our
759stratiﬁcation strategy still leaves aside a considerable subset of
760patients (e.g., from the G2 group). However, in view of the fact
761that GBM remains an incurable disease, our results may carry
762signiﬁcant clinical prospects in the ﬁght against GBM. Themodal-
763ities discussed here in the framework of our gene signature might
764be applicable for the management of both primary and recurring
765GBM.
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DNA Repair and Cell-Cycle Gene Signature in GBM
 
 
Supplementary data 1 
Gobin et al.  
This document details the differential gene expression analysis carried out using the Köln dataset. 
No TMZ-related changes in the expression profile of DNA repair and cell cycle genes at relapse 
We first used DESeq to identify differentially-expressed genes (DEGs) that might be 
informative of glioblastomagenesis, tumor progression and response to TMZ, using distinct pairwise 
comparisons. As expected since all patients were TMZ- naive at the time of first presentation, no 
DEGs were found when primary biopsies from TMZ-naive and TMZ-treated patients were compared 
(FDR<0.05 and [FC]>1.5) (data not shown). Notably, a similar observation was made when recurrent 
biopsies from both groups (TMZ-naive and TMZ-treated) were compared (data not shown), 
suggesting that any impact of TMZ on DNA repair and cell cycle gene expression was not detectable 
at the time of relapse.  
Given these observations, we decided to create 2 groups containing, respectively, all primary 
and all recurrent tumors (whether from TMZ-naive or -treated patients) for further analyses. We first 
identified tumor development/progression-relevant DEGs by comparing primary or recurrent tumors 
with control, tumor-adjacent tissue. Seventy-two DEGs were identified for the comparison of primary 
tumors vs control samples (PvsC) (Figure SD1A), and 71 for that of recurrences vs controls (RvsC), 
respectively (data not shown). Notably, 67 genes were common to both lists and displayed 
comparable fold-change directions (up or down) and intensities, as indicated by correlation analysis 
(Figure SD1B). Functional annotation of these DEGs using WebGestalt1 revealed that the main DNA 
repair pathways represented by the down-regulated genes corresponded to NER, BER and MMR, 
whereas the up-regulated genes were related to components of the cell cycle, as well as the repair of 
DNA double-strand breaks (DSBs) by homologous recombination (Table SD1). Finally, when 
primary and recurrent tumors were compared directly, no DEGs were identified (data not shown), 
suggesting that in the absence of patient stratification, no difference can be observed at the mRNA 
expression level between primary and recurrent biopsies.  
 
Reference 
1 Wang J, Vasaikar S, Shi Z, Greer M, Zhang B. WebGestalt 2017: a more comprehensive, 
powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res. 
2017. 
 
 
Figure SD1. Differentially expressed genes associated with primary GBM. A. Bar plot of the 
deregulation scores observed for the 72 DEGs identified in the comparison of combined primary 
biopsies with control, tumor-adjacent tissues (treshold: FDR < 0.05; [FC]>1.5). Up- and down-
regulated genes are indicated in dark and light gray, respectively, with the corresponding fold 
change presented in Y-axis. B. Scatter plot displaying the fold change correlation between the 
comparisons of primary tumors versus controls (PvsC) and recurrent tumors versus controls 
(RvsC), revealing a high significant (p < 0.0001) R2 value (0.74).  
 
Table SD1. 
 
 
 
 
Supplementary Figure S1. A. Gene expression correlation heatmap of the 156 genes included in the 
study showing the 52 high correlated genes (upper left corner) that were considered for NMF analysis. 
Correlation values are indicated by a red (high) to blue (low) color key. B. Heatmap showing the gene 
expression pattern and patient segregation proposed by the NMF analysis. Standardized expression 
values are depicted using a red (high) to green (low) color key. Neon green and yellow squares marks 
TMZ-negative and -positive patients, whereas blue and red squares denote primary and recurrent 
samples, respectively. NMF clustering is shown in light green (G1), grey (G2) and light red (G3). C. 
Heatmap illustrating the 2 components forming the 52-gene signature as defined by NMF analysis. 
D. Sankey diagram illustrating expression group transition (G1, green; G2, grey; G3, red) between 
primary and recurrent tumor pairs as stratified by the 27-gene signature. Numbers refer to the total 
number of samples in each group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S2. Validation of the 27 DNA repair and cell cycle gene signature. 
Representative validation heatmaps of the 27-gene signature in two independent cohorts of paired 
GBM specimens (A. Heidelberg; D. Wang) and their associated intergroup migration plots (B. 
Heidelberg; E. Wang). The neural (N), mesenchymal (M) and classical (C) transcriptional subtypes 
of the samples in the Wang cohort are superimposed to the heatmap in D. C and F. Linear regression 
analysis of the 27-gene signature performance across the Köln, Heidelberg and Wang datasets. Shown 
are scatter plots of the logFCs in G3 compared to G1 in the comparison of the Köln with and 
Heidelberg (C) or Wang (F) datasets. The consistency of the observed LogFCs is illustrated by the 
significant linear dependencies in both comparisons. The estimated linear models are shown in thick 
red lines, with thin lines depicting the 95% confidence interval of the linear model. 
 
 
 
Supplementary Figure S3. A. Heatmap showing the gene expression pattern and patient segregation 
proposed by the NMF analysis on the Murat et al.18 cohort of primary GBMs. Standardized expression 
values are depicted using a red (high) to green (low) color key. MGMT promoter methylation status 
is depicted in red (not available), neon green (methylated), and blue (unmethylated) squares, whereas 
patient therapy in light blue (TMZ + radiotherapy) and red (radiotherapy alone) squares. NMF 
clustering is shown in light green (G1), grey (G2) and light red (G3) on top of the heatmap. B. 
Distribution of the MGMT promoter methylation status (methylated vs un-methylated) amongst G1- 
and G3-group tumors within the Murat et al.18 cohort. C. Kaplan-Meier plots of the overall survival 
associated with G1- and G3-group tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S4. A. Heatmap showing the gene expression pattern and patient segregation 
proposed by the NMF analysis in the TCGA primary GBM RNA expression dataset (Affymetrix 
HuEx expression data, 440 patients). Standardized expression values are depicted using a red (high) 
to green (low) color key. NMF clustering is shown in light green (G1), grey (G2) and light red (G3) 
on top of the heatmap. B. Kaplan-Meier plots of the overall survival associated with G1-, G2- and 
G3-group tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S5. A. Volcano plot of the DEGs obtained in the comparison of G1 and G3 
samples in the Wang cohort. Each dot represents a gene, with green and red dots indicating genes 
significantly down- and upregulated in the G3 group compared to the G1 group, respectively 
([logFC]>1 and FDR < 0.001). The X-axis specifies the log(Fold Change) values and Y-axis the 
log10(False discovery rate). B. Representative gene ontology (GO) terms associated with the genes 
found upregulated (left panel) or downregulated (right panel) in the G3 group, as plotted by REVIGO 
analysis. Only GO terms with p-value < 0.05 were plotted. The bubble color (blue, very significant; 
red, less significant) indicates the p-value of each GO term whereas bubble size denotes its frequency 
in the GO database.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S6. DNA repair- and cell-cycle-based strategies for personalized 
management of GBM. A. Our current management of primary and recurrent GBM suffers from lack 
of adequate patient stratification and limited therapeutic options. B. Illustration of the clinical 
perspectives for personalized therapy offered by transcription profiling of the identified DNA repair 
and cell cycle gene signature in primary and recurrent GBM specimens. 
 
 
Supplementary Table S1. Summary of the studied genes, their related cellular pathways and the deregulated genes in 
the comparison of tumor to control tissue. 
Gene Definition (Genecards) 
UP        
(P vs C) 
UP       
(R vs C) 
DOWN 
(P vs C) 
DOWN 
(R vs C) 
ALKBH2 AlkB Homolog 2, Alpha-Ketoglutarate Dependent Dioxygenase     
APEX1 Apurinic/Apyrimidinic Endo-deoxyribonuclease 1     
ATM Ataxia Telangiectasia Mutated, ATM Serine/Threonine kinase      
ATR Ataxia Telangiectasia And Rad3-Related Protein, ATR Serine/Threonine kinase     
ATRX Alpha Thalassemia/Mental Retardation Syndrome X-Linked, Chromatin remodeler   yes yes 
AURKA Aurora Kinase A yes yes   
AURKB Aurora Kinase B yes    
BLM Bloom Syndrome RecQ Like Helicase yes yes   
BRCA1 Breast Cancer Type 1 Susceptibility Protein yes yes   
BRCA2 Breast Cancer Type 2 Susceptibility Protein yes yes   
BRCC3 BRCA1/BRCA2-Containing Complex Subunit 3     
BRIP1 BRCA1 Interacting Protein C-Terminal Helicase 1 yes yes   
CCNA2 Cyclin A2  yes yes   
CCNB1 Cyclin B1 yes yes   
CCND1 Cyclin D1     
CCND2 Cyclin D2     
CCNE1 Cyclin E1     
CDC25B Cell Division Cycle 25B yes yes   
CDC25C Cell Division Cycle 25C yes yes   
CDC6 Cell Division Cycle 6 yes yes   
CDK1 Cyclin dependent kinase 1 yes yes   
CDK2 Cyclin dependent kinase 2 yes yes   
CDK4 Cyclin dependent kinase 4 yes yes   
CDK6 Cyclin dependent kinase 6 yes yes   
CDKN1A Cyclin Dependent Kinase Inhibitor 1A yes yes   
CENPA Histone H3-Like Centromeric Protein A yes yes   
CENPB Centromere Protein B     
CENPF Centromere Protein F yes yes   
CHEK1 Checkpoint Kinase 1 yes yes   
CHEK2 Checkpoint Kinase 2 yes yes   
CUL4A Cullin 4A     
DCLRE1A DNA Cross-Link Repair 1A   yes yes 
DCLRE1C DNA Cross-Link Repair 1C, Artemis     
DDB1 Damage Specific DNA Binding Protein 1   yes yes 
DDB2 Damage Specific DNA Binding Protein 2  yes   
DSN1 DSN1 Homolog, MIS12 Kinetochore Complex Component  yes   
EME1 Essential Meiotic Structure-Specific Endonuclease 1  yes yes   
ERCC1 Excision Repair Cross-Complementation Group 1     
ERCC2 ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit     
ERCC3 ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit   yes yes 
ERCC4 ERCC Excision Repair 4, Endonuclease Catalytic Subunit      
ERCC5 ERCC Excision Repair 5, Endonuclease   yes yes 
ERCC6 ERCC Excision Repair 6, Chromatin Remodeling Factor   yes yes 
FAAP24 Fanconi Anemia Core Complex Associated Protein 24  yes   
FANCA Fanconi Anemia Complementation Group A yes yes   
FANCD2 Fanconi Anemia Complementation Group D2 yes yes   
FANCF Fanconi Anemia Complementation Group F     
FANCL Fanconi Anemia Complementation Group L   yes yes 
FANCM Fanconi Anemia Complementation Group M     
FEN1 Flap Structure-Specific Endonuclease 1     
GADD45G Growth Arrest And DNA Damage Inducible Gamma     
GRN Granulin Precursor yes yes   
HMMR Hyaluronan Mediated Motility Receptor yes yes   
HUS1 HUS1 Checkpoint Clamp Component     
PCLAF PCNA Clamp Associated Factor yes yes   
LIG1 DNA Ligase 1     
LIG3 DNA Ligase 3     
LIG4 DNA Ligase 4   yes yes 
MAD2L2 Mitotic Arrest Deficient-Like Protein 2 yes    
MBD4 Methyl-CpG Binding Domain 4, DNA Glycosylase     
MCM2 Minichromosome Maintenance Complex Component 2 yes yes   
MCM3 Minichromosome Maintenance Complex Component 3 yes yes   
MCM7 Minichromosome Maintenance Complex Component 7 yes yes   
MGMT O-6-Methylguanine-DNA Methyltransferase   yes yes 
MKI67 Marker Of Proliferation Ki-67 yes yes   
MLH1 MutL Homolog 1     
MLH3 MutL Homolog 3   yes yes 
MMS19 MMS19 Homolog, Cytosolic Iron-Sulfur Assembly Component   yes yes 
MPG N-Methylpurine DNA Glycosylase     
MRE11A Meiotic Recombination 11 Homolog, Double Strand Break Repair Nuclease     
MSH2 MutS Homolog 2   yes yes 
MSH3 MutS Homolog 3   yes yes 
MSH6 MutS Homolog 6     
MUS81 SLX3 Structure-Specific Endonuclease Subunit Homolog     
MUTYH MutY DNA Glycosylase homolog     
 
 
NBN Nijmegen Breakage Syndrome 1     
NEIL1 Nei Like DNA Glycosylase 1   yes yes 
NEIL2 Nei Like DNA Glycosylase 2   yes yes 
NEIL3 Nei Like DNA Glycosylase 3 yes yes   
NHEJ1 Non-Homologous End Joining Factor 1     
NSMCE2 Non-Structural Maintenance Of Chromosomes Element 2 Homolog     
NUDT1 Nudix Hydrolase 1 yes yes   
OGG1 8-Oxoguanine DNA Glycosylase     
PALB2 Partner And Localizer Of BRCA2     
PARG Poly(ADP-Ribose) Glycohydrolase   yes yes 
PARP1 Poly(ADP-Ribose) Polymerase 1     
PCNA Proliferating Cell Nuclear Antigen yes yes   
PLK1 Polo Like Kinase 1 yes yes   
PMS1 PMS1 Homolog 1, Mismatch Repair System Component     
PMS2 PMS1 Homolog 2, Mismatch Repair System Component   yes yes 
POLB DNA Polymerase Beta   yes yes 
POLD1 DNA Polymerase Delta 1, Catalytic Subunit yes yes   
POLH DNA Polymerase Eta     
POLK DNA Polymerase Kappa     
POLL DNA Polymerase Lambda   yes yes 
POLM DNA Polymerase Mu  yes   
POLQ DNA Polymerase Theta yes yes   
PRIM1 Primase (DNA) Subunit 1     
PRKDC Protein Kinase, DNA-Activated, Catalytic Polypeptide     
PSMD14 Proteasome 26S Subunit, Non-ATPase 14     
PTEN Phosphatase And Tensin Homolog   yes yes 
PTTG1 Pituitary Tumor-Transforming 1 yes yes   
RAD1 Rad1-Like DNA Damage Checkpoint Protein     
RAD17 RAD17 Checkpoint Clamp Loader Component     
RAD18 RAD18, E3 Ubiquitin Protein Ligase yes yes   
RAD23A RAD23 Homolog A, Nucleotide Excision Repair Protein     
RAD23B RAD23 Homolog B, Nucleotide Excision Repair Protein     
RAD50 RAD50 Double Strand Break Repair Protein   yes yes 
RAD51 RAD51 Recombinase yes yes   
RAD52 RAD52 Homolog, DNA Repair Protein     
RAD54B RAD54 Homolog B     
RAD54L RAD54-Like yes yes   
RAD9A RAD9 Checkpoint Clamp Component A     
RBM14 RNA Binding Motif Protein 14     
RDM1 RAD52 Motif Containing 1     
RECQL RecQ Like Helicase yes yes   
RECQL4 RecQ Like Helicase 4     
RECQL5 RecQ Like Helicase 5     
REV1 REV1, DNA Directed Polymerase     
REV3L REV3 Like, DNA Directed Polymerase Zeta Catalytic Subunit     
RFC1 Replication Factor C Subunit 1     
RFC2 Replication Factor C Subunit 2 yes    
RFC3 Replication Factor C Subunit 3     
RFC4 Replication Factor C Subunit 4 yes yes   
RNF168  Ring Finger Protein 168     
RNF4 Ring Finger Protein 4     
RNF8 Ring Finger Protein 8, E3 Ubiquitin Protein Ligase   yes yes 
RPA1 Replication Protein A1     
RPA2 Replication Protein A2     
RPA3 Replication Protein A3     
RRM1 Ribonucleotide Reductase Catalytic Subunit M1     
SEM1 SEM1, 26S Proteasome Complex Subunit     
SMC3 Structural Maintenance Of Chromosomes 3     
SMUG1 Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1     
TERT Telomerase Reverse Transcriptase   yes  
TOP2A Topoisomerase (DNA) II Alpha yes yes   
TP53BP1 Tumor Protein P53 Binding Protein 1   yes yes 
TUBG1 Tubulin Gamma 1     
UBE2I Ubiquitin Conjugating Enzyme E2 I     
UBE2T Ubiquitin Conjugating Enzyme E2 T     
UBE3B Ubiquitin Protein Ligase E3B   yes yes 
UIMC1 Ubiquitin Interaction Motif Containing 1     
UNG Uracil DNA Glycosylase     
USP1 Ubiquitin Specific Peptidase 1     
USP47 Ubiquitin Specific Peptidase 47     
XPA Xeroderma Pigmentosum Group A-Complementing Protein   yes  
XPC Xeroderma Pigmentosum, Complementation Group C     
XRCC1 X-Ray Repair Cross Complementing 1     
XRCC2 X-Ray Repair Cross Complementing 2 yes yes   
XRCC3 X-Ray Repair Cross Complementing 3     
XRCC4 X-Ray Repair Cross Complementing 4     
XRCC5 X-Ray Repair Cross Complementing 5     
XRCC6 X-Ray Repair Cross Complementing 6     
XRCC6BP1 XRCC6-Binding Protein 1     
 
 
 
 
 
 
Supplementary Table S2. Univariate Cox regression analysis of factors influencing PFS and 
OS in the Köln patient cohort. 
Variable Category 
p-value 
PFS OS 
Age Continuous 0.612 0.457 
Gender Male 
Female 
0.435 0.255 
KPS Continous 0.587 0.169 
MGMT promoter status Un-methylated 
Methylated 
0.527 0.918 
Groups (signature specific) G1 
G3 
0.019 0.132 
KPS, Karnofsky performance score; PFS, progression free survival; OS, overall survival 
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 CHAPTER 5 
 
RATIONALE 
 
The results described in this section are based on the identification of key DNA repair 
and cell cycle factors significantly deregulated in GBM biopsies. Specifically, we uncovered 
the dysregulation of all three members of the NEIL glycosylase family (NEIL1-3), with NEIL3 
being highly upregulated whereas NEIL1 and NEIL2 were downregulated. Based on these 
observations and the fact that NEIL3 has been shown to have a role in the repair of oxidized 
DNA damage at the telomeres but had hitherto not been described in the context of GBM, 
NEIL3 was chosen as candidate gene for further characterization in vitro. Our results indicate 
that shRNA-mediated depletion of NEIL3 sensitizes GBM cells to DNA damaging agents (TMZ 
and tert-butyl hydroxyperoxide (TBHP)). Importantly, loss of NEIL3 resulted in telomere 
erosion, the downregulation of the shelterin component TRF1 and the deregulation of long 
non-coding telomeric repeat-containing RNAs (TERRAs). Finally, NEIL3-depletion resulted in 
an increase in telomere dysfunction induced foci (TIFs), indicating that the DNA damage 
response was activated at telomeres upon loss of NEIL3. We propose that NEIL3 may 
represent an attractive therapeutic target for improving GBM treatment. The data is 
presented in the form of a manuscript.  
 
Personal contributions: The analysis of the deregulated gene lists generated from our 
gene expression analysis and the selection of the candidate gene was done in great part by 
me. Moreover, I sat up all the experiments and produced, as well as analysed, the majority of 
the data presented in the manuscript. For this project, I was helped by a Master student (8-
month traineeship) which was under my direct supervision. Finally, I was actively involved in 
the redaction of the manuscript.  
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INTRODUCTION 1 
Glioblastoma (GBM) is the most frequent, aggressive and lethal tumor of the central 2 
nervous system. Despite a treatment modality composed of maximal surgical resection 3 
followed by ionizing radiation (IR) and chemotherapy with the alkylating agent temozolomide 4 
(TMZ) (1), newly diagnosed patients face inevitable tumor relapse driven by DNA repair-5 
mediated chemoresistance mechanisms and poor prognosis. In addition to methyl base 6 
damage, single stranded DNA breaks (SSBs) and double stranded DNA breaks (DSBs), IR and 7 
TMZ induce oxidative DNA damage (2), thus exacerbating the damage load associated with 8 
replication stress in rapidly growing tumor cells and contributing to the constitutive activation 9 
of the DNA damage response (DDR) observed in GBM cells (3, 4).  10 
Telomeres, the physical ends of linear eukaryotic chromosomes, are constituted of 11 
repetitive, non-coding TTAGGG sequences bound by a protein complex named shelterin 12 
formed of TRF1, TRF2, POT1, TPP1, TIN2 and RAP1 (5). This complex protects chromosome 13 
ends from DNA degradation and from being recognized as DNA ends by the DSB repair 14 
machinery, thus preventing chromosomal end-to-end fusions. Telomeres also act as 15 
disposable DNA buffers, which are truncated after each cell division, to circumvent the end 16 
replication problem (6), thereby protecting upstream protein-coding regions. Responsible for 17 
telomere elongation and the maintenance of proper telomere length is a nucleoprotein 18 
reverse transcriptase called telomerase, composed of a catalytic subunit (TERT) and a RNA 19 
component (TERC) which serves as template for the synthesis of TTAGGG repeats (7, 8). Active 20 
in normal stem cells, telomerase undergoes strong negative regulation in all other cell types 21 
(9, 10). However, the activation of a telomere maintenance mechanism (TMM) through 22 
telomerase reactivation or alternative lengthening of telomeres (ALT) is a crucial step to 23 
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ensure telomere homeostasis and enable limitless replicative potential during tumorigenesis 24 
(11). In GBM tumors specifically, deregulation of telomere-associated parameters such as 25 
activating TERT promoter mutations (12) or the occurrence of ALT (13), have been shown to 26 
predict patient prognosis (14, 15) and have gained interest as potential therapeutic targets 27 
(16). Ensuring telomere homeostasis by protecting against DNA lesions has evolved as a 28 
critical task in cancer cells. Telomeres in particular are notably prone to oxidative stress (17, 29 
18) and represent preferential sites of persistent DNA damage (19). Given the reactivity of 30 
guanines towards oxidative stress, the richness in guanine of telomeres and their potential to 31 
assemble into G-quadruplex structures that modify the pathway of guanine oxidation 32 
compared to duplex DNA (20), protection is particularly required against oxidative guanine 33 
damage. Thus, 8-oxoG hinders telomerase activity (21) and disrupts the shelterin complex 34 
(22). Although not frequently observed, misincorporation of A opposite 8-oxoG can occur if 35 
left unrepaired which leads to mutagenesis in the telomeric sequence after replication (23). 36 
Likewise, oxidized dNTPs represent a serious threat since insertion of 8-oxoGTP opposite A 37 
during replication or by telomerase during telomere elongation (21) can generate GTAGGG 38 
and TGAGGG sequence variants (23), which perturb the binding of the shelterin complex to 39 
the telomeres. Besides, studies in budding yeast have shown that telomere sequence 40 
mutations, introduced via nucleotide substitutions in the RNA template of telomerase, led to 41 
telomere shortening progressing to cellular senescence (24) or unsegregated chromosomes 42 
due to delayed sister chromatid separation (25). Further oxidation of 8-oxoG to 43 
guanidinohydantoin (Gh) and spiroiminohydantoin (Sh) (26, 27) has also been shown to cause 44 
base mispairing mutagenesis (28).  45 
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Base excision repair (BER) is the predominant pathway for the repair of oxidative DNA 46 
base damage (29). In human cells, five DNA glycosylases (OGG1, NTH1, NEIL1, NEIL2 and 47 
NEIL3) initiate BER via excision of the damaged base (30, 31). OGG1 and NTH1 remove specific 48 
oxidative base lesions including 8-oxoG and thymine glycol (Tg) from duplex DNA, respectively 49 
(32, 33), while the NEIL glycosylase family, composed of NEIL1, NEIL2 and NEIL3, recognizes a 50 
much wider array of substrates present in different DNA contexts (34). Compared to its family 51 
members, NEIL3 presents unique structural features such as a long intrinsically disordered C-52 
terminal domain (35, 36) and exhibits a preference for oxidized purines present in the 53 
telomeric sequence (37). Notably, the C-terminal domain of NEIL3 mediates its direct 54 
recruitment to telomeres by the shelterin subunit TRF1 during S-phase. This association with 55 
telomeres, which increases upon oxidative stress, allows the mobilization of downstream BER 56 
components such as the AP endonuclease APE1, PCNA and FEN1, and subsequent repair of 57 
telomeric DNA (38). In the same study, siRNA-mediated knockdown of NEIL3 in colon 58 
carcinoma cells (HCT116) induced a 2-fold increase in telomere loss and sister chromatid 59 
fusions as well as extra telomeric signals, further implying a direct role of NEIL3 in telomere 60 
homeostasis. Intriguingly, recent studies have unveiled a role for NEIL3, independent of other 61 
BER components, in the excision and unhooking of both psoralen and AP site-induced DNA 62 
cross-links (39, 40). In addition, the evidence also suggests that NEIL glycosylases may have 63 
gene regulatory functions, including at the epigenetic level through active DNA demethylation 64 
(41, 42). Although the in vivo function of NEIL3 remains unclear, it has been shown to regulate 65 
proliferation of neural stem cells (43-45), in line with the observation that mouse Neil3 mRNA 66 
expression levels were particularly high at embryonic days E12-13, at the onset of 67 
neurogenesis, and the observation that during embryogenesis and in newborn mice, Neil3 68 
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expression was specifically apparent in brain areas such as the subventricular zone, known to 69 
host neural stem and progenitor cells (46). In addition, NEIL3 mRNA levels were found to be 70 
higher in a panel of 18 tumor tissues (gliomas were not included) compared to their normal 71 
counterparts (46). Notably, analysis of the Cancer Genome atlas (TCGA) database revealed 72 
the upregulation of NEIL3 and concomitant downregulation of NEIL1 and NEIL2 in a subset of 73 
13 different carcinomas where these deregulations were associated with an increased 74 
somatic mutation load (47). Interestingly, NEIL3 knockdown was shown to reduce cell 75 
proliferation and increase sensitivity to the oxidative toxicant paraquat and the DNA 76 
crosslinking agent cisplatin in mouse embryonic fibroblasts (48) and to ATR inhibitors in GBM 77 
cells (49). Although the available evidence pinpoints NEIL3 as a potential target in cancer cells, 78 
its role in telomere homeostasis, specifically in relation to glioma development and 79 
chemoresistance, remains vastly unexplored.  80 
In a previous analysis of DNA repair and cell cycle gene expression in clinical GBM 81 
biopsies, we identified NEIL3 as being highly upregulated compared to non-tumor, adjacent 82 
tissue (50). Intriguingly, both NEIL1 and NEIL2 were downregulated in these tumor samples 83 
compared to controls, corroborating the findings of Shinmura et al (47) for other cancer types 84 
(carcinomas) in the TCGA dataset. Our observations prompted us to characterize the function 85 
of NEIL3 in telomere dynamics and response to TMZ in GBM cells. Our results indicate that 86 
NEIL3 inhibition sensitized GBM cells to DNA damaging agents and interfered with telomere 87 
stability. Ultimately, these observations suggest that NEIL3 could present a novel therapeutic 88 
opportunity for GBM patients.  89 
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MATERIALS & METHODS 90 
Targeted gene expression analysis 91 
Analysis of DNA repair and cell cycle genes was conducted on a paired (primary and 92 
recurrent tumor from the same patient) GBM biopsy cohort. Differentially regulated genes 93 
were assessed by comparison of primary and recurrent patient biopsies to control, tumor 94 
adjacent samples. The study cohort and analysis are described in Gobin et al (50) and the 95 
complete gene expression data can be accessed under accession number E-MTAB-6425 96 
(ArrayExpress).  97 
Cell culture and shRNA-mediated gene knockdown  98 
The adherent U87 glioblastoma and U2OS osteosarcoma cell lines were cultured in 99 
DMEM serum-containing medium (DMEM High Glucose (Biowest, L0106-500), 10% FBS 100 
(Gibco, 10500-064), 4mM Ultraglutamine (Lonza, BE17-605E/U1), 100U Pen-Strep (Lonza, 101 
De17-603E)). The NCH644 spheroid glioblastoma stem-like cell line was cultured in NSC non-102 
serum containing medium (Neurobasal medium (Life technologies, 21103049), 2% B-27 103 
(ThermoFisher, 123587-010), 1U/mL Heparin (Sigma-Aldrich, H3149-25KU), 4mM 104 
Ultraglutamine (Lonza, BE17-605E/U1), 100U Pen-Strep (Lonza, De17-603E), 20ng/mL EGF 105 
(Provitro, 1325950500), 20ng/mL FGF (Miltenyi, 130-093-841)). Cells were subcultured every 106 
48-72h or when they reached 75% confluence.  107 
NEIL3 knockdown was achieved by shRNA-mediated RNA interference using 2 108 
individual sequences: shNEIL3-2 (Dharmacon, V2LHS_156511) and shNEIL3-3 (Dharmacon, 109 
V3LHS_327509)). The transduced cells were kept under selective pressure with 1µg of 110 
puromycin (pGIPZ-based shRNA plasmid). 111 
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Proliferation assay 112 
 On Day 0, 6x105 NCH644 shControl or shNEIL3 cells were seeded in 5mL of medium in 113 
a T25 flask. After 5 days, cells were harvested and counted before being reseeded in fresh 114 
medium (6x105 cells, same amount as Day 0). This was done for 5 consecutive times for a total 115 
of 25 days. Each time, cells were counted and at the end, the cumulative population doublings 116 
were calculated using: PD(t) = PD(t-1)+(log(Nt/N(T-1)) / log(2), where N(t) is the number of 117 
cells counted at time (t) and N(t-1) the number of cells counted at time (t-1). Triplicate results 118 
were plotted against time in order to generate proliferation curves.  119 
Real-time quantitative PCR 120 
Total mRNA extracted by TRIzol was retrotranscribed using the iScript cDNA synthesis 121 
kit (Biorad, 1708890) in a reaction composed of 1µg of RNA, 1x iScript mastermix (kit) and 1µL 122 
of iScript RT enzyme (kit). The sample was then incubated in a thermocycler using the 123 
following protocol: 5min at 25oC, 20min at 46oC, 1min at 95oC. Finally, the cDNA samples were 124 
diluted to a total volume of 100µL before quantitative PCR in a reaction (final volume 5µL) 125 
consisting of 1x FASTSybr Green mix, 1µL of cDNA (from total RNA RT or TERRA specific RT) 126 
and 250nM of gene specific forward and reverse primer. All the reactions were done in 127 
triplicate in a VIIA7 Real-time PCR system (Applied Biosystems) using the FastSybr protocol. 128 
Relative expression values were calculated using the 2-ddCT equation and a detailed description 129 
of the primers used is provided in Supplementary Table S1.  130 
Telomere Restriction Fragment (TRF)  131 
The classical TRF southern blot method followed by non-radioactive labelling using the 132 
TeloTAGGG kit (Sigma, 12209136001) was used to assess average telomere length. First, 133 
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genomic DNA was extracted from a total of 5x106 cells using the DNeasy Blood & tissue kit 134 
(Qiagen, 69504) and digested with HinfI and RsaI. The fragments were separated on a 0.8% 135 
agarose gel electrophoresis for 6h at 75V followed by 10min of depurination (0.25M HCl), 136 
2x15min of alkaline denaturation (0.5M NaOH, 1.5M NaCl) and 2x15min of neutralization 137 
(0.5M Tris-HCl, 3M NaCl, pH 7.5) before transfer by capillarity on a Hybond N nitrocellulose 138 
membrane (Amersham, RPN2020N). The stack was composed of a large whatman paper, gel, 139 
membrane, 2 whatman papers, topped by a pile of absorbent paper and weights to facilitate 140 
uniform transfer. After overnight transfer, the DNA was fixed to the membrane by UV 141 
crosslinking at 120mJ for 2min (UVP CL-1000L) and placed in a hybridization tube. The 142 
membrane was pre-hybridized in DIG Easy Hyb (kit) for 30min at 42oC before hybridization 143 
with the telomere probe (1:5000 dilution in DIG Easy Hyb) for 3h at 42oC in a hybridization 144 
oven under constant rotation (rotisserie). Several washes of 10min were performed with 145 
stringent wash buffer 1 (SSC 2x, 0.1% SDS), stringent wash buffer 2 (SSC 0.2x, 0.1% SDS) and 146 
wash buffer 1x (kit). The membrane was then incubated in freshly prepared blocking buffer 147 
(1x maleic acid (kit), 1x blocking buffer (kit)) for 30min at RT before being subjected to anti-148 
DIG working solution (1:10000 anti-DIG AP antibody diluted in blocking buffer) for 30min at 149 
RT under rotation (tube roller). After a last washing step with wash buffer 1x for 2x15min at 150 
RT, the membrane was incubated in detection buffer 1x (kit) for 5min before revelation of the 151 
signal with 2mL of substrate solution (kit). The chemiluminescent signal was collected using 152 
an imaging device (GE Healthcare, Imagequant LAS 4000) and the resulting image was 153 
analysed to estimate the telomere length.  154 
lncRNA TERRA expression 155 
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The telomeric transcripts TERRA were quantified using an adapted protocol described 156 
in Feretzaki and Lingner (51). First, column extracted RNA (free of gDNA contamination) from 157 
three biological replicates was retrotranscribed using the SuperScript III Reverse 158 
Transcriptase kit (Invitrogen, 18080044) in two separate reactions representing the 159 
housekeeping genes (GAPDH and GUSB) and TERRAs, respectively. The samples were first 160 
denatured for 5min at 65oC in a reaction containing 2pmol of gene specific oligonucleotides 161 
(GAPHD, GCCCAATACGACCAAATCC; GUSB, AATACAGATAGGCAGGGCGTTCG; TERRA, 162 
CCCTAACCCTAACCCTAACCCTAACCCTAA), 0.5mM dNTPs mix (Invitrogen, 18427-013) and 163 
either 1.5µg (housekeeping genes) or 3µg (TERRAs) of RNA. The reaction volume contained 164 
1x First strand buffer (kit), 5mM DTT (kit), 20U RNase inhibitor (kit) and 200U SuperScript III 165 
RT (kit) and the extension step was carried out at 55oC for 60min followed by 70oC for 15min 166 
in a PCR thermocycler. Finally, the cDNA was diluted to a final volume of 40µL before 167 
quantification by classical qPCR in a reaction (final volume of 5µL) containing 1x FASTSybr 168 
Green mix (Applied Biosystems, 4385612), 1µL of cDNA (housekeeping genes or TERRA) and 169 
50nM of specific forward and reverse primer. All the reactions were done in triplicate in a 170 
VIIA7 Real-time PCR system (Applied Biosystems) using the FastSybr protocol and the relative 171 
expression was calculated using the 2-ddCT method. The primer pairs used for quantification 172 
are detailed in Supplementary Table S1.  173 
Real-time Quantitative Telomeric repeat amplification protocol (qTRAP) 174 
The protocol was adapted from Hou et al (52). Briefly, total proteins from 5x105 cells 175 
were extracted in non-denaturing conditions using CHAPS buffer (5mg/mL CHAPS, 1mM 176 
MgCl2, 1mM EGTA, 10% glycerol, 5mM Tris-HCl pH 7.5, 1 tablet/10mL phosphatase (Roche, 177 
04906837001) and protease inhibitor (Roche, 04693132001), 1μL/mL RNase inhibitor 178 
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(Invitrogen, 10777019)) and telomerase activity was measured in triplicates using various 179 
amounts protein concentrations (range: from 0.01 to 1µg) in a qPCR reaction (final volume of 180 
10µL) containing 1x Fast SYBR Green Mastermix (Applied Biosystems, 4385612), 625µM dNTP 181 
mix, 800nM TS primer (AATCCGTCGAGCAGAGTT), 250nM ACX primer 182 
(GCGCGGCTTACCCTTACCCTTACCCTAACC). The samples were first incubated for 20min at 183 
25oC to allow elongation of the TS primer by telomerase before standard qPCR in a VIIA7 qPCR 184 
system using the FastSybr protocol. The Ct values were then plotted for each protein 185 
concentration and telomerase activity was visualized by linear regression curve fitting.  186 
Spheroid formation assay 187 
  A total of 1.5x105 cells were collected and run through a BD FACS Aria cell sorter. First, 188 
cell doublets and dead cells were filtered out and 1, 5 or 10 cells were then seeded 189 
automatically in individual wells containing 100µL of culture medium (NSC). The plates were 190 
incubated at 37oC for 3 weeks until first visible spheroids could be seen. At this stage, the 191 
spheroid-containing wells in each plate were counted and an average % of spheroid formation 192 
capacity was calculated. 193 
Unicolor FACS competition assay 194 
The assay was based on Burgess et al (53). A 1:1 mix ratio of U87 GFP-negative (wild-195 
type) and GFP-positive (harbouring shControl or shNEIL3) cells were plated under either 196 
control or 50µM TMZ treatment conditions. After 7 days of incubation at 37oC, cells were 197 
collected and counted by BD FACS Canto. Doublets and dead cells were left out prior to GFP-198 
specific gating.  A total of 2x105 events were recorded for each condition and the % of GFP-199 
negative and -positive population in each sample was assessed in triplicates.  200 
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Cytotoxicity/Viability assay 201 
 Sensitivity to temozolomide (TMZ) and tert-butyl hydroxyperoxide (TBHP) was 202 
assessed in adherent cells using the MTT Cell proliferation kit (Sigma, 11465007001) and in 203 
spheroid cells with the WST1 Cell proliferation reagent (Sigma, 11644807001). Either 1500 204 
cells (U87, adherent) or 4000 cells/well (NCH644, spheroid) were seeded in triplicates in a 96-205 
well plate (Greiner, 655101) followed by incubation with escalating drug concentrations for 206 
24h, 48h or 72h at 37oC in a total volume of 100µL. Adherent cells were then incubated with 207 
10% (of total volume) of MTT reagent for 4h followed by solubilization overnight using 100µL 208 
of buffer (kit), whilst spheroid cells were incubated with 10% (of total volume) of WST1 209 
reagent for 6h. Absorbance values (550nm: MTT; 450nm: WST and >630nm: reference 210 
wavelength) were determined using the Clariostar reader (BMG Labtech).  211 
Telomere-specific fluorescent in situ hybridization (Telo-FISH) 212 
 A total of 750.000 cells were seeded and treated with 0.5µg/mL of colcemide 213 
(Karyomax, Gibco 15212012) for 24h before collection for preparation of metaphase spreads. 214 
The cell pellet was resuspended with 7mL of pre-warmed hypotonic solution (0.54% KCl) and 215 
incubated for 20min at 37oC. The swollen cells were then fixed with 1mL of cold fixation buffer 216 
(3:1 mix of Ethanol 100% / acetic acid) and washed 2 times before being dropped onto a slide 217 
from a distance of 2m in order for the nuclei to blow up and spread the condensed 218 
chromosomes. The slides were then fixed with 4% PFA for 2min and treated with pepsin 219 
solution (0.001% pepsin, 100µM citric acid) before being fixed a second time with 4% PFA for 220 
2min. The nuclei were carefully washed after each step with PBS 1x for 3x5min. The slides 221 
were then dehydrated in an ethanol sequence (70%, 90% and 100%) for 1min and air dried, 222 
before being subjected to 60µL of hybridization mix containing 50nmole of Cy3-PNA C-rich 223 
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telomere probe (Eurogentec, PN-TC050-005) diluted in blocking buffer (70% formamide, 224 
5mM Tris pH 7.2, 10% blocking buffer (Roche, 11096176001)). The PNA probe and DNA was 225 
then denatured by placing the slide on a hot plate at 85oC for 3min before 2h of incubation in 226 
the dark at RT. Lastly, the slide was washed for 2x15min with wash 1 (50% formamide, 10mM 227 
Tris pH 7.2, 0.1% BSA) followed by 2x5min of wash 2 (10mM Tris pH 7.2, 150mM NaCl, 1.6% 228 
Tween-20). Nuclei were counterstained with DAPI and visualized by confocal microscopy 229 
(Zeiss LSM 880) at 630x magnification.  230 
 231 
Immunofluorescence-coupled fluorescent in situ hybridization (IF-FISH) 232 
  Cells mounted on a slide were first permeabilized in 0.5% TBS-Triton for 10min then 233 
fixed with 4% PFA for 10min at RT before being immunolabeled with γ-H2AX primary antibody 234 
(1:1000, Abcam ab22551) followed by Alexa 488 secondary antibody (1:500, Invitrogen 235 
A28180). The slides were then directly dehydrated for 1min in ethanol series (75%, 80% and 236 
100%) followed by air drying before hybridization at RT for 2h with 50nmole of Cy3-PNA C-237 
rich telomere probe (Eurogentec, PN-TC050-005) diluted in blocking buffer (70% formamide, 238 
5mM Tris pH 7.2, 10% blocking buffer (Roche, 11096176001)). The slides were then washed 239 
for 2x15min with wash 1 (50% formamide, 10mM Tris pH 7.2, 0.1% BSA) followed by 2x5min 240 
of wash 2 (10mM Tris pH 7.2, 150mM NaCl, 1.6% Tween-20). Nuclei were counterstained with 241 
DAPI and visualized by confocal microscopy (Zeiss LSM 880) at 630x magnification.  242 
243 
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RESULTS 244 
Deregulation of the NEIL glycosylase family in patient-derived GBM biopsies  245 
For this study, we took advantage of a targeted gene expression analysis 246 
encompassing 156 genes of the DNA repair and cell cycle pathways conducted on GBM 247 
patient-derived biopsies. The dataset was generated in the laboratory and is described in 248 
detail in (50). Briefly, we first identified DEGs by comparing primary or recurrent tumors with 249 
control, tumor-adjacent tissue. Seventy-two DEGs were identified for the comparison of 250 
primary tumors vs control samples (Supplementary Figure S1), and 71 for that of recurrences 251 
vs controls, respectively (data not shown). Notably, there was an extensive overlap between 252 
both lists, with 67 common genes displaying comparable fold-change directions and 253 
intensities. In the interest of finding potential novel targets for treatment strategies in newly 254 
diagnosed GBM, we focused on genes that were highly upregulated in the comparison of 255 
primary vs control tissue, hence suggesting a notable role in gliomagenesis and/or potential 256 
addiction in GBM cells. Intriguingly, we observed specific deregulation of the NEIL glycosylase 257 
family, with NEIL1 and NEIL2 being downregulated and NEIL3 highly upregulated 258 
(Supplementary Figure S1, genes highlighted in green). This observation was comforted by a 259 
study demonstrating reduced NEIL1 and NEIL2 expression whilst elevated NEIL3 expression 260 
levels in a subset of different cancer types (47). Despite NEIL3 being a well-characterized DNA 261 
glycosylase and known to be highly upregulated in different cancers, its function in 262 
tumorigenesis and specifically in GBM remains obscure.  263 
RNA interference-mediated knockdown of NEIL3 in glioblastoma patient-derived cell lines 264 
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 Since NEIL3 was found to be upregulated in GBM patient biopsies, we decided to 265 
examine the role of NEIL3 by gene knockdown in GBM patient derived cell lines. To this end, 266 
we had access to the well characterized U87 adherent cell line and the NCH644 patient-267 
derived spheroid cell line. Notably, NCH644 presents GBM stem-like cell properties and is able 268 
to recapitulate essential features of the original tumor when xenografted into 269 
immunodeficient mice (54). Knockdown of NEIL3 in the two cell lines was achieved by stable 270 
lentiviral integration of vectors expressing NEIL3-targeting shRNAs. Two independent shRNA 271 
constructs were used: shNEIL3-2 and shNEIl3-3. Reduced NEIL3 expression at the mRNA (Fig. 272 
1A) and protein level (Fig. 1B) was observed in NCH644. Similar reduction of mRNA levels 273 
were observed in U87 cells (data not shown). Notably, shNEIL3-3 showed a consistently higher 274 
knockdown efficiency than shNEIL3-2 in both cell lines. Furthermore, NEIL3 depletion had no 275 
apparent effect on cell proliferation (Fig. 1C) and spheroid formation capacity (Fig. 1D) in 276 
NCH644. In summary, we were able to efficiently reduce NEIL3 mRNA expression by RNA 277 
interference in both GBM cell lines (±80% in NCH644 and ±60% in U87, respectively) which in 278 
addition did not affect the stem-like cell properties of NCH644.  279 
Reduced NEIL3 expression sensitizes MGMT-negative and MGMT-positive GBM cells to the 280 
methylating agent TMZ and oxidative stress inducer TBHP  281 
Since NEIL3 was also found to be strongly upregulated in patient samples that 282 
underwent standard chemoradiation therapy (recurrent GBM specimen), we hypothesized a 283 
direct role of this DNA glycosylase in the resistance mechanism to TMZ and radio-therapy 284 
induced oxidative DNA damage. As stated in the Chapter 1, the expression of MGMT is a major 285 
determinant behind the resistance of GBM tumors to TMZ. Although U87 and NCH644 cells 286 
are clearly not isogenic, we thus took advantage of their different MGMT expression status 287 
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(U87: MGMT-negative; NCH644: MGMT-positive) to examine the effect of NEIL3 knockdown 288 
on treatment sensitivity in clinically relevant conditions. 289 
First, we observed increased sensitivity of both U87 shNEIL3 cell lines to escalating 290 
TMZ doses as assessed by standard cell viability analysis (Fig. 2A). This observation was 291 
reinforced by a cell growth competition assay in which U87 cells (GFP-negative) were mixed 292 
together in a 1:1 ratio with either U87 shControl or shNEIL3 cells (GFP-positive due to the 293 
presence of the GFP gene on the pGIPZ lentiviral vector expressing the shRNAs). The cell 294 
mixture was then treated or not with TMZ and after several days, the two populations were 295 
counted and discriminated by GFP fluorescence in a flow cytometer. In the non-treated 296 
condition, the population ratio remained unchanged in all the considered cell line 297 
combinations (Fig. 2B). In contrast, we observed a significant decrease of both shNEIL3 GFP-298 
positive populations when TMZ was added (Fig. 2B).  299 
In order to analyse the impact of NEIL3 depletion in MGMT-positive cells, we also 300 
subjected NCH644 to TMZ (48h) and TBHP (24h), a potent oxidative stress inducer in order to 301 
simulate oxidative DNA damage.  In both cases, a significant increase in sensitivity was 302 
observed in the NCH644 shNEIL3-3 cell line (Fig. 2C and D). Although not significant, a similar 303 
trend could be seen in shNEIL3-2 cells. The differences in sensitivity caused by the 2 shRNAs 304 
targeting NEIL3 is currently unknown. Notably, TBHP seemed to have a greater effect on cell 305 
survival than TMZ. This could be due to the fact that TBHP induces overall oxidative stress 306 
compared to TMZ, which mainly methylates DNA. Despite a significant difference, the impact 307 
of NEIL3 depletion on TMZ or TBHP sensitivity was relatively limited in NCH644 and U87 308 
shNEIL3 cell lines.  309 
Loss of NEIL3 impacts telomere length homeostasis and induces telomere dysfunction foci 310 
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Given the documented role of NEIL3 in removing telomeric DNA damage (55), we set 311 
out to analyse its role in telomere biology in GBM cells.  312 
To this end, we evaluated the average telomere length in both GBM cell lines using 313 
the TRF southern blot approach. NCH644 cells were found to be telomerase-positive, as 314 
illustrated by the size range (<15 kb) and homogeneous mean telomere length distribution 315 
observed by TRF analysis (Fig. 3A) (56). Surprisingly, we observed that NCH644 depleted cells 316 
presented significant reduced mean telomere length (Fig. 3A) compared to the control cell 317 
line. The reduction in length reached ~20% and ~25% in shNEIL3-2 and shNEIL3-3 cells, 318 
respectively (Fig. 3B). Notably, this telomere erosion phenotype was visible as early as 7 cell 319 
passages after introduction of the shNEIL3 plasmids and further passaging of the cells did not 320 
increase the extent of erosion nor reverse telomere length, suggesting the existence in 321 
NCH644 cells of a mechanism capable of maintaining the telomeres at a viable length but 322 
unable to restore their original size. In contrast to NCH644, no erosion was detected upon 323 
depletion of NEIL3 in U87 (Supplementary Fig. S2A). This observation could be explained by 324 
the fact that U87 displays shorter telomeres compared to NCH644 (3.5 vs 6.5kB, respectively, 325 
Fig 3A and Supplementary Fig. S2A) which could hinder an observable impact on telomere 326 
length in these cells. We also analysed the effect of TMZ and TBHP treatment on NCH644 and 327 
U87 telomeres. When applied for 72h, the genotoxic treatment did not exacerbate the 328 
telomere length deficit observed in NCH644 and did not induce any telomere loss in U87 329 
(Supplementary Fig. S2B). Considering that the telomere deficit phenotype was exclusive to 330 
NCH644, we decided to focus our efforts on this cell line.  331 
Telomere dysfunction (e.g., associated with telomere shortening and/or the 332 
dissociation of telomere-binding proteins) was shown to induce a DNA damage response in 333 
 16 
 
mammalian cells, characterized by the presence of telomere dysfunction-induced foci (TIFs) 334 
containing telomere-associated DNA damage factors (57). Furthermore, severe loss of 335 
telomere integrity can also trigger DSB repair mechanisms involving NHEJ, resulting in 336 
telomere fusions and chromosomal instability. Therefore, we analysed the co-localization of 337 
telomeres (using a telomeric probe FISH) and γ-H2AX (by IF) in control and NEIL3-depleted 338 
NCH644 cells. As presented in Figure 3C, TIFs were almost exclusively observed in the NEIL3-339 
depleted cells (white arrows). Indeed quantification indicated a 5-7 fold increase in the 340 
number of TIFs in NEIL3-depleted cells compared to control (Fig. 3D).  341 
Finally, to examine whether TIFs were associated with increased genetic instability in 342 
NEIL3-depleted cells, we examined metaphase spreads from control and NEIL3-depleted cells. 343 
Although careful analysis of several metaphase spreads remains to be done, our preliminary 344 
data indicate the increased occurrence of telomere abnormalities in NEIL3-depleted cells, in 345 
particular extra-chromosomal signals and loss of telomere signal (Fig. 3E). The overall 346 
telomere signal intensity was also more heterogeneous after NEIL3 depletion. However, we 347 
did not detect chromosome end-to-end fusions in our NEIL3-depleted cell lines, suggesting 348 
that telomere uncapping associated with loss of NEIL3 did not lead to dramatic 349 
rearrangements mediated by NHEJ. Moreover, the lack of deleterious telomere abnormalities 350 
(i.e. fusions) could explain why NEIL3 depletion did not impact the proliferation of NCH644.  351 
Knockdown of NEIL3 disrupts telomere stability and alters the expression of the lncRNAs 352 
TERRA 353 
  The observation that NEIL3 depletion induced such drastic telomere length attrition 354 
in NCH644 cells prompted us to analyze the integrity of the telomerase and shelterin complex. 355 
To this end, we quantified the expression of key components of the shelterin complex (TERF1, 356 
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TERF2, POT1 and TINF2) and the telomerase catalytic subunit hTERT by RT-qPCR in control 357 
and NEIL3-depleted cells. Interestingly, we observed significant upregulation of the 358 
transcripts encoding the enzymatic subunit of telomerase (hTERT) and the shelterin subunits 359 
POT1 and TIN2 (Fig. 4A). On the other hand, TRF2 was unaltered in NEIL3-depleted cells 360 
whereas TRF1 mRNA levels were significantly downregulated (Fig. 4A), and this observation 361 
was confirmed at the protein level (Fig. 4B and Supplementary Fig. S3).  362 
These observations suggest that NEIL3 depletion affects the expression of components 363 
of the shelterin complex, leading in particular to the downregulation of TRF1. We put distinct 364 
emphasis on TRF1 in view of a recent study demonstrating that recruitment of NEIL3 to the 365 
telomeres was associated to direct protein-protein interaction with TRF1 (38). Moreover, 366 
upregulation of both TIN2 and POT1 further imply the hypothesis that NEIL3 depletion-367 
mediated downregulation of TRF1 affects the stability of the shelterin complex.  In addition, 368 
these results suggest that telomere erosion is potentially stabilized by upregulation of the 369 
telomerase catalytic subunit.  370 
As NCH644 cells are telomerase-positive and since hTERT mRNA levels were 371 
upregulated in NEIL3-depleted cells, we next tested the possibility that the initial telomere 372 
erosion observed in these cells is counterbalanced by enhanced telomerase activity. For this 373 
reason, we determined telomerase activity in cell extracts prepared from control and NEIL3-374 
depleted cells using the qTRAP assay. A control protein extract from U2OS cells (a telomerase 375 
negative ALT cell line) was added to each experiment in order to determine the background 376 
activity obtained in the absence of telomerase. As presented in Fig. 4C, telomerase activity is 377 
detected in NCH644 cell extracts, confirming that these cells rely on telomerase activity for 378 
elongation of their telomeres. Strikingly, we did not observe any difference in telomerase 379 
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activity in NEIL3-depleted cells when compared to control cells (Fig. 4C), indicating that the 380 
resistance against further telomere erosion observed after a few passages following loss of 381 
NEIL3 is not mediated by increased activation of telomerase.  382 
 Long non-coding, chromosome-specific telomeric RNA sequences named TERRA play 383 
a crucial role in telomere length sensing and regulation (58). Particularly, upon telomere 384 
shortening, TERRA molecules were shown to accumulate into nuclear foci which promoted 385 
nucleation of telomerase on short telomeres, thus forming TERRA-telomerase clusters which 386 
promoted telomere elongation (59). In order to analyse if these lncRNAs were affected by 387 
NEIL3 depletion, we quantified the expression of TERRAs originating from specific 388 
chromosome ends (2q, 10q, 13q 15q, 17p and XpYp) by RT-qPCR (Fig. 4D). Compared to 389 
control cells, we observed significant upregulation (±50%) of 2q- and 10q-TERRA and 390 
downregulation of 13q- and 17p-TERRA (±50% and ±70%, respectively) in both NEIL3 depleted 391 
cell lines (Fig. 4D). These observations could indicate a possible mechanism by which NCH644 392 
shNEIL3 cells limit telomere dysfunction.  393 
 All these observations demonstrate that NEIL3 depletion gives rise to dysfunctional 394 
telomeres by affecting the shelterin complex and that telomerase activity in these cells is 395 
possibly sufficient to counteract NEIL3-mediated telomere shortening. Lastly, the altered 396 
expression levels of chromosome-specific TERRAs are further indications of the telomeric 397 
dysfunction caused by NEIL3 knockdown.  398 
  399 
 19 
 
DISCUSSION 400 
The safeguarding of telomere integrity and length homeostasis is a critical factor in 401 
rapidly dividing cells (i.e. tumor cells). Besides the protection of the chromosome ends by the 402 
shelterin complex, cells have to maintain intact telomeric repeats which are otherwise prone 403 
to undergo oxidative DNA damage. The repair of such insults is predominantly achieved by 404 
BER with specific DNA glycosylases recognizing and removing distinct lesions present at the 405 
telomeres.  406 
Compared to its family members, NEIL3 was found to be highly upregulated in a DNA 407 
repair and cell cycle targeted gene expression analysis comparing primary and recurrent GBM 408 
biopsies to control, tumor adjacent tissue. This first observation was corroborated by a recent 409 
in silico study analysing the expression of the three NEIL family members in different types of 410 
carcinomas from the TCGA (47), indicating a peculiar role of this enzyme in GBM. In this study, 411 
we focused on the role of the NEIL3 DNA glycosylase in GBM cells by examining the 412 
phenotypes associated with RNAi-mediated depletion of NEIL3.  413 
Notably, knockdown of NEIL3 in the telomerase-positive NCH644 cell line induced 414 
telomere shortening and the deregulation of key factors of the shelterin complex and TERRAs. 415 
Several DNA glycosylases involved in the repair of oxidative lesions by BER have been shown 416 
to preserve telomere integrity, including OGG1 (60) and NTHL1 (61). However, disruption of 417 
Ogg1 in yeast and mice led to telomere elongation (60), whereas Nth1 deficiency in mice 418 
resulted in increased telomere fragility due to defective repair of oxidative base lesions and 419 
telomere shortening (61). These observations suggest that the various DNA glycosylases that 420 
operate at telomeres exert specific functions that impact telomere integrity differently. 421 
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 Moreover, in a recent study, NEIL3-deficient HCT116 cells presented increased 422 
telomere dysfunction and pinpointed TRF1 as the primary factor recruiting NEIL3 to the 423 
telomeres (38). Intriguingly, we observed specific downregulation of TRF1 both at the mRNA 424 
and protein level in NEIL3 depleted cells (NCH644), while the expression of other shelterin 425 
factors were found to be upregulated (TIN2 and POT1) or unchanged (TRF2). However, 426 
whether the deregulation of TRF1 is associated with its dissociation from telomeres remains 427 
to be determined. Nevertheless, in view of these observations, it is tempting to suggest an 428 
increase in oxidative DNA damage at the telomeres, as a result of NEIL3 loss, which in turn 429 
possibly disturbs the binding of TRF1 on the telomeric sequence. Since TRF1 directly binds the 430 
telomeric sequence to promote the recruitment of the other members of the shelterin 431 
complex, loss of TRF1 would impact proper assembly of the complex at the chromosome 432 
ends, leading to telomere de-protection and erosion, as suggested by the 5-7 fold increase in 433 
telomere dysfunction-induced foci (TIFs) observed in these cells. In addition, a recent study 434 
in GBM, demonstrated that genetic or chemical depletion of TRF1 led to increased DNA 435 
damage located at the telomeres as well as impaired tumor initiation and progression in 436 
xenografted mice (62). Thus, it will be crucial to verify that the decreased TRF1 levels are 437 
indeed associated with its loss at telomeres, by specific experiments such as ChIP analysis 438 
looking at telomere occupancy by TRF1 in NEIL3 depleted cells. In line with our observation 439 
that both TIN2 and POT1 were upregulated in shNEIL3 cells, it was shown that TRF1 loss from 440 
telomeres increased the association of TIN2 with TRF2 (63) and overexpression of POT1 was 441 
demonstrated to protect against loss of telomeric ssDNA in TRF2 negative cells (64). This 442 
further implies that TRF1 downregulation could be associated with loss of its binding at the 443 
telomeres and that the upregulation of the TIN2/POT1 shelterin factors potentially helps 444 
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stabilizing the dysfunctional telomeres. Again it will be important to examine the association 445 
of TRF2 and POT1 at telomeres in NEIL3-depleted cells. 446 
 The erosion of telomeres observed upon loss of NEIL3 seemed to reach a stable limit, 447 
suggesting that mechanisms are at hand to prevent further erosion and potentially 448 
deleterious effects on chromosomal stability. Telomerase is the primary responsible for 449 
telomere lengthening in cells and we observed that TERT mRNA levels were upregulated in 450 
these cells, suggesting the possibility that increased telomerase activity counterbalances the 451 
dysfunction of telomeres in the absence of NEIL3. However, our data indicate that the activity 452 
of the telomerase is not affected by NEIL3 depletion, suggesting that the level of telomerase 453 
activity in these cells is sufficient to counter telomere erosion when telomere length falls 454 
below a certain threshold, or that other mechanisms contribute to prevent further telomere 455 
length deficit. It is notable that in a telomerase null background, mouse Nth1-/- bone marrow 456 
cells underwent severe telomere loss at some chromosome ends, indicating that NTHL1 and 457 
TERT cooperate in maintaining telomere function in replicating cells (61). On the other hand, 458 
the expression of TERT has been shown to increase resistance to chemotherapeutics and pro-459 
apoptotic signals (65), modulate chromatin structure and response to DNA damage (66), and 460 
enhance the DNA repair capacities in TERT overexpressing fibroblasts (67), indicating several 461 
telomere-independent functions of telomerase. It would therefore be interesting to examine 462 
whether telomere loss is exacerbated in GBM cells carrying the double depletion of TERT and 463 
NEIL3, as well as in ALT-positive cells carrying the NEIL3 depletion.  464 
The expression levels of the lncRNAs TERRA were deregulated upon loss of NEIL3, with 465 
up- or down-regulation observed for specific telomeres. A role for TERRA in telomere 466 
regulation has been proposed and it has been demonstrated that telomere shortening 467 
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induces TERRA expression (68). Because TERRAs, like the shelterin complex, have also been 468 
shown to help recruit telomerase enzymes to short telomeres (69), it is possible that the 469 
upregulation of TERRAs facilitates its recruitment, hence preventing further telomere erosion 470 
in NCH644 shNEIL3 cells. It remains to be seen whether the upregulation of TERRA seen at 471 
specific telomeres reflects an exacerbated erosion of these telomeres. Importantly, TERRAs 472 
have also been shown to recruit chromatin remodelling factors to the telomeres (70), 473 
suggesting another mechanism whereby telomere erosion might be counterbalanced in 474 
NEIL3-depleted cells. Finally, as downregulation of TERRA was also observed (in 13p and 17q), 475 
it is possible that certain telomeres are long enough and hence do not need high TERRA 476 
expression levels. Knowledge of the specific length of all telomeres in NCH644 cells and how 477 
each telomere is affected by NEIL3 depletion will be required to test this hypothesis. Finally, 478 
as ALT represents an important telomere maintenance mechanism in GBM cells, particularly 479 
in pediatric GBM, it will be crucial to extend these studies and examine the impact of 480 
depleting NEIL3 on the mechanisms that operate to maintain ALT in GBM cells.   481 
Interestingly, NEIL3 knockdown also sensitized both U87 and NCH644 cell lines, which are 482 
MGMT promoter methylation negative and positive cells respectively, to TMZ and TBHP. Of 483 
note, NEIL3 was uncovered independently during an in vitro shRNA screen targeting the DDR 484 
by Hélène Erasimus, a previous PhD student in the lab, as a novel candidate target for the 485 
sensitization of NCH644 cells to TMZ. Although the telomere length deficit was not observed 486 
in U87 cells, probably as a result of shorter base telomere length compared to NCH644, 487 
further experiments are needed to assess the impact of shorter telomeres on the sensitization 488 
of both cell lines to TMZ and TBHP. Nevertheless, our observations highlight NEIL3 as an 489 
attractive target in improving GBM standard-of-care in both all GBM patient populations, 490 
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including MGMT methylation-negative patients which do not profit from TMZ chemotherapy. 491 
In this regard, a high-throughput drug screen revealed that small purine analogs and several 492 
drugs (ellipticine, aurintricarboxylic acid, CGP-74514A) were potent inhibitors of the 493 
combined glycosylase/AP lyase activity of NEIL1 in mouse embryonic fibroblasts (71), 494 
suggesting that these compounds could also potentially inhibit NEIL3 activity. Genetic 495 
depletion of NEIL3 was found to compromise HR-mediated repair of DSBs at the replication 496 
fork and sensitize GBM cells to ATR inhibitors  (49), further implying the potential clinical 497 
applications of NEIL3 targeting in GBM. Hence, the BER-independent functions of NEIL3 such 498 
as the management of ICLs blocking the replication fork, also seem important in cancer cells 499 
and further experiments would need to clarify and assess if this function is important in the 500 
context of GBM. Finally, since they lack the C-terminal domain mediating interaction with 501 
TRF1, it may be expected that NEIL1 and NEIL2 overexpression will not rescue the telomere-502 
dysfunction phenotype associated with NEIL3-depletion. It remains to be learned, however, 503 
whether such an overexpression would rescue the increased sensitivity to TMZ and TBHP 504 
displayed by NEIL3-depleted cells. Such experiments may help identify to which extent the 505 
telomeric defects induced by loss of NEIL3 contribute to the sensitivity of NEIL3-defective cells 506 
to these genotoxicants. 507 
Telomeres can also directly alter gene expression by silencing nearby genes through 508 
spreading of telomeric heterochromatin. This reversible process, known as telomere position 509 
effect (TPE), is well characterized in yeast and it has been shown that the effect can extend a 510 
few kb towards the subtelomeres (72) or over long distances by looping of the telomeric 511 
sequence (73) by spreading of telomeric heterochromatin marks such as tri-methylation of 512 
the H3 histone at position K9. The effect was also observed in human fibroblasts on genes 513 
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located near telomeres (74), and shortening of telomeres was found to elicit a loss of TPE 514 
(75). Moreover, the presence of the heterochromatic mark H3K9me3 at telomeres has been 515 
shown to regulate TERRA levels (76). Hence, telomere length deficit in NEIL3 knockdown 516 
NCH644 cells could result in the deregulation of genes repressed by the TPE and impact the 517 
observed sensitivity to TMZ and TBHP. This reasoning can also be extended to the 518 
deregulation of chromosome-specific TERRAs observed in this study. Thus, the effect of NEIL3 519 
depletion on TPE should be investigated using an engineered cell system based on a luciferase 520 
reporter stably integrated in the genome of HeLa cells either at a telomeric position or an 521 
internal chromosomal position (control cell line) (77) and validated in the context of NCH644 522 
shNEIL3 cell lines using either whole transcriptomic assays to assess global gene expression 523 
changes or quantification of genes known to be regulated by TPE.  524 
In summary, our observations underline NEIL3 as an attractive candidate target in GBM. 525 
However, our knowledge on the telomere dysfunction phenotype induced by NEIL3 depletion 526 
illustrates just one of the aspects associated with this DNA glycosylase; further experiments 527 
will be needed to extend our insights into the broader aspects of GBM biology and resistance 528 
to standard-of-care. 529 
  530 
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FIGURES 737 
 738 
Figure 1. Knockdown of the NEIL3 DNA glycosylase in NCH644 GBM stem-like cells. A. 739 
Relative mRNA expression of NEIL3 in control and NEIL3-depleted NCH644 cells as assessed 740 
by RT-qPCR. The expression values were normalized against GAPDH and compared to 741 
shControl. Significance was determined by t-test (*, p-value < 0.05; **, p-value < 0.01). B. 742 
Western blot analysis of NEIL3 in total cell extracts confirming the mRNA expression levels. C. 743 
Effect of NEIL3 knockdown on cell proliferation as assessed by cumulative population 744 
doubling time over 25 days. D. Impact of NEIL3 on spheroid formation capacity of 1, 5 or 10 745 
cells seeded in individual wells and incubated for 3 weeks. Visible spheroid were then counted 746 
and the percentage of spheroid-containing wells was calculated. Significance was assessed by 747 
t-test.  748 
  749 
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 750 
Figure 2. Effect of TMZ and TBHP treatment in U87 and NCH644 shNEIL3 cell lines. A. Viability 751 
of U87 shNEIL3 compared to shControl cells after 72h TMZ treatment as assessed by the MTT 752 
reagent. B. Cell growth competition assay in U87 shNEIL3 cells. A 1:1 ratio of U87 (GFP-753 
negative) and U87 shRNA cells (GFP-positive) were mixed together and treated (50µM) or not 754 
with TMZ. Viable cells were counted by FACS using a GFP gating strategy to discriminate the 755 
two populations. The percentage of viable cells was assessed in each condition. C and D. Effect 756 
of 48h of TMZ (C) and 24h of TBHP (D) treatment on the viability of NCH644 shNEIL3 compared 757 
to shControl cells as assessed by WST1 reagent. In all experiments, differences in sensitivity 758 
between the cell lines was analyzed by direct t-test comparison and the significance is 759 
indicated by * (p-value <0.05).  760 
  761 
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 762 
Figure 3. Impact of NEIL3 depletion on telomeres in NCH644 cells. A. Representative TRF 763 
Southern blot for evaluation of telomere length in NCH644 shNEIL3. Molecular weight is 764 
presented in kb and white dots indicate mean telomere length in each cell line. B. Relative 765 
mean telomere length comparing shNEIL3 to shControl cells. Significance was calculated by t-766 
test and displayed as * (p-value < 0.05) and ** (p-value < 0.01). C. Representative images of 767 
telomere dysfunction-induced foci (TIFs) in NCH644 shNEIL3 cells. Co-localization of γ-H2AX 768 
foci (immunofluorescence) and telomeres (FISH) are indicated by white arrows. Scale bar 769 
represents 5µm. D. Quantification of TIFs per nucleus in NCH644 shNEIL3 cells. Significant 770 
 34 
 
differences were calculated by t-test comparisons and are represented by * (p-value < 0.05) 771 
or ** (p-value <0.01). E. Visualization of telomeres using fluorescent in situ hybridization 772 
(FISH) in NCH644 shNEIL3 depleted and control cells. White arrows indicate loss of signal or 773 
extra-telomeric signals. Telomere abnormalities were not quantified due to insufficient 774 
biological replicates. Scale bar represents 5µm. 775 
  776 
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 777 
Figure 4. Knockdown of NEIL3 deregulates the expression of shelterin components and 778 
chromosome-specific TERRAs. A  Relative mRNA expression of the telomerase enzymatic 779 
subunit (hTERT) and shelterin complex factors (POT1, TERF1, TERF2 and TINF2) in NCH644 780 
shNEIL3 compared to shControl cells as assessed by RT-qPCR. Expression values were 781 
normalized using GAPDH and ezrin. B. Representative WB of TRF1 and TRF2 in NCH644 782 
shControl and shNEIL3 cells. Note that TRF1 is observed as a doublet with the lower band 783 
considered to represent a spliced form of TRF1, lacking 20 amino acids (78). TRF2 is also 784 
observed as a doublet but the difference between these two forms is not known (79). Actin-785 
β was used as loading control and the molecular weight of each protein is indicated in kDa on 786 
the left of the blot. C. Quantification of telomerase activity by qTRAP. Triplicate Ct values at 787 
each protein concentration was plotted for all cell lines and linear regression analysis was 788 
performed. The U2OS telomerase-negative ALT cell line was used as negative control of 789 
telomerase activity. D. Relative RNA expression of different chromosome-specific TERRAs (2q, 790 
10q, 13q, 15q 17p and XpYp) in NCH644 shNEIL3 compared to shControl cells as assessed by 791 
RT-qPCR. Expression values were normalized using GAPDH and GUSB. In all the experiments, 792 
significant differences are represented with * (p value < 0.05) and ** (p-value < 0.01). 793 
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SUPPLEMENTARY FIGURES 794 
 795 
 796 
Supplementary Figure S1. Volcano plot of DNA repair and DDR gene expression 797 
deregulation in primary GBM biopsies compared to control tissue. Upregulated genes are 798 
depicted in red and downregulated genes are shown in blue. Members of the NEIL glycosylase 799 
family are highlighted in green. FDR threshold was set to 0.05 (red dotted line in Y-axis) and 800 
log2(FC) > 0.6 (black dotted line in X-axis) (data taken from 50). 801 
  802 
 37 
 
 803 
 804 
Supplementary Figure S2. Representative visualization of the mean telomere length in U87 805 
and the effect of TMZ and TBHP treatment on both NCH644 and U87 shNEIL3 cells. 806 
Representative TRF Southern blots of U87 telomeres upon NEIL3 depletion (A) and (B) effect 807 
of TMZ/TBHP (72h) treatment on the telomere length of NCH644 (left panel) and U87 (right 808 
panel).  809 
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 811 
 812 
 813 
 814 
 815 
 816 
 817 
 818 
 819 
 820 
Supplementary Figure S3. Quantification of the protein levels of TRF1 and TRF2 in NCH644 821 
shNEIL3 cells. Shown are the relative protein levels of TRF1 and TRF2 in NCH644 NEIL3 822 
depleted when compared to control cells. 823 
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Supplementary Table S1. Description of the qPCR primer pairs used in the study. 
mRNA target Sequence (5’->3’) 
Size 
(bp) 
Tm 
(oC) 
Orientation Design 
Ezrin 
TGCCCCACGTCTGAGAATC  19 59 forward 
qPrimerDepot 
CGGCGCATATACAACTCATGG  21 59 reverse 
GAPDH 
CATGAGAAGTATGACAACAGCCT 23 58 forward 
qPrimerDepot 
AGTCCTTCCACGATACCAAAGT 22 59 reverse 
hTERT 
CCGATTGTGAACATGGACTACG 22 59 forward 
qPrimerDepot 
CACGCTGAACAGTGCCTTC 19 59 reverse 
NEIL3 
GCCTGGAGTAGGGAACATCA 20 58 forward 
qPrimerDepot 
GAGCAAGTCCTGCTTTACGG 20 59 reverse 
POT1 
AGCCTTACGTGTTTGGGCATC 21 61 forward 
qPrimerDepot 
GCATTGGCTGAACATCACACAA 22 60 reverse 
TERF1 
AACAGCGCAGAGGCTATTATTC 22 58 forward 
qPrimerDepot 
CCAAGGGTGTAATTCGTTCATCA 23 59 reverse 
TERF2 
CAGTGTCTGTCGCGGATTGAA 21 60 forward 
qPrimerDepot 
CATTGATAGCTGATTCCAGTGGT 23 58 reverse 
TINF2 
GTGGAACATTTTCCGCGAGTA 21 58 forward 
qPrimerDepot 
GCCCATACAAAGGCGTTCG 19 59 reverse 
GAPDH 
(qTERRA) 
AGCCACATCGCTCAGACAC 19 57 forward Feretzaki and 
Lingner, 2017 GCCCAATACGACCAAATCC 19 52 reverse 
GUSB 
(qTERRA) 
CAGCGTGGAGCAAGACAGTGG 21 63 forward Feretzaki and 
Lingner, 2017 AATACAGATAGGCAGGGCGTTCG 23 62 reverse 
2q-TERRA 
AAAGCGGGAAACGAAAAGC 19 57 forward Feretzaki and 
Lingner, 2017 GCCTTGCCTTGGGAGAATCT 20 60 reverse 
10q-TERRA 
ATGCACACATGACACCCTAAA 21 57 forward Feretzaki and 
Lingner, 2017 TACCCGAACCTGAACCCTAA 20 57 reverse 
13q-TERRA 
CTGCCTGCCTTTGGGATAA 19 57 forward Feretzaki and 
Lingner, 2017 AAACCGTTCTAACTGGTCTCTG 22 58 reverse 
15q-TERRA 
GCAAATGCAGCAGTCCTAATG 21 58 forward Feretzaki and 
Lingner, 2017 GACCCTGACCCTAACCCTAA 20 57 reverse 
17p-TERRA 
CTTATCCACTTCTGTCCCAAGG 22 58 forward Feretzaki and 
Lingner, 2017 CCCAAAGTACACAAAGCAATCC 22 58 reverse 
XpYp-TERRA 
AAGAACGAAGCTTCCACAGTAT 22 57 forward Feretzaki and 
Lingner, 2017 GGTGGGAGCAGATTAGAGAATAAA 24 58 reverse 
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 CHAPTER 6 
 The purpose of this thesis was to address the DNA repair mechanisms that mediate 
resistance to the current first line genotoxic treatment for GBM (RT + TMZ). Particularly, we 
investigated the expression of key factors of the DNA damage response and cell cycle in 
clinically relevant paired GBM patient biopsies. The generated gene expression dataset set the 
foundation for the identification of a DNA repair and cell cycle based gene profiling of GBM 
patients with the prospect of personalized therapy and also uncovered a promising novel target 
gene in the fight against glioblastoma. The data presented in the previous chapters underline 
the benefit of a targeted gene expression study using paired biopsies in GBM and also raise a 
number of exciting points that would deserve further investigation.  
 In Chapter 3, we provided an overview of the DNA repair mechanisms driving 
chemoradiation resistance and tumor relapse in GBM, including novel DNA damage response-
related biomarkers gaining interest in the community. Recent progress in the knowledge of the 
major pathways involved in the removal of IR- and TMZ-induced DNA lesions were put into 
perspective with the current therapeutic strategies relying on DNA repair inhibitors tested in 
vitro or in clinical trials. In line with these studies, we presented cellular systems as well as 
animal models most suitable for the study of DNA repair in the context of glioblastoma. 
Finally, we discussed the potential for personalized therapy of novel genetic and epigenetic 
alterations that were found to affect the DNA damage response of GBM in both adult and 
pediatric patients. Emerging topics in GBM not discussed in this review but worth considering 
include circulating tumor cells (CTCs) which are known to disseminate via the bloodstream 
and are involved in tumor spreading and recurrence (Chistiakov and Chekhonin 2018). In GBM 
specifically, detection of CTCs in the blood of patients was achievable based on the 
quantification of telomerase activity (Macarthur et al., 2014), a feature of a majority of adult 
GBMs extensively discussed in Chapter 3. As pointed out by Chistiakov and Chekhonin 
(2018), “The identification of glioblastoma CTCs might have a promising clinical potential for 
early tumor diagnosis and prognosis”. Furthermore, it may also be argued that knowledge of 
the DNA repair status of these cells may help dictate novel therapeutic strategies. Indeed, in 
breast cancer, CTCs were found to be more resistant to chemotherapy compared to primary 
tumor cells (Gong et al., 2015). Moreover, inhibition of the checkpoint kinases Chk1 and Chk2 
resensitized these cells to cisplatin both in vitro and in xenografted mice. Lastly, the 
identification and isolation of CTCs in the blood of cancer patients and the possibility to 
generate so-called CTC derived explants, which recapitulate the molecular traits as well as the 
patient’s response to chemotherapy in mouse models (Lallo et al., 2017), present themselves 
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as valuable tools for preclinical studies to tailor treatment strategies directly adapted to the 
patient. This non-invasive procedure is particularly interesting in tumors, such as GBM, for 
which biopsy extraction is very delicate. 
 In Chapter 4, we proposed a novel, clinically relevant GBM patient stratification 
strategy based on a DNA repair and cell cycle gene signature. Current efforts to identify 
molecular profiles specific to chemoradiotherapy resistance focused on whole transcriptomic 
expression data generated from GBM specimens collected before treatment (Murat et al., 
2008). In this study, we performed a DNA repair and cell cycle targeted gene expression 
analysis in a cohort of paired tumor samples from patients treated with RT or the combination 
of RT and TMZ. The availability of paired GBM specimens, specifically predating the 
introduction of TMZ in the clinic, still represent a limited resource but their use is gaining 
momentum with the constant improvement of biobanking protocols in close partnership with 
clinicians. Ours is one of the first studies to demonstrate the benefit of using paired GBM 
specimens. Specifically, it led to the identification of a 27-gene signature that resulted in the 
classification of our GBM specimens in two major groups displaying inversed expression 
profiles associated to patient prognosis and a third, less defined group. Analysis of the gene 
components of this signature revealed possible group-specific vulnerabilities against DNA 
damaging agents as well as DDRi and cell cycle inhibitors, which have emerged as important 
therapeutic tools against many cancers. It is unfortunate that our patient profiling strategy still 
leaves aside a considerable amount of patients (G2 group). In addition, although our 
preliminary experiments with G1 and G3 patient-derived cell lines indicated that significant 
differences in sensitivity were observed, none of the tested compounds appeared to completely 
eradicate one population or the other when applied as mono-treatments. It is clear that 
combinations will need to be tested to identify effective G1- and G3-specific treatments.  
Yet, our analysis of the mutations and chromosome alterations underlying these two 
groups suggest that G1 and G3 GBMs are driven by distinct pathways frequently altered in 
GBM. Targeting these pathways thus represents an attractive therapeutic approach. Most 
notably, we demonstrated that G1 tumors frequently amplified the EGFR and PDGFRA 
receptors, which have been the subject of a considerable amount of advanced clinical trials in 
recurring GBM patients, with the use of specific inhibitors such as erlotinib (EGFR) and 
dasatinib (PGFRA) in combination with TMZ, that unfortunately have not shown any 
significant survival benefit to date (Lassman et al., 2015; van den Bent et al., 2009). 
Additionally, the increased frequency of PTEN deletion, which has been shown to drive cell 
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growth by activation of the AKT/mTOR pathway (Miller et al., 2011), in G1 samples, 
advocates the use of inhibitors of this particular pathway such as temsirolimus (mTOR 
inhibitor) (Wick et al., 2016) in the context of PTEN-deficient GBM tumors. Finally, 
deregulation of the RB pathway by deletion of RB1 or CDKN2A, is a common feature seen in 
GBM (Wiedemeyer et al., 2010). In this regard, as we observed increased RB1 deletion rates 
in G3 patients, the use of CDK4 or CDK6 inhibitors could be proposed as therapeutic options 
for these patients. In combination with RT, the CDK4 inhibitor palbociclib has been shown to 
provide a significant survival advantage in preclinical settings (Whittaker et al., 2017). To 
conclude, patient profiling based on our DDR gene signature also highlights the potential 
application of G1 or G3 specific treatment approaches targeting pathways other than the DNA 
repair/cell cycle and ultimately novel synthetic lethality approaches combining multiple 
pathway inhibitors could be considered. 
 As exposed beforehand, GBM patients are in dire need of novel therapeutic strategies 
since the IR and TMZ combination treatment, introduced in 2005, is still currently applied in 
the clinic for lack of better alternatives. In cancer, the chromosome ends play a vital role in 
their proliferation potential and thus targeting their integrity is gaining interest in the 
community. Telomere maintenance plays an important role in glioma predisposition, initiation 
and prognosis (Walsh et al., 2015). In glioblastoma specifically, the picture is quite complex, 
with adult GBMs mainly reactivating telomerase whereas ALT is observed in a significant 
portion of pediatric GBMs. In Chapter 5, we identified NEIL3 as a potential candidate target 
gene in GBM based on the impact of its depletion on telomere homeostasis and sensitivity to 
TMZ and oxidative DNA lesions. Notably, we observed telomere shortening in conjunction 
with deregulation of shelterin components such as TRF1, POT1 and TIN2 as well as 
chromosome-end specific TERRAs, upon knockdown of NEIL3 in GBM cells. Interestingly, 
NEIL3 was shown to be directly recruited by TRF1 to promote BER-mediated repair of 
oxidative guanine lesions at the telomeres (Zhou et al., 2017). Moreover, expression of NEIL3 
in mouse cells was found to provide resistance to ciplatinum agents that cause DNA adducts 
and crosslinks (Rolseth et al., 2013), in line with the recent demonstration of its involvement 
in the unhooking of psoralen- or abasic site-induced inter-strand crosslinks (ICLs), thus 
suggesting an additional, BER-independent role of this enzyme in the support of genomic 
stability (Martin et al., 2017; Semlow et al., 2016). Thus, the targeting of NEIL3 in cancer cells 
could provide means to induce telomere-associated DNA damage and overall genetic 
instability. Thus it is tempting to propose treatment strategies based on the use of genotoxic 
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agents such as TMZ or cisplatin in combination with small molecule inhibitors targeting 
NEIL3, which are under investigation as a few molecules were already found to specifically 
target NEIL1 and NEIL2 (Jacobs et al., 2013). In this context, it is important to note that a 
shRNA screen targeting the DDR conducted in the laboratory, identified NEIL3 as a TMZ 
sensitizer in NCH644 GBM cells but not in the human neural stem cell line hNSC100, 
indicating that NEIL3 inhibition in combination with genotoxicants could provide means to 
target the tumor cells without generating additional detrimental side effects.  
In addition, therapeutic strategies aiming to destabilize telomere homeostasis are 
currently under intense scrutiny in GBM, in great part through the use of G quadruplex ligands 
capable of hindering the binding and activity of telomerase (Lagah et al., 2014; Zhou et al., 
2016), resulting in anti-proliferative effects mediated by telomere instability. To note, drug-
induced resistance to telomerase activity inhibitors in telomerase-positive cells may occur 
through activation of the alternative lengthening of telomeres (ALT) mechanism (Hu et al., 
2012). Interestingly, the G4 ligand telomestatin has been shown to effectively cause telomere 
dysfunction and trigger the DDR in various ALT cells (Temime-Smaali et al., 2009). 
Additionally, the G4 stabilizing compound TMPyP4 was found to suppress the proliferation of 
ALT-positive cells (Kim et al., 2003). The fact that GBMs present up to 25% of ALT tumors 
(Hakin-Smith et al., 2003) further encourages the study and testing of G-quadruplex stabilizing 
drugs in this particular context. Combining the anti-proliferative activity of such G4 ligands, 
in both telomerase-positive and ALT cells, with the inhibition of telomeric DNA damage repair 
via NEIL3 targeting could provide novel means of treatment in GBM patients in the future.  
Finally, despite extensive biochemical characterization of the enzymatic activity of 
NEIL3, its ubiquitous cellular function, apart from its role in promoting proliferation of neural 
and cardiac stem cells (Olsen et al., 2017; Sejersted et al., 2011), remains unsettled. Hence, the 
functional characterization achieved in GBM cells contributes to provide a novel and 
innovative candidate in the fight against this deadly disease. The observations presented and 
discussed in this manuscript are crucial preliminary results that pave the way to more in-depth 
analyses of the role of NEIL3 in telomere homeostasis in the context of GBM.  
 In conclusion, our original aims have been fulfilled with the generation of valuable 
DNA repair and cell cycle gene expression data which, after analysis, contributed to a clinically 
relevant gene signature for GBM patient profiling with the prospect of personalized treatment 
strategies, and the identification of a novel, promising candidate target gene for innovative 
therapeutic approaches. 
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